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ABSTRACT 
Primary hyperoxaluria type 1 (PH1) is a rare autosomal recessive disorder 
characterized by the deposition of insoluble calcium oxalate crystals at first 
in the kidneys and urinary tract and then, in the absence of appropriate 
treatments, in the whole body. PH1 is caused by the deficiency of human 
liver specific peroxisomal enzyme alanine:glyoxylate aminotransferase 
(AGT). AGT is a pyridoxal 5'-phosphate (PLP)-dependent enzyme, which 
converts glyoxylate to glycine, thus preventing glyoxylate oxidation to 
oxalate and calcium oxalate formation. Only two curative therapeutic 
approaches are currently available for PH1: the administration of pyridoxine, 
a precursor of PLP, which is only effective in a minority of patients (10-
30%), and liver transplantation, a very invasive procedure. AGT is encoded 
by the gene AGXT for which two main polymorphisms can be found: the 
major allele (AGT-Ma) and the minor allele (AGT-Mi). Up to now, more than 
150 mutations have been identified that lead to PH1 and several studies 
have tried to clarify the genotype/phenotype correlations. However, the 
mechanisms by which each mutation causes AGT deficiency at the protein 
level are still poorly understood. Therefore, we performed a side-by-side 
comparison between normal AGT and nine purified pathogenic variants in 
terms of catalytic activity, coenzyme binding mode and affinity, 
spectroscopic features, oligomerization and thermal stability of both the 
holo- and apo-form. Moreover a detailed analysis of the structural 
properties of the S187F-Ma variant and of the molecular and cellular 
properties of Gly161 variants has been undertaken. Altogether, the data 
obtained has allowed us (i) to provide evidence for the structural and/or 
functional effects caused by each mutation on the protein, (ii) to reassess 
previous data obtained with crude cellular extracts, and (iii) to indicate a 
suitable therapy among those already available, and to suggest new 
treatments strategies for patients bearing the mutations analysed. 
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taken, in which you have amalgamated the complementary approaches of classic biochemistry, 
enzymology, biophysics, structural biology and cell biology, has provided exciting new insights 
into the molecular aetiology and pathogenesis of PH1. In particular, I liked your fine dissection of 
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colleagues.  
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1.1 Primary Hyperoxaluria Type I (PH1) 
Primary Hyperoxaluria Type I is a human metabolic autosomal recessive 
disease whose principal hallmark is the formation of calcium oxalate stones, 
forming at first in the kidneys and then in the whole body [1]. Although the 
first clinical manifestations of this disorder are related to renal dysfunction, 
the cause is the deficiency of a liver peroxisomal enzyme, 
alanine:glyoxylate aminotransferase (AGT)[2]. AGT is a pyridoxal 5'-
phosphate (PLP)-dependent enzyme, encoded by the AGTX gene located 
on chromosome 2q37.3. AGT catalyzes an essentially irreversible 
transamination reaction in which the amino group of L-alanine is transferred 
to glyoxylate, leading to the formation of pyruvate and glycine. In the 
absence of functional AGT, glyoxylate accumulates in the peroxisomes and 
is transported to the cytosol were it is oxidized to oxalate by lactate 
dehydrogenase. Oxalate is an end product of metabolism and is excreted 
from the body, mainly by the kidneys[3] (Fig. 1).  
 
 
 
Fig. 1: Metabolic consequences of AGT deficiency. Sites and mechanisms of oxalate 
formation are shown. 
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In PH1 patients the over-production of glyoxylate and consequent oxalate 
accumulation allows the formation and deposition of calcium oxalate 
crystals (CaOx) in the kidneys and urinary tract. The progressive 
urolithiasis and nephrocalcinosis that follow finally lead to renal failure[4]. In 
these conditions the increased oxalate production is compounded by the 
decreased ability to eliminate it, thus leading to CaOx deposition at 
numerous sites within the body, a potentially fatal condition named 
systemic oxalosis and associated with various symptoms depending on the 
tissue involved (Table 1).  
 
Table 1: Tissue involved in PH1 and related symptoms 
 
PH1 is difficult to treat. Classical treatments have the main objective of 
either preventing kidney failure, by decreasing the amount of oxalate and 
increasing the ability to eliminate it from the body, or restoring kidney 
function. They are aimed at [5]: 
! Reducing the exogenous oxalate intake. Dietary restriction is aimed 
at decreasing the total body's intake of oxalate. Since several 
studies have shown that oxalate is only poorly absorbed from the 
diet [6-9] this strategy is not regarded as being very helpful. 
! Reducing the endogenous oxalate synthesis. About 40% of the 
oxalate production appears to be derived from the 
glycine/glyoxylate metabolism[10, 11] thus, attempts to develop a 
therapeutic strategy to normalize endogenous oxalate synthesis in 
PH1 have been centered around glyoxylate metabolism and can be 
TISSUE  CLINICAL SYMPTOM 
Kidney and urinary tract Urolithiasis, nephrocalcinosis, renal failure 
Bone Bone pain, multiple fractures, and osteosclerosis 
Eye Retinopathy and optic atrophy 
Heart Heart block, myocarditis, and cardioembolic stroke 
Nerves Peripheral neuropathy 
Deep vasculature Vasospasm 
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divided into two main areas: 1) the inhibition of glyoxylate oxidation 
to oxalate, by inhibiting xanthine oxidase[12], glycolate oxidase 
(GO)[13], and lactic dehydrogenase (LDH)[14]; 2) the inhibition of 
glyoxylate synthesis by the administration of competitive inhibitors 
of D-aminoacid oxidase, or the reduction of  the available glycine 
pool. 
! Preventing CaOx crystallization, by the administration of 
crystallization inhibitors (i.e. magnesium and potassium citrate), 
hyperhydratation, and, the removal of CaOx stones by lithotripsy, 
which is the main treatment for PH1 patients. 
! Treating renal failure and associated uremia by dialysis or kidney 
transplantation. 
 
All these approaches address the more distal aspects of PH1, i.e. the 
symptoms rather than the causes. Thus, they do not represent a real cure 
for the disease because they only slow down disease progression.  
Only two therapeutic approaches directed to the causes of the disease are 
currently available for PH1 patients. The first one is the administration of 
pharmacological doses of pyridoxine (Vitamin B6). It is known that 
pyridoxine can be converted in the body to PLP, the essential cofactor of 
AGT, but the molecular mechanism of action of this molecule has not been 
clarified. Moreover, only a minority (10!30%) of patients is responsive to 
pyridoxine therapy and clinical studies seem to indicate that 
responsiveness is confined to mutations that result in AGT mistargeting[15]. 
The only curative approach available for PH1 patients unresponsive to 
pyridoxine, is liver transplantation, which has the main objective of 
reintroducing most of the body's requirements of AGT. However, it 
represents a very wasteful intervention because an entire organ is 
employed to replace only one defective gene[5]. For these reasons it would 
be necessary to engage in new strategies to develop innovative and non-
invasive treatments directed to the causes of the disease, which are 
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expected to provide long!term benefits, thus improving the treatment of 
PH1 patients.  
 
 
1.2 AGT structure, function and intracellular localization  
AGT is present in human hepatocytes as an 86 KDa homodimeric protein 
and each subunit comprises 392 aminoacids. The structure of the enzyme 
in complex with the inhibitor amino-oxyacetic acid solved in 2003[16] has 
revealed that it belongs to the Fold Type I class of PLP-dependent 
enzymes. Each subunit is composed of (Fig. 2): 
! an N-terminal extension (residues 1-21) wrapping over the surface 
of the neighboring subunit,  
! a large domain (residues 22-282) containing most of the active site 
and the dimerization interface,  
! a C-terminal domain (residues 283-392) containing the peroxisomal 
targeting information.  
The PLP coenzyme is covalently bound to the apoprotein by a Schiff 
base linkage with the "-amino group of Lys209 forming a complex 
called internal aldimine. 
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Figure 2. Dimeric structure of AGT (PDB file 1H0C). One monomer is colored gray, while 
the other one is colored yellow (N-terminal arm), green (C-terminal domain) and orange 
(large domain). PLP is represented as red sticks. The figure was rendered by using 
PyMol[17]. 
Other weak interactions at the active site stabilize the apoprotein-
coenzyme interaction (Fig. 3). These are: (i) a ring stacking interaction 
between the pyridine ring of PLP and Trp108, (ii) a salt bridge between the 
protonated pyridine nitrogen and Asp183 and (iii) hydrogen bonds between 
the hydroxyl group of PLP and Ser158 as well as between the phosphate 
group of PLP and the residues His83 and Gly82, Tyr260* and Thr263* (* 
stands for residues belonging to the adjacent subunit) [16]. 
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Figure 3: AGT active site (PDB file 1H0C). PLP is colored green. The residues that interact 
with the coenzyme are shown blue. The two orange residues interact with PLP but belong to 
the other monomer. The figure was rendered using PyMol[17] 
The AGT spectroscopic features are those typical of PLP-dependent 
enzymes (Fig. 4A and B). The enzyme displays an absorption maximum at 
420 nm, associated with a positive dichroic band at 429 nm, and a shoulder 
at about 340 nm, associated with a small negative dichroic signal at 335 
nm probably corresponding to the ketoenamine and enolimine tautomers of 
the internal aldimine, respectively. Moreover, the enzyme shows positive 
dichroic bands in the 285-290 nm region and a negative dichroic band in  
the 256-266 region, which would indicate the asymmetry of some aromatic 
amino acids most probably located in the proximity of the active site[18]. 
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Introduction 
!")!
 
 
 
 
 
 
 
Figure 4: Absorbance (A) and CD-Visible (B) spectra of holo-AGT in 0.1M potassium 
phosphate buffer, pH7.4 
 
AGT catalyzes the reversible transamination of L-alanine and glyoxylate to 
pyruvate and glycine by a classical ping-pong mechanism (Scheme 1). In 
the first half-reaction, after the binding of the substrate to the catalytic site 
of the enzyme in the internal aldimine form (AGT-PLP) and the formation of 
the Michaelis complex, the "-amino group of Lys209 is replaced by the #-
amino group of L-alanine, thus generating the external aldimine. The 
extraction of the C#-proton from the external aldimine yields a quinonoid 
intermediate, which is reprotonated at the C4’ of the coenzyme to give the 
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ketimine intermediate. The latter is then hydrolyzed to pyridoxamine 5’-
phosphate (PMP) and pyruvate. In the second half transamination, 
following the same steps of the first half-reaction but in reverse order, 
glyoxylate reacts with the AGT-PMP complex and is converted to glycine, 
thus regenerating AGT-PLP [18]. 
 
 
Scheme 1 Mechanism of the reaction catalyzed by AGT[18]. 
Kinetic studies have indicated that AGT is highly specific for the glyoxylate-
to-glycine conversion, in agreement with the proposed physiological role of 
the enzyme in glyoxylate detoxification. In fact, the equilibrium constant of 
the overall transamination is about 9400 and the kcat for the overall 
transamination reaction of the alanine/glyoxylate pair is around 100-fold 
higher than that of the glycine/pyruvate pair (45 s-1 vs 0.3 s-1). Moreover, it 
has been shown that the enzyme has an higher affinity for PMP than for 
PLP, and that PMP remains tightly bound to the apoprotein during the 
catalytic cycle, thus making the enzyme more reactive toward oxo acids[18]. 
The study of the spectral changes occurring on AGT during the two half-
transamination reactions have suggested that both the external aldimine 
formation and the interconversion between AGT-PLP and AGT-PMP are 
accompanied by conformational changes at the active site of the enzyme 
[18]. By means of computational analyses, it has been suggested that subtle 
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rearrangements of aromatic residues at the active site and a tilting of the 
coenzyme could occur and that these structural rearrangements could be 
determinant in the tight PMP binding and subsequent catalysis [18]. 
The localization of AGT inside the cell can vary from one species to 
another. During the evolution the targeting of AGT has been under the 
influence of strong dietary selection pressure, so that AGT tends to be 
mitochondrial in carnivores, peroxisomal in herbivores, and both 
peroxisomal and mitochondrial in omnivores. In many species, including 
the rat and marmoset, AGT is localized both in peroxisomes and in 
mitochondria. In some species, such as human, rabbit, guinea pig, and saki 
monkey, AGT is exclusively peroxisomal. In other species, such as the 
domestic cat, AGT is exclusively mitochondrial[19] 
In human hepatocytes, like the large majority of peroxisomal proteins, AGT 
is synthetized in the cytosol and then transported inside the peroxisome 
trough the Pex5p carrier protein. The interaction between the AGT and the 
carrier occurs through a non-canonical type I peroxisomal targeting 
sequence (PTS1), i.e. a C-terminal KKL sequence instead of the SKL 
sequence normally found in the vast majority of peroxisomal proteins. This 
led to the hypothesis that AGT could possess an ancillary targeting 
sequence (PTS1A), which could work properly by interacting with Pex5p 
with the aid of an unidentified specific adaptor molecule[20]. 
Immunofluorescence and two-hybrid system studies had allowed the 
identification a putative ancillary peroxisomal targeting information (PTS1A) 
within the small C-terminal domain, in the region Val324-Ile345[20, 21]. 
Recently Fodor K. et al have solved the crystal structure of the complex of 
AGT and Pex5p[22]. This study has demonstrated that the two proteins are 
able to interact without the presence of an adaptor molecule and that the 
AGT-Pex5p interface consists of three regions: (i) the C-terminal PTS1 
(residues 389-392) (ii) an “extended PTS1”, that includes the C-terminal 
part of the # helix 13 (residues 381-388) and the loop connecting the $ 
strand 9 and the # helix 12 (residues 327-330), and (iii) a region 
topologically separate from the PTS1 formed by residues 303-307 [22].  
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1.3 Polymorphic mutations of AGT, the minor allele 
As mentioned earlier, AGT is encoded by AGXT gene, located on 
chromosome 2q37.3. The AGXT gene is present in human population as 
two polymorphic variants, namely the “major allele” and the less common 
“minor allele”. The frequency of the minor allele varies among different 
populations, ranging from 2% in the Japanese population, to the 20% of 
Europeans and North Americans to 28% in the Saami population[23, 24]. The 
minor allele differs from the major allele by a 74-bp duplication in intron 1 
and two point mutations (32C-T and 1020 A-G) leading to the Pro11Leu 
and Ile340Met amino acid substitutions[25]. Although the presence of the 
minor allele polymorphism is not pathogenic “per se”, it makes AGT more 
susceptible to the effect of several missense mutations, which are 
predicted to be non-pathogenic when associated with the major allele[26]. 
For this reason many investigations have been carried out to understand 
the differences between the two allelic forms of AGT at cellular and 
molecular level.   
Studies performed on human hepatocytes [24, 26] indicate that the protein 
encoded by the minor allele (AGT-Mi) has a specific activity of about 70% 
compared with that encoded by the major allele (AGT-Ma) [26] Moreover, 
while AGT-Ma is entirely located in peroxisomes, AGT-Mi is localized  in 
peroxisomes for about 95% and in mitochondria for 5% [24]. It has been 
demonstrated that the mislocalization is due to the P11L mutation, which 
creates a putative mitochondrial targeting sequence (MTS) at the N-
terminus of AGT [27, 28]. However, the large part of AGT-Mi is not imported to 
mitochondria, probably because the protein quickly dimerizes, thus 
preventing the interaction with the mitochondrial import machinery that only 
acts on partly unfolded monomeric proteins.  
The biochemical properties distinguishing the two allelic forms of AGT have 
been thoroughly analysed in vitro with purified recombinant AGT-Ma and 
AGT-Mi[29]. These studies have indicated that the P11L/I340M mutations do 
not affect either the UV-visible absorbance, dichroic and fluorescence 
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features of AGT or the equilibrium dissociation constant for PLP (KD(PLP)) 
value, thus suggesting that no gross conformational changes have 
occurred and that the two species share a similar active site architecture. 
However, in agreement with the results obtained on human hepatocytes, 
the mutations induce a slight decrease (about 30%) of the kcat value for the 
overall transamination of L-alanine and glyoxylate. 
Yeast complementation assays[30], along with pulse-chase and cross-linking 
experiments performed on cell-free transcription/translation products [31] 
have indicated that AGT-Mi is less stable in vivo and is more susceptible to 
proteolytic degradation and aggregation with respect to AGT-Ma. In 
agreement with these results, thermal and chemical unfolding studies have 
provided evidence that both holo- and apoAGT-Mi show a decreased 
overall stability and a more unstable dimeric structure compared with the 
corresponding forms of AGT-Ma. The destabilization can be imputed to the 
P11L mutation [29]. It has been suggested that the substitution of Pro11 with 
a leucine residue would loosen the interaction of the N-terminal arm of one 
subunit of AGT with the large domain of the opposite subunit, thus 
facilitating dimer dissociation. This perturbation could also be transmitted to 
the AGT active site through a loop (residues 24-32), which contributes to 
the PLP binding site. These analyses, besides elucidating the differences 
between AGT-Ma and AGT-Mi, have represented the starting point to 
investigate the effect of pathogenic mutations associated with the major or 
the minor allele.  
 
 
1.4 Pathogenic mutations of AGT 
 
PH1 is considered a very heterogeneous disease from a genetic, 
enzymatic and clinical point of view. Up to now, more than 150 different 
pathogenic mutations on the AGXT gene have been identified, including 
nonsense, frameshift and the most common missense mutations. The latter 
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group, comprises mutations associated with the major allele, mutations that 
cosegregate and functionally interact with the minor allele, and mutations 
that can be found associated with the major or the minor allele (Table 2).  
While nonsense and frameshift are null mutations that lead to a complete 
loss of the gene product, missense point mutations lead to single amino 
acid substitutions that cause the synthesis of an aberrant gene product.  
A wide variety of enzymatic phenotypes, i.e. of mechanisms by which a 
missense pathogenic mutation leads to AGT deficiency, have been 
identified. Up to now, the mutations have been classified on the basis of 
western-blot and enzymatic activity analyses of either patient liver samples 
or crude lysates of eukaryotic and/or prokaryotic cells expressing the AGT 
variants[5, 26, 31-38]. The classes of mutations are defined as: 
! ENZ-/CRM+: mutations that lead to the loss of the AGT catalytic 
activity without loss of immunoreactivity, and represent about 20% 
of the total;  
! ENZ-/CRM-: mutations that lead to the absence of both AGT 
catalytic activity and immunoreactivity , and are the large majority of 
PH1-causing mutations; 
! ENZ+/CRM+: mutations that cause the mistargeting of AGT from 
peroxisomes to mitochondria without negatively influencing either 
the catalytic activity or the immunoreactivity of the protein. This 
group includes the G170R substitution associated with the minor 
allele, the most frequent PH1-causing mutation that affects about 
one third of all the patients. 
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Table 2: Some of the most common PH1 mutations in the AGXT gene. 
 
 
 
The resolution of the AGT crystal structure[16] has allowed to rationalize the 
impact of some pathogenic mutations, at least in terms of their likely effects 
on AGT tertiary and quaternary conformation. Moreover, in the last few 
years, more detailed studies on the pathogenic variants either in the 
recombinant purified form, or expressed in mammalian cells or in cell-free 
expression systems, have been performed to define how a particular amino 
 
MUTATION 
 
EXON 
 
AMINO ACID 
SUBSTITUTION 
 
FREQUENCE 
 
ALLELE 
 
367G>A 
549G>A 
444T>C 
630G>A 
576T>A 
735T>C 
853T>C 
243G>A 
243G>A 
244G>T 
 
2 
3 
2 
4 
4 
6 
7 
1 
1 
1 
 
G82E 
D183N 
W108R 
G170R 
F152I 
S205P 
I244T 
G41R 
G41R 
G41V 
 
?%* 
?%* 
?%* 
30% 
1% 
<1% 
9% 
1% 
?%* 
?%* 
 
major 
major 
minor 
minor 
minor 
major 
minor 
minor 
major 
major 
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acid substitution could alter the AGT structural and/or functional properties. 
These analyses have made it possible to identify the following molecular 
mechanism leading to AGT deficiency in PH1 (Figure 5): 
! The loss of catalytic activity and/or the reduction of coenzyme 
binding affinity, such as the G82E mutation associated with the 
major allele and the F152I associated with the minor allele. The 
biochemical characterization of the G82E-Ma variant in the purified 
form has shown that the mutation leads to a perturbation of the 
active site microenvironment, which causes a strong reduction of 
the PLP binding affinity and of the catalytic efficiency for the overall 
transamination reaction [18]. In the case of the F152I-Mi variant, a 
strongly reduced affinity for the PMP coenzyme has been reported, 
leading to a release of PMP during the overall transamination 
reaction[39]. 
! The loss of immunoreactivity of the protein, such as the G41R, 
G170R, F152I and I244T mutations, associated with the minor allele 
as well as the G41R and G41V mutations associated with the major 
allele. It has been demonstrated that various mechanisms can lead 
to a reduced immunoreactivity:  
1. a reduced dimer stability. Cross-linking studies on the G41R-
Ma, G41R-Mi and G41V-Ma variants expressed either in 
mammalian cells or in cell-free expression systems have 
indicated a higher population of the monomer form of these 
variants with respect to AGT-Ma or AGT-Mi[31]. Moreover, 
size exclusion chromatography (SEC) and thermal and 
chemical denaturation studies of the G170R-Mi, F152I-Mi, 
G41R-Mi, G41R-Ma and G41V-Ma variants in the purified 
form have demonstrated that the mutations reduce the 
stability of the dimeric structure of the protein in the apo-
form[29, 39-42]. 
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2.  a higher susceptibility to proteolytic degradation, such as 
can be found for  the G41R and I244T mutations associated 
with the minor allele as well as the G41R and  G41V 
mutations associated with the major allele. Analyses on the 
pathogenic variants both in the purified form and expressed 
in cell-free transcription-translation systems have shown that 
the mutation of Gly41 increases the sensibility to 
degradation of AGT, while the I244T mutation strongly 
sensitizes AGT to trypsin treatment. [31, 43, 44]. 
3. an increased aggregation propensity of the protein, as found 
for the G41R, I244T and F152I mutations associated with 
the minor allele as well as the G41R and G41V mutations 
associated with the major allele. A propensity to aggregate 
has been shown for these variants expressed in cell-free [31] 
and cellular systems[44, 45]. Moreover dynamic light scattering 
(DLS) and SEC studies of these variants in their purified 
form have confirmed that the G41V, G41R and F152I 
mutations lead to protein aggregation[26, 39, 40]. However, 
while the aggregation of the F152I-Mi variant is due to 
protein monomerization, the aggregation of G141R-Ma, 
G41V-Ma and G41R-Mi is driven by electrostatic interactions 
between dimers. 
  
! The mislocalization of the protein, such as that found for F152I, 
G170R and I244T mutations on the background of the minor allele. 
Studies performed on patient liver biopsies or in mammalian cells 
expressing the G170R-Mi, F152I-Mi and the I244T-Mi variants, 
have led to the conclusion that the molecular defect of these 
variants is the mislocalization of the protein to mitochondria instead 
of peroxisomes[35, 36, 45]. In the last few years, the biochemical 
characterization of the G170R-Mi and F152I-Mi variants in their 
purified form[29, 39], has allowed to conclude that the variants display 
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a lower stability of the dimer structure in the apo-form, leading to the 
hypothesis that these mutations could affect the conversion of the 
partially unfolded monomer or of the folded monomer to the 
apodimer. The consequent accumulation of a partially unfolded 
monomer would synergize with the presence of the putative MTS, 
thus making the protein compatible with the interaction with the 
mitochondrial import machinery. 
 
Figure 5: Molecular mechanisms leading to AGT deficiency 
 
All together these results, besides demonstrating that the mechanisms 
leading to AGT deficiency are more complicated than previously thought, 
have highlighted that in order to have a more complete picture of the 
molecular defect of a pathogenic variant one should integrate data from (i) 
the inspection of the AGT crystal structure, (ii) the biochemical 
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characterization of the purified variant in both the holoenzymatic and the 
apoenzymatic form, and (iii) the study of variants expressed in mammalian 
cell lines.  
Moreover, results from published studies have allowed to understand the 
basis for the therapeutic response and to suggest new therapeutic 
approaches for patients bearing the examined mutations. In particular, it 
has been suggested that the responsiveness to pyridoxine therapy in 
patients bearing the G170R or F512I mutations is due not only to a 
prosthetic role of PLP, which shifts the equilibrium from the apo to the more 
stable holo-form of the protein, but also to a conformational role of PLP, 
which could bind to the unfolded or partially unfolded monomer leading to 
the formation of a folded dimer that can be imported in peroxisomes. 
Moreover, it has been suggested that an approach with pharmacological 
chaperones would be useful for patients bearing the G41R, G41V and 
I244T mutations. Pharmacological chaperones are small drug!like 
molecules that diffuse into the cell and bind site!specifically to folding 
intermediates during the biosynthesis of a mutated protein, thereby 
improving its folding efficiency. Pharmacological chaperones could possibly 
rescue for the protein instability of the G41R-Ma, G41R-Mi, G41V-Ma and 
I244T-Mi AGT mutants. 
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Primary Hyperoxaluria Type I (PH1) is a rare disease caused by mutations 
in the gene encoding hepatic alanine:glyoxylate aminotransferase (AGT). 
AGT deficiency causes the formation and deposition of calcium oxalate 
crystals at first in the urinary tract and then in the whole body. PH1 is a 
heterogeneous disease in respect to the clinical manifestations, the 
response to treatment and the pathogenic mechanisms. In fact, more than 
150 pathogenic mutations have been identified so far and the molecular 
mechanisms by which missense mutations cause AGT deficiency include 
functional, structural and subcellular localization defects. The only two 
curative treatments available for PH1 are pyridoxine therapy, which is 
effective only in a minority of patients, and liver transplantation, which is a 
very invasive and problematic procedure. Thus, approaches aimed at a 
deeper knowledge of genotype/phenotype correlations as the base to 
develop new treatment strategies appear to be desirable. Although in the 
last few years several efforts have been done to better understand the 
molecular defects of PH1-associated mutations, knowledge of the defect of 
the AGT variants at a protein level is still poor. Thus, we performed a side-
by-side comparison between normal AGT and several purified pathogenic 
variants in terms of catalytic activity, coenzyme binding mode and affinity, 
spectroscopic features, oligomerization and thermal stability of both the 
holo- and apo-form. On the basis of the obtained results, a more detailed 
analysis of the S187F-Ma variant, by crystallographic, spectroscopic and 
kinetic analyses, as well as of the Gly161 variants, by biochemical studies 
on the purified proteins paired with cell biology studies, has been 
undertaken.  
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3.1 Materials 
PLP, pyridoxine, L-alanine, sodium glyoxylate, rabbit muscle L-lactic 
dehydrogenase, isopropyl-$-D-thiogalactoside (IPTG), EDTA and imidazole 
were all purchased from Sigma. Ham’s F12 Glutamax medium was 
purchased from Invitrogen. All other chemicals were of the highest purity 
available. The rabbit polyclonal anti-AGT human and guinea-pig anti–
peroxisomal proteins antibodies were kindly provided by Prof. C.J. Danpure 
of University College London (UK); the anti-rabbit HRP antibody was 
purchased from GE Healthcare. Oligonucleotides for site directed 
mutagenesis were purchased from MWG Biotech AG (Anzinger, Germany) 
3.2 Site directed mutagenesis 
The constructs encoding for the polymorphic and pathogenic variants of 
AGT were constructed starting from the pAGT-His construct, kindly 
provided by Prof. Christopher J. Danpure of the University College London 
(UK). This vector contains the complete open reading frame of AGT 
together with a C-terminal histidine-tag (AVDHHHHHH), cloned in a 
pTrcHis2A expression plasmid (Invitrogen)[26]. This vector allows to express 
recombinant AGT in E. coli under the lactose operon controller by adding 
IPTG to the culture broth. Moreover, the presence of a C-terminal 6-
Histidine tag allows a one step purification of the protein by Immobilized 
Metal Affinity Chromatography. 
For cell biology studies, the cDNA encoding human AGT was cloned in the 
mammalian expression vector pcDNA3.1/V5-His-TOPO, by means of the 
TOPO cloning kit (Invitrogen). This expression vector contains the human 
cytomegalovirus enhancer-promoter sequences upstream of the 
multicloning site, the transcription-termination sequence of the bovine 
growth hormone gene (bGH) downstream of the multicloning site and the 
gene for neomycine resistance. 
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The desired mutations were introduced on the desired vector by the 
QuikChange site-directed mutagenesis kit (Stratagene), which employs  
double-stranded DNA as a template, two complementary oligonucleotide 
primers containing the desired mutation, and DpnI endonuclease to digest 
the parental DNA template. The oligonucleotides used for mutagenesis are 
reported in Table 3. 
 
Table 3: DNA sequence of the primers used for site-directed mutagenesis (5’-3’). The 
underlined codons indicate the mutated aminoacid. 
 
 
 
AGT variant DNA sequence of the mutagenic primers (5'-3 ') 
   
W108R-Mi   GGGGCCAATGGCATTAGGGGGCAGCGAGCCGTG         CACGGCTCGCTGCCCCCTAATGCCATTGGCCCC 
S158L-Ma   CCACGGGGAGTTGTCCACCGGCG               CGCCGGTGGACAACTCCCCGTG                           
G161C-Mi   GAGTCGTCCAACCTGCGTGCTGCAGC GCTGCAGCACGCAGGTGGACGACTC                        
G161S-Mi   GAGTCGTCCAACCAGCGTGCTGCAGC GCTGCAGCACGCTGGTGGACGACTC  
D183N-Ma   CCTGCTCCTGGTGAATTCGGTGGCATCCC    GGGATGCCACCGAATTCACCAGGAGCAGG 
S187F-Ma   
GGATTCGGTGGCATTCCTGGGCGGGAC 
GTCCCGCCCAGGAATGCCACCGAATCC 
S218L-Ma   CCCCTCCAGGGACCTTGCTCATCTCCTTC      GAAGGAGATGAGCAAGGTCCCTGGAGGGG                              
P319L-Ma   GCGCTCCGGCTTCTCACAGTCACCACT           AGTGTGACTGTGAGAAGCCGGAGCGC 
G350D-Mi   GAGATCATGGGTGACCTTGGGCCCTCC        GGAGGGCCCAAGGTCACCCATGATCTC 
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3.3 Expression and purification of the AGT variants 
E. coli JM109 cells transformed with the constructs encoding the AGT 
variants were grown in 750 ml of Luria broth at 37°C to an absorbance at 
600 nm of 0.4-0.6. Expression was induced with 0.1 mM IPTG for 15 h at 
30°C. Cells were harvested and resuspended in 20 mM sodium phosphate 
buffer, pH 7.4 containing 0.5 M NaCl, 20 mM imidazole and 100 µM PLP. 
Lysozyme was added to a concentration of 0.2 µg/ml and the culture was 
incubated for 15 min at room temperature. After a freeze-thaw, leupetin 
(0.5 µg/ml) and pepstatin (0.7 µg/ml) were added and the suspension was 
centrifuged at 30,000 g for 30 min at 4°C. The lysate was loaded on a 
HisPrep FF 16/10 (GE Healthcare) equilibrated with 20 mM sodium 
phosphate buffer pH 7.4 containing 0.5 M NaCl and 20 mM imidazole. A 
linear gradient was then inserted (0-100% in 200 ml) with the same buffer 
containing 500 mM imidazole. Soluble AGT elutes from the Ni2+ resin 
between 300 and 400 mM imidazole. After addition of 100 µM PLP, the 
protein solution was concentrated; imidazole and unbound coenzyme were 
removed by extensive washing with 100 mM potassium phosphate buffer, 
pH 7.4, using Amicon Ultra 10 concentrators (Amicon)[18]. AGT can be 
stored at -20 °C without loss of activity for more than 6 months. Protein 
concentration was determined by using the apparent molar absorption 
coefficient of 95400 M-1 cm-1 at 280 nm. The PLP content was determined 
by releasing the coenzyme in 0.1 M NaOH and by using the apparent molar 
absorption coefficient of 6600 M–1 cm–1 at 388 nm [18, 46]. 
3.4 Preparation of the apoenzyme 
AGT in the apo form was prepared by incubating AGT-Ma, AGT-Mi or the 
variants (10–20 %M) in the holo-form with 500 mM L-alanine for 5-120 min, 
on the basis of the kcat, at 25 °C of the enzymatic species, in a final volume 
of 2 ml. The reaction mixture was concentrated to 0.2 ml by a Amicon Ultra 
4 device (Millipore), washed twice with 2 ml of 1 M potassium phosphate 
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buffer, pH 6 and then 4–5 times with 100 mM potassium phosphate buffer, 
pH 7.4. 
3.5 Determination of the equilibrium dissociation constants of the 
variants for PLP 
The equilibrium dissociation constant for PLP (KD(PLP)) of G161C-Mi, 
G161S-Mi, P319L-Ma and G350D-Mi variants was determined by 
measuring the quenching of the intrinsic fluorescence of the apo-enzymes 
(0.1 µM) in the presence of PLP at a concentration range of 0.01–10 µM. In 
the case of W108R-Mi, S158L-Ma, D183N-Ma and S81L-Ma variants the 
KD(PLP), was determined by measuring the CD signal at 430 nm of the apo 
forms at a concentration of 10 µM in the presence of PLP at concentrations 
ranging from 5 to 300 µM. All the experiments were carried out in 100 mM 
potassium phosphate buffer, pH 7.4. 
The KD(PLP) values for the mutant-coenzyme complexes were obtained by 
fitting the data to the following equation: 
 
 
Y =Ymax
[E]t +[PLP]t +KD(PLP ) ! [(E]t +[PLP]+KD(PLP ) )2 ! 4[E]t[PLP]t
2[E]t
  (1) 
 
where [E] t and [PLP]t represent the total concentrations of the mutant and 
PLP, Y refers to either the intrinsic fluorescence quenching or the 430 nm 
dichroic signal changes at a PLPt concentration, [PLP], and Ymax refers to 
the aforementioned changes when all enzyme molecules are complexed 
with coenzyme. 
The KD(PLP) for the S187F-Ma variant has been estimated as the upper limit 
value by the following procedure: samples of holo- and apo-S187F-Ma at 
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various protein concentrations (from 0.01 to 1 µM, being 0.01µM the 
detection limit) were incubated overnight at 25 °C in 100 mM potassium 
phosphate buffer, pH 7.4. The intrinsic fluorescence emission at 336 nm of 
each sample was registered and the percentage of fluorescence quenching 
at each protein concentration was then calculated. 
 
3.6 Kinetic studies 
The kinetic parameters for the overall transamination reaction for the pair 
alanine/glyoxylate of the AGT variants (0.1–10 µM) were determined in the 
presence of saturating PLP concentrations by varying the substrate 
concentration at a fixed saturating co-substrate concentration. At different 
times, the reactions were stopped by adding TCA 10% (v/v). In the case of 
the G161C-Mi, G161S-Mi, S218L-Ma, P319L-Ma and G350D-Mi variants 
the produced pyruvate was measured by a spectrophotometric assay using 
the coupled lactate dehydrogenase system[18]. In the case of the W108R-
Mi, S158L-Ma, D183N-Ma and S187F-Ma variants, pyruvate production or 
glyoxylate consumption was measured by an HPLC assay based on the 
derivatization with 2,4-dinitrophenylhydrazine [47]. The mixture was injected 
onto a SupelcoTM Discovery C18 column connected with a Jasco HPLC 
system and run with 25 mM sodium phosphate, 25mM sodium acetate, 
20% acetonitrile. A Jasco UV-1570 detector set at 340 nm was employed 
and the flow rate was 0.9 ml/min.  
Data of initial velocity (v) as a function of substrate concentration were 
fitted to the Michaelis-Menten equation: 
 
][
][
Et SKm
Skv cat
+
=     (2) 
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where Et is the total enzyme concentration, S is the substrate concentration, 
kcat is the turnover number, and Km is the Michaelis-Menten constant. 
The AGT enzymatic activity of CHO cell lysates expressing AGT-Ma, AGT-
Mi, G161R-Ma, G161S-Mi and G161C-Mi, was determined by incubating 
90 µg of lysate with 0.5 M L-alanine and 10 mM glyoxylate for 30-150 min 
in 100 mM phosphate buffer pH 7.4. The reactions were stopped by adding 
TCA 10% (v/v) and the pyruvate production was measured using the 
spectrophotometric assay coupled with lactate dehydrogenase described 
above. 
The kinetic parameters for the overall transamination of the 
alanine/glyoxylate pair of the S187F mutant in the presence of 5 mM 
pyruvate were determined by measuring the amount of glyoxylate 
consumed by HPLC after derivatization with 2,4-dinitrophenylhydrazine as 
described above. Substrate saturation curves were fitted using equation 3, 
and dead-end inhibition data were fitted using equation 4 for competitive 
inhibition: 
 
v =VA (Ka + A) (3)  
v =VA Ka [1+ I Kis ]+ [A] (4)  
where v is the initial velocity, V is the maximum velocity, A is substrate 
concentration, K# is the Km for substrate A, and Kis is the slope constant.  
The half-transamination reaction of holoS187F (15 µM) with L-alanine (5–
500 mM) was performed in 100 mM potassium phosphate buffer, pH 7.4, at 
25°C in a total volume of 250 µl. The decrease in the 413 nm absorbance 
signal was measured as a function of time and fitted to the equation: 
 
(5) 
 
where At is the absorbance at time t, &A1 is the amplitude of the fast phase, 
1()exp()exp( 2211 tkAtkAAA obsobst !"+!"+= #
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&A2 is the amplitude of the slow phase, kobs1 is the observed rate constant 
of the fast phase, kobs2 is the observed rate constant of the slow phase and 
A !  is the final absorbance. 
The kmax and apparent Kmapp values for each phase of the L-alanine half-
reaction were determined by plotting the observed rate constants versus L-
alanine concentrations and fitting the data to equation 6: 
kobs =
kmax[S]
Kmapp + [S]
(6)  
The detection and quantification of PLP and PMP during the L-alanine half-
transamination was performed by HPLC upon sample denaturation with 
10% trichloroacetic acid (v/v). A SupelcoTM Discovery C18 column 
connected with a Jasco HPLC system equipped with a Jasco UV-2075 
detector set at 295 nm was used. The eluent was 50 mM potassium 
phosphate buffer, pH 2.35, at a flow rate of 1 ml/min. PLP elutes as a 
single peak at ~ 6.5 min, while PMP elutes as a single peak at ~ 5.3 min. 
 
3.7 Spectroscopic measurements 
Absorption measurements were made with a Jasco V-550 
spectrophotometer with 1 cm path length quartz cuvettes at a protein 
concentration of 1-10 µM in 100 mM potassium phosphate buffer pH 7.4. 
The aggregation kinetics of Gly161 variants in both the holo- and the apo-
form at 2 µM concentration was monitored by following the absorbance at 
600 nm as a function of time under physiological conditions (150 mM ionic 
strength, pH 7.4, 37°C). 
Intrinsic fluorescence emission spectra were recorded on a Jasco FP-750 
spectrofluorimeter equipped with a thermostatically controlled cell holder by 
using a 1 cm path length quartz cuvette. Protein emission spectra were 
taken from 300 to 500 nm (excitation at 280 nm) with both the excitation 
and the emission slits set to 5 nm. The protein concentration was 1 or 5 %M. 
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Spectra of blanks, i.e. of samples containing all components except the 
enzyme, were taken immediately before the measurements of samples 
containing protein. 
Visible and far-UV CD spectra were recorded on a Jasco J-710 
spectropolarimeter equipped with a Peltier temperature controlled 
compartment, by using 1 cm and 1 mm path length cells, respectively. The 
enzyme concentration was 1-10 %M. Routinely, three spectra were 
recorded at a scan speed of 50 nm/min-1 with a bandwidth of 2 nm and 
averaged automatically, except where indicated.  
DLS analyses were performed on filtered stock solutions of the AGT 
variants either in the holo or the apo-form at 10 %M concentration in 100 
mM potassium phosphate buffer, pH 7.4 at 25°C. PLP at saturating 
concentrations was added to the holoenzyme solutions and each sample 
was incubated for 10 min at 25°C. The aggregation kinetics of AGT-Ma, 
AGT-Mi, G161S-Mi and G161C-Mi under physiological conditions was 
studied by incubating each enzymatic species at 1 µM concentration in 60 
mM phosphate buffer pH 7.4 at 37°C. All DLS measurements have been 
performed on a Zetasizer Nano S device (Malvern Instruments) equipped 
with a Peltier temperature controller by using disposable 12.5 x 45-mm 
cells with stopper.  
 
3.8 Thermostability studies 
Thermostability studies on purified AGT variants in the holo- (in the 
presence of saturating PLP) or in the apo-form were performed by both 
CD-monitored thermal unfolding and differential scanning fluorimetry 
(DSF). In the first method, the CD signal at 222 nm of AGT variants at 10 
µM concentration in 100 mM potassium phosphate buffer, pH 7.4, was 
registered with temperature increasing from 25 to 90 °C at a heating rate of 
1.5 °C/min. PLP dissociation during thermal unfolding of the holoenzymes 
was monitored by measuring the CD signal at 430 nm under the same 
experimental conditions reported above. Calculation of the melting 
temperature (Tm) was carried out by fitting the CD signal either to a two or 
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a three state unfolding model using the Origin Pro7 software according to 
the method of Pace [48]. The rates of PLP dissociation and loss of 
secondary structure at the melting temperature for both AGT-Ma and AGT-
Mi were measured by monitoring the CD signal at 430 and 222 nm with 
time and fitting the data to a single exponential curve. DSF experiments 
were performed with purified AGT variants at 1 µM concentration in 100 
mM potassium phosphate buffer pH 7.4 containing 5X SYPRO orange, 
according to the method of Niessen et al.[49]. Considering the high 
background fluorescence of the holo- and apo-forms of W108R-Mi at 25 
°C, the SYPRO orange final concentration was kept to 2.5X. Proteins were 
subjected to a ramp of 2.15° C/min in a Mastercicle EP Realplex 4 device 
(Eppendorf) at a temperature gradient from 25°C–90°C. Graph generation 
and calculation of Tm were carried out by using the Realplex software. 
 
3.9 Crystallographic studies on the S187F variant 
 
The crystal structure of the S187F-Ma variant was determined in 
collaboration with the group of Prof. Wilmanns at the European Molecular 
Biology Laboratory (EMBL) in Hamburg. Crystals of the S187F-Ma variant 
were obtained by mixing 1 %l of protein at 5 mg/ml concentration with 1 %l 
of a reservoir solution, composed of 0.1 M HEPES, pH 7.5, 0.1 M LiSO4, 
23% (w/w) PEG4000 and by submitting the mixture to hanging drop vapor 
diffusion at 200C. X-ray data were collected at X13 at DORIS III (Doppel-
Ring Speicher) synchrotron radiation storage ring, Hamburg, Germany. 
Data were processed with XDS [50] and scaled with SCALA [51]. 5 % of the 
reflections were randomly selected for cross-validation. The structure of the 
S187F variant was solved by molecular replacement with Phaser [52] using 
normal AGT as starting model (PDB entry: 1H0C) [16]. REFMAC [53] was 
used to refine the initial structural model, applying translation/libration/srew 
parameterization, and including restraints from the non-crystallographic 
symmetry (NCS) between the AGT chains. Manual building and structure 
analysis were carried out in COOT [54]. The structure quality was assessed 
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with MOLPROBITY [55]. Programs of the CCP4 package [56] were used for 
average B-factor calculation, structure manipulation, analysis and validation.  
 
3.10 Molecular modelling studies 
 
Molecular modelling studies were perfomed in collaboration with Dr. 
Alessandro Paiardini from the University of Rome “La Sapienza”. The 
three-dimensional coordinates of the S187F-Ma mutant in the internal 
aldimine form were used as a starting point to generate the external 
aldimine and the PMP bound forms of the enzyme by energy minimization 
means using the BIOPOLYMER package from InsightII (V.2000, MSI, Los 
Angeles, USA). PMP and external aldimine were positioned into the active 
site of S187F-Ma, initially following the binding mode of PLP. Atomic 
potentials, partial and formal charges were defined using the Cff91 
forcefield, and it was verified that the proper values had been assigned. 
Each complex was then subjected to further energy minimization. The 
minimization protocol adopted was based on a multi-step approach: first, all 
atoms except added hydrogens were fixed to allow hydrogens to adjust to 
the atomic environment. To this purpose, 1000 steepest descents steps 
were performed, a distance-dependent dielectric constant and a cut-off 
distance of 40 Å were used during each simulation, until the maximum 
energy derivative was less than 41.8 kJ,mol-1Å-1. Then main-chain atoms 
were fixed and side-chains of every residue comprised in a sphere of 5 Å 
from the coenzyme were subjected to a gradually decreasing tethering 
force (from 4180 kJ,Å-2 to 418 kJ,Å-2) using conjugated gradients, until 
maximum derivative was less than 4.18 kJ,mol-1Å-1. Finally, a decreasing 
tethering force (until the system was totally relaxed) was applied on PMP, 
external aldimine and ketimine, and every side-chain atom comprised in a 
sphere of 5 Å from PLP, using conjugated gradients until the maximum 
derivative was less than 0.0004 kJ,mol-1Å-1. Discover 2.9 and Analysis 
package of InsightII were used for minimization.  
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3.11 Cell culture and lysis 
 
CHO cells were cultured at 37°C under O2/CO2 (19:1) in Ham’s F12 
Glutamax medium (Invitrogen) supplemented with fetal bovine serum (10%, 
v/v), penicillin (100 units/ml) and streptomycin (100 µg/ml). When the cells 
were 70–80 % confluent they were trypsinized, counted and re-seeded into 
6-well plates or 60 mm dishes at a density of 0.3-0.6 ' 106 cells/well 
respectively. After over night incubation at 37(C, cells were transfected with 
Turbofect™ Transfection Reagent (Fermentas) according to the 
manufacturer’s instructions. After 4 hours from transfection cell were 
washed in phosphate buffered saline (PBS) and the medium was changed 
with complete Ham’s F12. Where indicated, 100 µM pyridoxine was added 
to the medium. Transfection experiments were designed to minimize the 
variability introduced by transfection efficiency, which was controlled by co-
transfection with pmaxGFP (Lonza), and only transfections with variability ) 
10% were used. Except where indicated, cells were harvested after 24 
hours and lysed in phosphate saline buffer (PBS), pH 7.2, plus protease 
inhibitor cocktail (Complete Mini, Roche), by five freeze/thaw cycles 
followed by treatment with DNAse (1 unit) at RT for 45 min. The whole cell 
extract was separated by centrifugation (29200 g, 10 min, 4°C) to obtain 
the soluble fraction. The pellets were then resuspended in an equal volume 
of denaturing gel loading buffer to obtain the insoluble fraction. The total 
protein concentrations in the cell lysate and/or in the soluble fraction, was 
measured using the Bradford protein assay. 
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3.12 Transcript expression analysis 
CHO cells were grown in a 6-well plate and transfected using Turbofect 
(Fermentas) as described above. Cells were harvested, washed with PBS, 
and RNA was extracted using RNeasy mini kit (Qiagen). The cDNA was 
synthetized from 1 µg of mRNA using the Supersctipt VILO cDNA 
synthesis kit (Invitrogen, Carlsbad, CA) according to manufacturer’s 
instructions. Real-time PCR was performed using 3 µl of a 1:10 cDNA 
dilution in a 25 µl reaction volume using SYBR Premix Ex Taq master mix 
(TaKaRa) on a Corbett RotorGene 6000 thermocycler. The reaction 
conditions were initial denaturation at 95°C for 15 min followed by 45 
cycles of PCR which included 15 sec melting at 95°C, 30 sec annealing at 
55°C and 30 sec extension at 72°C. The samples were examined for the 
expression of human AGT using the forward primer 5’-
AGCCCAGGATGTACCATCAC-3’ and the reverse primer 5’- 
GCCACCCATGATCTCAATGTC-3’. The amount of the AGT-Ma, AGT-Mi 
and G161 variants mRNA was calculated in relation to the glyceraldehyde 
3’-phosphate dehydrogenase (GAPDH) mRNA in the same sample. 
Quantitation of individual transcripts was performed using the ‘Comparative 
Quantitation’ software supplied by Corbett Research for the RotorGene. 
The mean efficiency of a group of cycling curves is calculated at the point 
that the cycling curves take off and used to calculate a fold change 
according to the formula: fold change = efficiency Ct1–Ct2, where Ct1 and 
Ct2 are the take off values of the cycling curves being compared. All 
reactions were performed in duplicate.  
 
 
3.13 Western blotting analysis and chemical cross-linking 
 
10 µg of cell lysate were loaded per lane on a Mini Protean TGXTM pre-cast 
gel (Biorad) along with Precision plus protein Kaleidoscope™ (Bio-Rad) as 
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molecular mass markers. Following transfer on a nitrocellulose membrane 
by the iBlot device (Invitrogen) the membrane was blocked in 5% bovine 
serum albumin (BSA) for 1 h at 37°C. For AGT detection the membrane 
was incubated with polyclonal rabbit anti AGT serum (dilution 1:2000), 
washed three times in TBST (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% 
Tween 20) and then incubated with peroxidase-conjugated anti rabbit IgG 
(dilution 1:1000). Blotted proteins were detected and quantified with ECL® 
(Millipore), using the ChemiDoc XRS Imaging System (Bio-Rad, Hercules, 
CA). 
Cross-linking was performed with bis-N-succinimidyl-(pentaethylene 
glycol)ester, BS(PEG)5 (Pierce). Cells were lysed as described above, then 
25 µl of the whole lysate at 1 mg/ml total protein concentration was cross-
linked with BS(PEG)5 at fifty molar excess (1.25 mM final concentration), 
and quenched in 50 mM Tris–HCl after 30 min. 10 µg of each samplewere 
analysed by western blotting as above. 
 
 
3.14 Pulse-chase experiments 
 
Two million cells were seeded in a 10 cm dish and transfected with the 
pcDNA3.1 vectors encoding AGT-Ma, AGT-Mi, G161R-Ma, G161S-Mi or 
G161C-Mi. After 24 hours cells were incubated for 1 hour in Dulbecco's 
Modified Eagle Medium (DMEM) without methionine and cysteine (Gibco) 
and pulse labelled with 50 µCi of 35S methionine/cysteine (EasyTagTM 
EXPRESS 35S Protein Labeling Mix, [35S], Perkin Elmer). After 30 min an 
excess of unlabelled aminoacids was added and cells were split and 
incubated in Ham’s F12 medium for chase periods from 4 to 48 hours. The 
soluble fraction of each cell lysate (50 µg) was incubated over night with 2 
µg of guinea-pig anti-AGT antibody on a rotator at 4°C. Thereafter, the 
immunoprecipitation reaction was performed at room temperature by 
adding 30 µl of agarose-protein A (GE, Healthcare) to the mixture and by 
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incubating the solution for 1 h on a rotator at room temperature. The 
immunoprecipitated complex was pelleted by centrifugation at 29200 g at 4 
°C for 5 min, washed three times with IP wash/lysis buffer (Thermo 
Scientific), and resuspended in 20 µl of denaturing gel loading buffer. 
Proteins were separated by SDS-PAGE and radiolabelled AGT was 
detected by autoradiography. 
 
3.15 Gel filtration analyses 
 
9 x 106 of CHO cells were transfected with the vector encoding AGT-Ma or 
the G161R-Ma variant. 24 hours after transfection cells were harvested and 
lysed in 500 µl of PBS as previously described. Lysates were than loaded 
onto a Superdex S200 H10/30 column (GE Healtcare) equilibrated in PBS 
plus 1mM EDTA, 1 mM EGTA and 1 mM DTT. 20 % (v/v) trichloroacetic 
acid (TCA) was added to each eluted fraction and the samples were 
incubated overnight at 4°C. After centrifugation at 16000 g for 30 min, the 
precipitated protein was washed twice in PBS and resuspendend in 20 µl of 
denaturing gel loading buffer 1X. 10 µl of each sample were separated by 
SDS-PAGE and immunoblotted against anti-AGT. 
 
 
3.16 Immunoflurescence studies 
 
CHO cells were grown and transfected in a 24-well plate on glass 
coverslips. 24 hours after transfection CHO cells were fixed in 4% (w/v) 
paraformaldehyde, permeabilized with 0.3% Triton X-100 in phosphate 
buffer saline (PBS), and blocked in 3% bovine serum albumin (BSA). For 
the immunolabelling, rabbit polyclonal anti-human AGT and anti-
peroxisomal protein form guine-pig were used as primary antibodies, and 
Alexa Fluor conjugated antibodies (AF488 and AF555, Life technologies) 
were used as secondary antibodies. Mitochondria were stained with 
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Mitotracker Red (CMXRos version, Molecular Probes, Invitrogen) and 
nuclei with DAPI. The coverslips were mounted over slides in AF1 medium 
(Dako). The images were captured using a confocal laser-scanning 
fluorescence microscope (Leica Microsystem, Manheim, Germany) at 63' 
magnification and processed using Adobe Photoshop and ImageJ software 
(Rasband, W.S., ImageJ, U. S. National Insti- tutes of Health, Bethesda, 
Maryland, USA, http://rsb.info.nih.gov/ij/, 1997–2008). 
 
 
3.17 Immunoelectron microscopy 
 
Immunoelectron microscopy (IEM) analysis of AGT distribution were 
perfotmed in collaboration with Dr. Polishchuck of the Telethon Institute of 
Genetics and Medicine (TIGEM), Naples. The cells were fixed for 2 h in a 
mixture of 4% paraformaldehyde and 0.4% glutaraldehyde in 0.2 M PHEM 
buffer (60 mM Pipes, 25 mM Hepes, 10 mM EGTA, 2 mM MgCl2 pH 6) and 
washed with a PBS-glycine solution. After washing, cells were detached 
from the dishes, pelleted and embedded in 10% gelatin, cooled in ice and 
cut into 1-mm3 blocks. The blocks were infused with 2.3 M sucrose at 4°C 
overnight and frozen in liquid nitrogen. Ultrathin cryosections were cut 
using a Leica EM FC7 cryoultratome and picked up using a 1:1 mix of 2% 
methylcellulose and 2.3 M sucrose. Sections were mounted on formvar 
carbon-coated copper grids, and the localization of AGT in the cryosections 
was analyzed using the rabbit polyclonal anti-human AGT followed by 
protein A conjugated with 10 nm gold particles. After labeling, the 
cryosections were embedded in methylcellulose–uranyl acetate mixture. 
Cryosections were further investigated using a FEI Tecnai-12 electron 
microscope (FEI, Einhoven, The Netherlands) equipped with an Veletta 
CCD camera for digital image acquisition. 
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3.18 Statistical analysis 
 
Experiments have been performed in triplicate and in any case the 
standard error mean (SEM) was less than 10%. Statistic analysis was 
performed with Origin® 7.03 (Origin Lab) or GraphPad Prism Version 5.0 
(GraphPad software, San Diego, CA, USA). 
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Impact of nine mutations associated with PH1 on the 
biochemical properties of AGT 
 
Up to now, the effects of most missense mutations on the AGXT gene 
leading to PH1 have been defined by measuring the AGT transaminase 
activity (expressed as specific activity) and/or the protein expression level 
in patient liver samples, crude cellular extract or cell-free expression 
systems [26, 32-35, 43, 57]. However, in the case of mutations that reduce both 
the specific activity and the expression level of AGT, this approach does 
not allow to assess if the mutation exerts a structural and/or a functional 
effect on the protein. In the last years, our research group has carried out a 
detailed biochemical and bioinformatics characterization of several 
pathogenic variants in the recombinant purified form[18, 29, 39, 40, 46]. These 
studies have allowed not only to define the molecular defect associated 
with each pathogenic mutation, but also to predict the responsiveness to 
the pyridoxine therapy of the patients bearing the examined mutations. 
Thus, the definition of the defect of as many as possible AGT variants at 
molecular level would be highly desirable. To this aim, we decided to 
elucidate the molecular basis underlying AGT loss of function in a subset of 
nine pathogenic variant spread over the structure of AGT. We chose four 
pathogenic variants in which the mutated residues are located in the large 
domain of AGT either within the active site and interacting with the 
coenzyme or in its proximity (W108R-Mi, S158L-Ma, D183N-Ma and 
S218L-Ma) (Fig.6A), and five pathogenic variants in which the mutated 
residues are far from the active site either in the large or in the small 
domain (G161S-Mi, G161C-Mi, S187F-Ma, P319L-Ma and G350D-
Mi)(Fig.6B). 
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Figure 6: 3D representations of the AGT structure (PDB file 1H0C). (A) The AGT active site. 
PLP is represented as yellow sticks. Residues directly interacting with PLP are represented 
as dark grey sticks or, if their mutation is analyzed in this study, as orange sticks. Ser218 is 
represented as magenta sticks. The dotted lines indicate possible hydrogen bond 
interactions.  (B) Overall structure of the AGT dimer. One monomer is coloured grey, while 
in the opposite monomer the N-terminus, the large domain and the small domain are 
coloured magenta, blue and green, respectively. PLP is represented as yellow sticks. Pro11 
and Ile340 are represented as red sticks, while Gly161, Ser187, Pro319 and Gly350 are 
represented as magenta sticks. The figure was rendered using PyMol[17]. 
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4.1 In silico analyses 
In order to predict the possible local effect of each pathogenic mutation on 
the structure of AGT, we carried out a first inspection of the AGT-Ma crystal 
structure and performed in silico mutagenesis studies using the software 
PyMol[17]. The results of these analyses indicate that: 
! the W108R, S158L and D183N mutations affect residues directly 
interacting with the coenzyme. Thus, they could have a functional 
effect on AGT by possibly altering the binding of the coenzyme 
and/or the catalytic activity of the enzyme. 
! the S218L mutation involves an active site residue that does not 
directly interact with the coenzyme, but might be involved in the 
proper positioning of helix 4 that also comprises Gly82, a residue 
hydrogen-bonded to the PLP phosphate. Thus, the Ser218-to-Leu 
mutation is predicted to have a local structural effect on the large 
domain, possibly resulting in the distortion of the coenzyme binding 
cleft. 
! the G161S, G161C and S187F mutations involve residues located 
in the large domain far from the active site. Gly161 is located 
between the large and the small domain and its substitution is 
supposed to alter intradomain contacts. Ser187 is located in a 
random coil region on the re side of the coenzyme and its mutation 
is supposed to indirectly affect the large domain/small domain 
contacts by possibly changing the positioning of the loop 154-169. 
! the P319L and G350D mutations involve residues located in two 
random coil regions of the small domain. Both mutations are 
supposed to cause a structural effect limited to the small domain. In 
the case of the P319L mutation, the effect is due to the 
mispositioning of helix 11 on the surface of the protein, while in the 
case of the G350D mutation, it is due to the induction of steric 
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clashes in the small domain. In particular, the G350D mutation 
changes the conformation of the loop 343–357 at the entrance of 
the AGT active site, thus possibly affecting substrate binding.   
 
4.2 Expression and purification of the AGT variants 
Bacterial expression vectors encoding for the selected pathogenic variants 
were constructed by site-directed mutagenesis starting from the minor or 
the major allele of AGT according to the actual genotype of PH1 patients in 
whom each mutation was identified. The nine variants were expressed E. 
coli and purified to homogeneity, as indicated by a single band on SDS-
PAGE at an apparent molecular weight of about 45 kDa (data not shown), 
by a previously developed protocol[18]. As compared with AGT-Ma and 
AGT-Mi, all the variants were present in good amounts in the soluble 
extract with the exception of Gly161 variants whose yield is about 10% that 
of AGT-Ma or AGT-Mi.  
 
4.3 Impact of the mutations on the AGT secondary and quaternary 
structure  
To study the impact of the examined pathogenic mutations on the 
secondary structure of AGT we registered the far-UV CD spectrum of the 
variants in their apo-form. Since no significant differences were observed 
between the spectra of the variants and that of apoAGT-Ma or apoAGT-Mi, 
it can be concluded that the mutations do not change the secondary 
structure composition of AGT. Moreover, in order to investigate the effect of 
each mutation on the dimeric structure of the enzyme, the molecular 
dimensions of the variants in both their holo- and the apo-form have been 
determined by DLS. For each protein, a peak with a size ranging from 9.2 
to 10.8 nm, corresponding to that of a dimer, could be seen. Considering 
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that the intensity of the DLS signal is a function of the sixth power of a 
particle diameter, the dimer must be the most abundant species in solution, 
thus indicating that the mutations do no exert any major effect on the 
quaternary structure of AGT. However, the presence of low amounts of 
small aggregates (100-400 nm) could be noticed for W108R-Mi, S218L-Ma, 
S187F-Ma, G161S-Mi, G161C-Mi and G350D-Mi in both holo- and apo-
forms as well as for G350D-Mi in the apo-form (data not shown). 
Altogether, these data indicate that the nine examined mutation do not alter 
the gross conformation of AGT and do not prevent the formation of a 
dimeric structure.  
 
4.4 Impact of the mutations on PLP binding 
To study the impact of the analysed PH1-causing mutations on the 
coenzyme binding affinity of AGT, the KD(PLP) of each variant has been 
determined and compared with those previously determined for AGT-Ma 
and AGT-Mi[18, 39] .  
From the results reported in Table 4 it can be observed that while G161C-
Mi, G161S-Mi, P319L-Ma and G350D-Mi display an unaltered or even 
increased affinity for PLP, W108R-Mi, S158L-Ma, D183N-Ma and S218L-
Ma, even if to a different extent, show a significantly reduced affinity for the 
coenzyme. This could be explained by considering that the residues 
Trp108, Ser158, Asp183 and Ser218 directly interact with the cofactor. In 
the case of the S187F-Ma variant, we could only estimate an upper limit 
value for the KD(PLP) of 0.01 µM, because the lowest protein concentration 
required for fluorescence experiments far exceeds the KD(PLP) value. 
However, it is possible to conclude that the S187F mutation causes an at 
least 27-fold increment of the affinity for PLP. 
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Table 4: Equilibrium dissociation constants for PLP (KD(PLP)) and optical activity values of 
AGT-Ma, AGT-Mi and the pathogenic variants. 
 
 
 
 
 
 
 
 
 
 
      
             afrom ref [18] 
              bfrom ref[39] 
 
In all the PLP-dependent enzymes, the binding of the coenzyme to the 
apoenzyme gives rise to both absorbance and CD signals in the visible 
region of the spectra. In particular, as previously described, the binding of 
PLP to AGT gives rise to a 420 nm absorbance band, associated with a 
positive CD signal, and a 340 nm band, associated with a negative dichroic 
signal, attributed to the ketoenamine and enolimine tautomers of the 
internal aldimine, respectively. The optical activity, which is the ratio 
between the millidegrees and the absorbance values at 420 nm and gives 
Enzymatic 
species 
KD(PLP) (µM) Optical activity 
AGT-Ma 0.27 ± 0.03a 97 mdeg/Abs 420nma 
AGT-Mi 0.26 ± 0.02b 97 mdeg/Abs 420nmb 
W108R-Mi 96  ± 19 4.73 mdeg/Abs 434nm 
S158L-Ma 272 ± 47 45 mdeg/Abs 430nm 
G161S-Mi 0.46 ± 0.07 66 medeg/Abs 430nm 
G161C-Mi 0.56 ± 0.09 57 mdeg/Abs 414nm 
D183N-Ma 2.1 ± 0.1 84 mdeg/Abs 430nm 
S187F-Ma < 0.01 103 mdeg/Abs 414nm 
S218L-Ma 24.2 ± 0.1 31 mdeg/Abs 428nm 
P319L-Ma 0.19 ±0.04 88 mdeg/Abs 420nm 
G350D-Mi 0.031 ± 0.005 88 mdeg/Abs 420nm 
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information about the coenzyme microenviroment, is 97 mdeg/Abs 420 
nm[18] for both AGT-Ma and AGT-Mi. Figure 7 shows the UV-visible CD 
spectra of the variants at 10 µM protein concentration in the presence of 
saturating coenzyme. The optical activity values (expressed as 
millidegrees/absorbance at 410-430 nm) are reported in Table 4.  
It can be observed that only the W108R, G161S, G161C, S158L and 
S218L mutations change the microenvironment of the internal aldimine. In 
the case of the W108R, S158L and S218L mutations, this result is in line 
with the increased KD(PLP) value and it can be understood considering that 
the mutated residues are located at or near the AGT active site. More 
difficult is to explain the change of the active site microenvironment caused 
by the Gly161 mutations. One could argue that the mutation of Gly161 
could cause some structural perturbations that indirectly affect the active 
site. Moreover, it is worth noting that the absorbance and dichroic band of 
the ketoenamine tautomer of the internal aldimine of the S187F-Ma variant 
is 6 nm blue shifted as compared to that of AGT-Ma. This finding, together 
with the increment of at least 27-fold in the coenzyme binding affinity, 
suggests that, although the mutation does not alter the optical activity value, 
it may induce some local structural changes at the AGT active site (chapter 
5.1).  
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Figure 7: CD spectra of AGT-Ma, AGT-Mi and pathogenic variants. (A) CD spectra of AGT-
Ma (black), S158L-Ma (red), D183N-Ma (blue), S187F-Ma (violet), S218L-Ma (green) and 
P319L-Ma (orange).(B) CD spectra of AGT-Mi (black), W108R-Mi (green), G161C-Mi 
(fucsia), G161S-Mi (blue) and G350D-Mi (orange). All CD spectra are registered in the 
presence of saturating PLP concentrations in 100 mM potassium phosphate buffer, pH 7.4, 
at an enzyme concentration of 9 µM.  
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4.5 Impact of the mutations on the enzymatic activity for the overall                           
transamination of the alanine-glyoxylate pair 
 
In order to define if and how each mutation affects the AGT catalytic activity, 
the steady-state kinetics parameter for the overall transamination of the 
alanine/glyoxylate pair were measured for each variant (Table 5).  
Comparing the catalytic efficiency of the variants with those of AGT-Ma or 
AGT-Mi is possible to observe that, [33, 43, 58]: (i) the W108R-Mi, S158L-Ma, 
D183N-Ma, S187F-Ma, S218L-Ma and G350D-Mi variants display a 
reduced catalytic activity, (ii) the G161C-Mi, G161S-Mi and P319L-Ma  
variants display an enzymatic activity comparable to that of AGT-Ma or 
AGT-Mi. While in most cases the reduced specific activity is due to a 
decreased kcat value, in the G350D-Mi variant it is due to an increased Km 
value for L-alanine. It is reasonable to suggest that, the reduced catalytic 
efficiency of the D183N-Ma variant is due to the role of Asp183 in AGT in 
stabilizing the positive charge at N(1) of PLP, in analogy with what 
observed for Asp222 in E. coli aspartate aminotransferase[59]. The finding 
that the mutation of Trp108, Ser158, or Ser218 causes a reduction of the 
AGT catalytic activity can be understood by considering that these residues 
are part of the active site of the enzyme or are located nearby, and that the 
spectroscopic studies reported below (chapter 4.4) have indicated the 
presence of alterations of the active site microenvironment for the W108R-
Mi, S158L-Ma and S218L-Ma variants. 
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Table 5: Steady-state kinetic parameters of AGT-Ma, AGT-Mi and pathogenic variants for 
the alanine-glyoxylate pair. 
 
Enzymatic 
species Substrate 
Co-
substrate 
kcat 
Km L-
alanine 
Km Glyoxylate kcat/Km 
(s-1) (mM) (mM) (s-1/mM-1) 
AGT-Maa A G 45 ± 2a 31 ± 4a  1.4 ± 0.2
a 
  G A 45 ± 2a  0.23 ± 0.05
a 196 ± 4a 
AGT-Mia A G 33 ± 5b 28 ± 2b  1.2 ± 0.2
b 
  G A 37 ± 1  0.22 ± 0.01
b 168 ± 8b 
W108R-Mi A G 0.0013±0.0003 36 ± 3  0.00004±0.00001  
  G A n.d.  n.d. n.d..  
S158L-Ma A G 0.41 ± 0.03 25 ± 6  0.016 ± 0.001 
  G A 0.41 ± 0.04  0.35 ± 0.09 1.2± 0.3 
G161S-Mi A G 55 ± 2 70 ± 9  0.8 ±0.1 
  G A 58 ± 2  0.63 ± 0.07 92 ± 2 
G161C-Mi A G 36.1 ± 0.7 103 ± 6  0.35 ± 0.02 
  G A 36.6 ± 0.7  0.21 ± 0.02 174 ±  1 
D183N-Ma A G 0.008 ± 0.003 140 ± 17  0.00006 ± 0.00001 
  G A n.d.  n.d. n.d. 
S187F-Ma A G 0.13 ± 0.01 12 ± 2  0.0108 ±0.0002 
  G A 0.12 ± 0.01  0.13 ± 0.04 0.92 ± 0.09 
S218L-Ma A G 2.7 ± 0.1 29 ± 6  0.09 ± 0.02 
  G A 2.95 ± 0.08  0.19± 0.02 15 ± 2 
P319L-Ma A G 27.5 ± 0.8 44 ± 5  0.63 ± 0.01 
  G A 26.2 ± 0.7  0.11 ± 0.02 238 ± 44 
G350D-Mi A G 15.0 ± 0.7 328 ± 51  0.046 ± 0.007 
  G A 15 ± 1   0.29 ± 0.04 52 ± 7 
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A, L-alanine; G, glyoxylate; n.d., not determined because the rate of glyoxylate half-
transamination is comparable to that of PMP dissociation/PLP association at sub-saturating 
glyoxylate concentrations; a from ref [18], b from ref [39]. 
 
 
More difficult is to explain the effect on the AGT catalytic activity of the 
mutation of Ser187 or Gly350, two residues located far from the active site. 
The fact that the S187F-Ma variant displays a higher affinity for PLP and a 
different coenzyme binding, as compared with AGT-Ma, make it possible to 
hypothesize that this mutation causes some structural rearrangements that 
affect the active site topology. In the case of the G350D-Mi variant, the in 
silico mutagenesis studies have shown that the G350D mutation changes 
the conformation of the loop 343-357 at the entrance of AGT active site, 
thus possibly affecting substrate binding. 
 
4.6 Impact of the mutations on the thermal stability of the variants in 
the holo-form. 
Protein thermal unfolding, is widely used to study the stability of a protein. 
To investigate whether the analysed PH1-associated mutations could affect 
the stability of AGT, the thermal denaturation process of each variant in the 
holo-form has been studied by monitoring both the decrease of the dichroic 
signal at 222 nm and 430 nm, which are indicative of the loss of the protein 
secondary structure and of the PLP-bound content, respectively, and the 
signal on different scanning fluorimetry (DSF), a technique that allows to 
measure the exposure of hydrophobic groups during unfolding. In Table 6 
have been reported the Tmholo values, derived from the loss of the 222 nm 
CD signal and DSF measurements, and the TmPLP, derived from the loss of 
the 430 nm CD signal, for AGT-Ma, AGT-Mi and the pathogenic variants in 
the holo-form. 
By analyzing the AGT-Ma and AGT-Mi thermal unfolding process (Fig. 8), it 
can be observed that both species are denatured and release PLP in a 
single-step process with melting temperatures of 78°C and 74°C, 
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respectively. Moreover, the rate of PLP release is higher than that of global 
unfolding, as shown by the kinetics of the 222 nm and 430 nm signal 
changes at the melting temperature. In fact, while the rate constants of the 
loss of the 430 nm dichroic signal are 0.0042 ± 0.0001 s-1 and 0.0057 ± 
0.003 s-1, those of the loss of the 222 nm dichroic band are 0.0024 ± 
0.0001 s-1 and 0.0021 ± 0.001 s-1, for AGT-Ma and AGT-Mi, respectively. 
Additionally, the irreversible binding of the coenzyme, by NaBH4-reduction 
of the Schiff base linkage, increases the thermal stability of both enzymatic 
species, as shown by the increase in the Tmholo of 7°C and 5°C for AGT-Ma 
and AGT-Mi, respectively.  
 
 
Figure 8: Far-UV CD-monitored heating scans of holoAGT-Ma and holoAGT-Mi. Far-UV CD 
changes of holoAGT-Ma (black curve, straight line) and holoAGT-Mi (grey curve, straight 
line) in the presence of 10 %M exogenous PLP. The enzyme concentration was 10 %M, and 
the buffer was 100 mM potassium phosphate, pH 7.4.  
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Altogether, these data indicate that: (i) the two amino acid substitutions 
typical of the minor allele (P11L and I340M) reduce the AGT thermal 
stability, in agreement with the results previously obtained by differential 
scanning calorimetry[40] and thermal inactivation[29] experiments, (ii) AGT-Mi 
displays a lower local stability of the PLP binding site with respect to AGT-
Ma, in line with the higher sensitivity to urea stress of the PLP-bound state 
of AGT-Mi previously reported[29], and (iii) a conversion from the holo- to the 
apo-form occurs during the AGT thermal unfolding, thus suggesting that the 
Tmholo values are affected by the sensitivity of the AGT active site to thermal 
stress. 
 
Table 6: Tmholo and TmPLP values of AGT-Ma, AGT-Mi and pathogenic variants 
 
a they represent apparent Tm values and are the mean of two independent experiments. The 
error is within ± 0.3 °C. 
 
On these bases, it is possible to conclude that only the W108R-Mi, S158L-
Ma, G161C-Mi, G161S-Mi and S218L-Ma variants show a reduced 
sensibility of the active site to the thermal stress. In this regard, it is worth 
Enzymatic species 
Tmholoa(°C) 
CD 222 nm 
TmPLPa(°C) 
CD 420nm 
Tmholoa(°C) 
DSF 
AGT-Ma 77.5 78 78.6 
AGT-Mi  73.6  73.6 74.1 
W108R-Mi 54.1  53.4 53.9 
S158L-Ma 67 64 64.7 
G161S-Mi 62.5  62.8 61.8 
G161C-Mi 64  64.2 63.8 
D183N-Ma 80.8  79.6 80.1 
S187F-Ma 76.7 74.4 73.6 
S218L-Ma 57.8 57.9 56 
P319L-Ma 77.9  76.3 77.5 
G350D-Mi 73.5  73.7 72.6 
                                                                                   Results and discussion 
! '$!
noting that the variants W108R-Mi and S218L-Ma show the most 
pronounced alteration with Tmholo of 54° and 57°C, respectively. However, it 
has been shown that the W108R-Mi variant displays a considerably high 
(~10-fold) ground state fluorescence signal at 25°C in comparison with 
AGT-Mi, thus suggesting that the variant is characterized by an increased 
hydrophobicity even in the absence of a thermal stress. More difficult is to 
explain the great destabilization induced by the S218L mutation on 
holoAGT-Ma. Although it can be speculated that the mutation could induce 
a conformational change that makes the protein more susceptible to 
unfolding at high temperature, further studies on the folding/unfolding 
pathway of the S218L-Ma variant would be required. 
 
 
4.7 Impact of the mutations on the thermal stability of the variants in 
the apo-form 
To define the impact of the examined pathogenic mutations on the intrinsic 
stability of AGT we investigated the thermal stability of the apo-forms of 
AGT-Ma, AGT-Mi and the variants through far-UV CD and DSF 
experiments.  
Fig. 9 shows the thermal unfolding profiles of apoAGT-Ma and apoAGT-Mi. 
Both species display a two-phases unfolding profile, in which the first phase 
is characterized by a melting temperature (Tm1apo) of 61°C and 53°C for 
AGT-Ma and AGT-Mi, respectively, and the second phase is characterized 
by a melting temperature (Tm2apo) of 66°C for both AGT-Ma and AGT-Mi.   
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Figure 9: Far-UV CD-monitored heating scans of apoAGT-Ma and apoAGT-Mi. Far-UV CD 
changes of apoAGT-Ma (black curve, straight line) and apoAGT-Mi (grey curve, straight 
line). The enzyme concentration was 10 %M, and the buffer was 100 mM potassium 
phosphate, pH 7.4.  
 
On the basis of these data, several considerations can be drawn. First, the 
fact that both Tm1apo and Tm2apo are lower than the corresponding Tmholo 
indicate that, in agreement with previous data[29, 30], AGT-Ma and AGT-Mi in 
the apo-form are significantly less stable than the corresponding holo-forms. 
It can be suggested that the coenzyme PLP, located at the interface 
between the two subunits of AGT, could increase the thermal stability of the 
protein by stabilizing its dimeric structure. Second, the presence of two 
transitions in the apoenzymes, as opposed to the single transition of the 
holoenzymes, suggests that the large and the small domain unfold in a 
concerted and cooperative way in the holo-forms, while they appear to be 
differentially stabilized in the apo-forms. Considering that PLP makes 
                                                                                   Results and discussion 
! '&!
several contacts only with the large domain, it can be speculated that in the 
apoenzymes the large domain could be less stable than the small one. 
Following this view, it is possible to describe the three state model of 
thermal denaturation of apoAGT as a process in which the low-temperature 
transition represents the unfolding of the large domain while the high-
temperature transition represents the unfolding of the small domain. Third, 
the apo-form of the minor allele is less stable than the apo-form of the 
major allele probably as a consequence of a lower stability of the large 
domain, as shown by the ~8°C reduction of the Tm1apo. Previous reports 
have suggested that the reduced stability of AGT-Mi might depend on a 
distortion of the N-terminal arm of the protein caused by the P11L 
substitution[16]. Since the N-terminal arm wraps over the surface of the 
opposite subunit that interacts with the large domain, the distortion of the 
N-terminus caused by the P11L polymorphic mutation could specifically 
destabilize the large domain of AGT, thus explaining why the effect of the 
polymorphic mutations is limited to the Tm1apo.   
Table 7 shows the melting temperatures of each of the examined 
pathogenic variants in the apo-form. ApoS158L-Ma and apoD183N-Ma 
variants unfold in a single step process with a Tmapo value similar to or 
higher than that of the high-temperature transition of AGT-Ma, thus 
indicating that the large domain mutations S158L and D183N do not 
decrease the AGT stability. ApoG161S-Mi, apoG161C-Mi and apoS187F-
Ma are characterized by a single thermal transition with a mid-point 
temperature lower than the Tm1apo of apoAGT-Ma and apoAGT-Mi, thus 
allowing to conclude that these large domain mutations cause a 
destabilizing effect not limited to the large domain but extended to the small 
domain. 
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Table 7: Tmapo values of AGT-Ma, AGT-Mi and pathogenic variant 
 
a they represent Tm values and are the mean of two independent experiments. The error is 
within ± 0.3 °C. 
 
 
These findings are consistent with in silico analyses indicating that Gly161 
is located at the interface between the large and the small domain, and that 
the bulky hindrance of the side chain of phenylalanine at position 187 could 
cause a mispositioning of the loop 154-168 involved in interdomain 
interactions. ApoW108R-Mi and apoS218L-Ma unfold in a two steps 
process in which both transitions are left shifted and Tmapo values are lower 
than those of AGT-Ma and AGT-Mi. These data suggest that the mutations 
not only exert destabilizing effects of the large domain, in which they are 
located, but also influence the structural stability of small domain. The 
finding that apoW108R-Mi shows a single Tm similar to the Tm2apo of AGT-Mi 
on DSF analyses could be explained considering that this apovariant has a 
ground state fluorescence 100-fold higher than that of apoAGT-Mi, due to 
an increased hydrophobicity of the protein possibly caused by a partial 
 
Enzymatic 
species 
Tm1apoa (°C) 
CD 222 nm 
Tm2apoa (°C) 
CD 222 nm 
Tm1apoa (°C)  
DSF 
Tm2apoa 
(°C) DSF 
AGT-Ma 61.1  66.4 61.9 67.3 
AGT-Mi 53.1  66 54.2 66.5 
W108R-Mi 48.9  54  53.3 
S158L-Ma 65.9   64.3  
G161S-Mi 46.8  46.5  
G161C-Mi 51.1   51.3  
D183N-Ma 70.2   70.3  
S187F-Ma 48.2  45.3  
S218L-Ma 50.9  57.8 47.2 55.7 
P319L-Ma 61.6  60.1  
G350D-Mi 53.6   52.5  
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unfolding, which could cover the signal of the first transition in DSF 
experiments. Finally, the P319L and the G350D mutations in the small 
domain cause a complete loss of the Tm2apo without affecting the Tm1apo, 
thus indicating that these mutations affect only the stability of the domain in 
which they are located. 
 
4.8 Identification of the major defect of the AGT pathogenic variants 
On the basis of previous analyses performed on crude lysates[26, 32-35, 37, 43, 
57, 60], all the examined pathogenic mutations causing PH1 were classified in 
the group comprising mutations leading to a reduction of both enzymatic 
activity and expression level. The biochemical characterization of the AGT 
pathogenic variants in their recombinant purified holo- and apo-form, by 
clarifying the various effects caused by each mutation on the protein, and 
allow us to define the major defect of each pathogenic variant (Table 8). In 
particular: 
1. The D183N-Ma variant is characterized only by a functional defect 
that consists in a reduced catalytic activity and PLP binding affinity.  
2. The G161S-Mi, G161C-Mi and P319L-Ma variants are 
characterized only by a structural defect.  While the mutations 
associated to Gly161 cause the destabilization of both the holo- and 
the apo-form of the protein, the P319L mutation appears to cause 
the structural defect only on the apoenzyme. 
3. The W108R-Mi, S158L-Ma, S187F-Ma, S218L-Ma and G350D-Mi 
variants are characterized by both a structural and a functional 
defect.   
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Table 8: Major defect(s) of AGT pathogenic variants analysed on recombinant purified 
proteins 
 
 
AGT 
variants 
PLP binding 
affinity 
PLP 
binding 
mode 
Specific 
activity 
Tmholo 
and 
TmPLP 
Tmapo Defect 
W108R-Mi - - - A - - - - - - - - - 
functional 
and 
structural 
S158L-Ma - - - A - - - - - - + 
functional 
and 
structural 
G161S-Mi - A               - - - - - - - 
 
structural 
G161C-Mi -  A - - - - - - - structural 
D183N-Ma - - - S A - - - + - functional 
S187F-Ma + + + U - - -  U + + + 
functional 
and 
structural 
S218L-Ma - - - A - - - - - - - - - 
functional 
and 
structural 
P319L-Ma +  S A - U - structural 
G350D-Mi + + + S A - - - U - - - 
functional 
and 
structural 
--- decreased, - slightly decrease, +++ increased, + slightly increased, U 
unaltered, A altered and S slightly altered. 
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On the basis of these results, possible therapeutic approaches for patients 
bearing the examined mutations can be suggested. In particular, B6 
supplementation is expected to be beneficial for patients carrying the 
G161C and G161S mutations on the minor allele as well as the P319L on 
the major allele. Since the major impact of these mutations is on the 
thermostability of the apo-form of AGT, the coenzyme is expected to shift 
the equilibrium toward the holo-form. In the case of patients bearing the 
G350D mutation on the minor allele, a combination of L-alanine and 
pyridoxine could be suggested to overcome the reduced affinity for the 
substrate and the reduced thermal stability of the apo form. 
Again, the administration of molecules acting as chemical chaperones 
could be effective for patients harbouring the S218L mutation on the major 
allele, considering that the S218L-Ma variant has a reduced thermal 
stability in both the holo and the apo form and retains a significant specific 
activity. On the other hand, no suggestions can be advanced for a 
pharmacological treatment of patients carrying the W108R mutation on the 
minor allele or the S158L, D183N and S187F mutations on the major allele. 
 
 
 
 
 
 
 
 
 
                                                                                   Results and discussion 
!(+!
The biochemical characterization of the AGT variants in their purified form 
has indicated that the S187F-Ma and the Gly161 variants display a peculiar 
behaviour. In fact, although Ser187 is far from the active site, it’s mutation 
to Phe affects the AGT functional properties. On the other and, the 
mutation of Gly161 does not affect the enzyme catalytic activity and the 
PLP binding but strongly reduces the protein thermal stability. Thus to shed 
light on the molecular defect of S187F-Ma, G161R-Ma, G161S-Mi and 
G161C-Mi, a more detailed characterization of the effects of the Ser187 
and Gly161 mutation has been undertaken. 
 
Impact of the S187F mutation on the structural 
properties of AGT 
 
The C*T mutation at position 682 in the major allele of the AGXT gene, 
leading to the S187F amino acid substitution, has been initially found in a 
PH1 patient showing less than 1% AGT catalytic activity with respect to 
normal subjects as well as the nearly complete loss of AGT 
immunoreactive protein in liver biopsy. The genetic analysis revealed that 
the patient was heterozygous for the mutation, with the allele bearing the 
C682*T mutation producing an mRNA of normal size and abundance, 
while the other allele did not produce detectable amounts of mRNA[34].  
Ser187 is a large-domain residue conserved in the mammalian AGTs and 
belongs to a random-coil region far from the active site [16]. Cell-free 
expression studies have revealed that the S187F variant has reduced 
dimer stability and increased sensitivity to proteasomal degradation and 
that PLP is able to increase the stability of the protein [31, 43]. As reported 
above, the S187F variant in the recombinant purified form displays a 
reduced thermal stability in the apo-form with respect to normal AGT and 
the presence of bound PLP is able to relieve the protein instability [61]. 
Nevertheless, we found that, although Ser187 is located far from the active 
site, its Ser-to-Phe substitution also affects the AGT functional properties. 
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In fact, the purified recombinant S187F-Ma variant has a remarkable 
reduced catalytic efficiency, an affinity for PLP increased of at least 27-fold, 
and a different coenzyme binding mode with respect to normal AGT [61]. 
This implies that the variant might be characterized by structural changes 
remote from the mutation site with effects on the topography of the active 
site.  
 
5.1 The S187F crystal structure reveals that the mutation affects the 
enzyme active site topology 
In collaboration with the group of Prof. Matthias Willmans at the EMBL 
(Hamburg), we have determined the crystal structure of the S187F-Ma 
variant at 2.9 Å resolution (PDB entry: 4I8A). The asymmetric unit contains 
two AGT dimers, of which the complete polypeptide chain is visible in the 
final electron density, except for the N-terminal residues 1-5 (molecules A 
and C) or 1-4 (molecules B and D), and the C-terminal residues 391-392 of 
molecules B, C and D. Interestingly, the complete C-terminus, known as a 
peroxisomal targeting signal type 1 (PTS1), is visible in chain A, possibly 
due to the proximity of the N-terminal domain of molecule C that stabilizes 
the C-terminal loop (data not shown). 
The S187F structure superimposes well onto the normal AGT counterpart, 
with a root-mean-square deviation (RMSD) of 0.48 Å. Although the overall 
conformation of the two proteins is virtually identical, significant structural 
changes can be observed near the mutated amino acid (Fig. 10) as well as 
at the active site of the protein (Fig. 11). 
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Figure 10. Superposition of the structure of the S187F variant (green) with that of normal 
AGT (orange) in the area of the cofactor binding site. Residues are labelled with the 
respective colors. The hydrophobic cleft that is formed by residues 185-188 triggers a 
conformational change in the loop where the PLP-binding lysine is located. 
 
 
Figure 11. (A) Stick representation of the active site in the S187F variant (green) and 
normal AGT (orange). Due to the mutation, the main chain atoms of Lys209 in the mutant 
enzyme move closer to the PLP, which results in a shortened side chain conformation of 
Lys209. Other active site residues are only slightly affected by the mutation induced 
structural changes. (B) Changes in the PLP-Lys209 and PLP-Val185 distances are 
represented by dashed lines in the respective colors. 
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As a result of the mutation, the loop that contains Phe187 substantially 
changes its conformation, and moves Phe187 into the position of Leu188 of 
normal AGT. Due to this displacement, Val185 of the mutant protein also 
changes position, and its side chain moves away from the PLP. The small 
hydrophobic pocket that is formed by Phe187 and Leu188 can 
accommodate Ala210, which eventually causes a shift of Ala210 and 
Lys209 towards Phe187 (Fig. 10). While these conformational changes 
slightly alter the position of the PLP cofactor and of some active site 
residues (Trp108, Ser158, His83, and Asp183), they result in a significant 
displacement of Lys209 and the loop 183-188 (Fig. 10). In fact, the 
distance between the C# of Lys209 and the C3’ of the PLP methylpyridine 
ring decreases from 8.0 Å in the normal AGT enzyme to 6.5 Å in the mutant 
enzyme (Fig. 11), and the distance between the C# of Val185 and the C3’ of 
the PLP methylpyridine ring increases from 4.9 Å in the normal AGT 
enzyme to 6.7 Å in the mutant. Moreover, as calculated by Pocket Finder 
[62], in S187F the PLP cavity has a volume of 1073 Å3, while in normal AGT 
it has a volume of 949 Å3. These structural data allow us to explain why the 
mutation of a residue whose C# is located at 10.5 Å from the C4’ of the 
coenzyme, strongly affects the AGT functional properties. In particular, the 
observed shortened conformation of the lysine side chain could account for 
the reduced catalytic activity of the S187F variant, since Lys209 is a key 
residue taking part in the AGT catalytic mechanism, while the slightly 
altered position of several active site residues could account for the 
different PLP binding mode of S187F. Moreover, although it is difficult to 
understand the increased PLP binding affinity of the variant with respect to 
normal AGT [61], it can be speculated that it is ascribable to the increased 
volume of the PLP-binding pocket that could allow a better coenzyme 
accommodation.  
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5.2 The S187F mutation affects the PMP binding mode and affinity 
and the external aldimine microenvironment: spectroscopic and 
computational analyses 
We investigated if the active site conformational changes of the S187F-Ma 
variant revealed by its crystal structure could affect the binding of other 
reaction intermediates besides the PLP coenzyme [61]. We found that even 
a prolonged incubation time of apoS187F with PMP (up to 350 µM) does 
not result in the appearance of the positive dichroic signal at 340 nm, 
typical of the AGT-PMP complex formation [18]. However, a 1 h incubation 
of the apo form of the mutant (10 µM) with 350 µM PMP in 100 mM 
potassium phosphate buffer, pH 7.4 (final volume of 500 µl) followed by 
concentration to about 10 µl by a Microcon device and four washing with 
500 µl of the above buffer, results in a retentate that contains about 8 µM 
PMP. Thus, since only 40% of the variant is in the PMP bound form, the 
K(D(PMP)) should be of ~ 10 µM, at least 100-fold higher than that of normal 
AGT (data not shown) [18]. We have also monitored the spectral changes 
occurring in the S187F variant upon addition of D-alanine, an unproductive 
substrate analogue that mimics the formation of the external aldimine 
intermediate. The CD spectrum of S187F in the presence of a saturating 
concentration of D-alanine displays a positive band at 415 nm, 10-nm blue-
shifted with respect to that of normal AGT. Altogether, these data indicate 
that the variant is characterized by an altered PMP binding mode and 
affinity as well as by a different microenvironment of the external aldimine. 
To have insights about the possible impact of the S187F mutation on the 
active site topography of these reaction intermediates, we compared 
docking models indicative of the putative binding mode of PMP and of the 
external aldimine with L-alanine (Figure 12A and B), obtained in 
collaboration with Prof. Alessandro Paiardini from University of Rome “La 
Sapienza”, with those of normal AGT [18].  
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Figure 12. Modelling of the active site of the PMP- (pink) and of the L-alanine external 
aldimine (yellow) bound forms of normal (A) and S187F (B) AGT. The internal aldimine 
(orange) is also shown for reference. Oxygen, nitrogen and phosphorous atoms are 
coloured red, blue, and orange, respectively.  
 
The putative position of the manually docked molecules and their 
neighbouring residues was relaxed by energy minimization means. Besides 
small changes related to the position of Tyr260*, the most striking feature 
that distinguishes the S187F variant from normal AGT is the relative 
positioning of the coenzyme moiety and of Trp108. In fact, in S187F both 
the AGT–PMP complex and the external aldimine are tilted by approx. 25° 
with respect to PLP towards Trp108 and Asp183 and the Trp108 side-chain 
(on the re side of PLP) undergoes a remarkable conformational change, 
flipping by approx. 45° around the C#–C$ bond. This predicted movement, 
probably due to the need to accommodate the amino group of PMP or the 
substrate’s moiety and to avoid steric clashes with Lys209, is energetically 
impaired in normal AGT by the location of Val185 on the si side of the 
coenzyme[18]. Although these represent simulated conformations, the 
predicted changes would result in loss of stabilization of PMP and the 
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external aldimine on both re and si side of the pyridine ring. This is 
consistent with our experimental data and could account for the changes in 
both PMP binding mode and affinity and in the microenvironment of the 
external aldimine with D-alanine with respect to normal AGT. 
 
5.3 The S187F mutation decreases the catalytic efficiency of the L-
alanine half-transamination 
We have previously reported (section 4.5) that the S187F variant in the 
absence of exogenous coenzyme has kcat for the alanine/glyoxylate pair, 
KmL-alanine and KmGlyoxylate values equal to 0.147 ± 0.009 s-1, 52 ± 2 mM and 
0.038 ± 0.008 mM, respectively. In order to investigate if the decrease in 
the catalytic efficiency was due to an impact of the mutation on the first 
and/or the second half-transamination reaction, we compared the kinetics 
of the L-alanine half-transamination of the variant (15 µM) with that of 
normal AGT. Similar to what already observed in normal AGT [18], we 
couldn’t detect the external aldimine with L-alanine and the quinonoid 
intermediates of the S187F variant. Nevertheless, while both the decrease 
of the 429 nm absorbance band and the concomitant PLP " PMP 
conversion are single exponential processes in normal AGT [18], they 
display a biphasic behaviour in the variant (Fig. 13). Both the apparent first-
order rate constants, kobs, of the fast and the slow phases show a 
hyperbolic dependence on L-alanine concentration, with kmax and Kmapp 
values of 0.15 ± 0.02 s-1 and 64 ± 15 mM and of 0.015 ± 0.002 s-1 and 132 
± 38 mM for the fast and the slow phase, respectively. Thus, the S187F 
mutation strongly affects the first half-reaction by causing a ~550-fold 
decrease of its catalytic efficiency with respect to normal AGT [18]. This is 
not unexpected, considering the mispositioning of Lys209, as revealed by 
the crystal structure of the S187F mutant, and the role of the PLP-binding 
lysine in aminotransferases on C# proton abstraction and C4’ reprotonation 
[63]. 
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Figure 13. Time-dependent L-alanine half-transamination of the S187F variant. Plot of the 
413 nm absorbance with time for the reaction of 15 %M S187F with 5 mM L-alanine. The line 
represents a two exponential fit. Insets: dependence of the rate constants (kfast and kslow) as 
a function of L-alanine concentration. The lines represent the data fitted to eq.5.  
 
According to this view, replacement of Lys209 with Arg completely 
abolishes the AGT catalytic activity [26]. Since Lys209 is supposed to act as 
an acid/base catalyst in both half-reactions of AGT, an effect of the S187F 
mutation on the ketoacid half-transamination would also be expected. 
Unfortunately, this reaction cannot be monitored because the apoenzyme 
of the S187F variant is unstable and prone to aggregation at the high 
enzyme concentration required to obtain an apo-PMP complex (at least 
100 %M). 
How can be explained the biphasic kinetics of the L-alanine half-
transamination of the S187F mutant? The finding that the PLP binding 
kinetics is a monophasic process and that the kinetics of the L-alanine half-
!
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transamination does not change upon addition of D-alanine, allows to 
exclude that the S187F variant could exist in solution as a mixture of a fast 
and a slow reacting form. Moreover, since about 10 µM pyruvate is formed 
at the end of the fast phase and the variant exhibits a Ki value for the 
competitive inhibition of pyruvate against glyoxylate identical to that of 
normal AGT [18] (2.2 ± 1.3 mM), the slow phase of the half-transamination is 
not due to pyruvate inhibition. Nevertheless, we found that (i) the L-alanine 
half-transamination becomes a single exponential process (with a kobs 
value comparable to that of the fast phase) when it is coupled to the 
LDH/NADH reaction system, (ii) 100% of the PMP formed during the fast 
phase is bound at the AGT active site, and (iii) a 40% of bound PMP is 
present at the end of the slow phase. These results indicate that pyruvate 
is not released in solution in two kinetically-distinguishable processes and 
that the slow phase is due to the accumulation of bound PMP that, in the 
presence of pyruvate, leads to an equilibrium between the forward and the 
reverse reaction. Consistent with this idea, a gradual recovery of the 413 
nm absorbance is clearly detected at the end of the slow phase, indicative 
of the occurrence of the reversal transamination reaction.  
 
5.4 The molecular defect of the S187F-Ma variant and its 
implications for the treatment of patients bearing the S187F mutation 
Being PH1 a disease characterized by a remarkable heterogeneity in terms 
of enzymatic phenotype, the choice of the treatment strategy suitable for 
each patient strongly depends on the elucidation of the molecular 
mechanism leading from each specific mutation to AGT deficiency. Until 
now, the effect of many PH1-causing missense mutations has been 
rationalized in terms of the position of the mutated residue in the crystal 
structure of normal AGT [16]. However, this approach does not always 
guarantee the elucidation of the molecular defect of each variant. An 
example is herein presented for the S187F variant. As previously 
mentioned, the liver biopsy of a patient bearing the S187F mutation shows 
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a very low AGT catalytic activity and expression level [34]. This result along 
with the fact that, basing on the AGT-Ma crystal structure, the Ser187 is not 
part of the active site, might lead to hypothesize that the variant only has a 
structural defect and that a treatment with pharmacological chaperones, 
able to stabilize the folded conformation of the variant, would be the best 
therapeutic strategy for patients bearing the S187F mutation. However, we 
previously found that replacement of Ser187 by Phe in the recombinant 
protein causes both structural (reduced thermostability of the apo form) and 
functional (reduced catalytic efficiency and altered PLP binding mode and 
affinity) defects [61]. In this study, the crystal structure of the variant paired 
with bioinformatics analysis, has shown that the mutation causes a 
remarkable perturbation of the active site resulting in a mispositioning of (i) 
the PLP-binding lysine, (ii) the AGT-PMP complex, and (iii) the external 
aldimine. These data are consistent with biochemical analyses indicating a 
reduced rate of L-alanine half-transamination, a different PMP binding 
mode and affinity as well as an altered microenvironment of the external 
aldimine with D-alanine in comparison with normal AGT. On the basis of 
these data showing that even the folded variant exhibits structural defects 
at the active site responsible for a low transaminase activity, we can 
conclude that a therapy with pharmacological chaperones will likely have 
only limited effects for patients bearing the S187F mutation. Instead gene 
therapy or enzyme administration approaches most likely represent the 
preferred therapeutic strategies.  
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Impact of the Gly161 mutation on the molecular and 
cellular proprieties of AGT 
Gly161 is a highly conserved residue and represents a hot-spot mutation 
site within the AGT sequence. In fact, three pathogenic mutations that 
affect the GCC triplet in exon 4 of the AGXT gene have been reported: the 
G161R mutation, co-segregating with the major allele, and the G161S and 
G161C mutations, both co-segregating with the minor allele. The AGT 
crystal structure reveals that Gly161 is far from the active site and is part of 
the loop 154-168 located in the large domain in close contact with the small 
domain (Fig.14)[37]. 
!"#$%$&
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Fig. 14: Position of Gly161 residue in the AGT structure. The figure represents the crystal 
structure of AGT (PDB code 1H0C) in which one monomer is colored gray, while in the 
other monomer the large domain, the small domain and the N-terminal extension are 
represented orange, green and yellow respectively. The cofactor PLP is represented as red 
sticks, while Gly161 is represented as magenta sticks and the loop 154-168 is colored blue. 
The inset shows the position and the microenvironment of Gly161. 
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The substitution of the small side chain of glycine with the larger side 
chains of arginine, serine or cysteine is predicted to perturb the folding of 
both domains of the protein. We have shown (chapters 4.4, 4.5) that the 
G161S and G161C mutations do not significantly alter the catalytic activity 
and the PLP binding of AGT, but remarkably reduce the thermal stability of 
the protein in both the holo- and the apo-form. Moreover, crude E.coli 
lysates expressing the G161C-Mi, G161S-Mi and G161R-Ma variants 
display very low specific activity and AGT expression level [33, 60]. Finally, 
Coulter-Mackie M.B. et al [43] have reported cell-free expression 
experiments indicating that the G161R-Ma variant is prone to proteasomal 
and tryptic degradation. Although these data confirm that the mutation of 
Gly161 could induce structural perturbations in AGT, a detailed 
investigation of the mechanism by which it exerts its pathogenic effect is 
still lacking.  
 
6.1 Gly161 variants show strongly reduced expression level in E. coli 
 
As previously mentioned (chapter 4.2), when the G161S-Mi and G161C-Mi 
variants are overexpressed in E. coli, a large portion of the protein is 
present in the insoluble fraction and the purification yield drops to about 
10% when compared to that of AGT-Ma. Unfortunately, when the G161R-
Ma variant is expressed using the same procedure, the expression level is 
less than 5% with respect to AGT-Ma and the mutant protein is insoluble in 
crude extracts. Any attempt to reduce protein aggregation by lowering the 
expression temperature, by adding exogenous PLP and small osmolytes to 
the culture, or by using E.coli strains overexpressing molecular chaperones, 
have been unsuccessful. This has prevented us to obtain and characterize 
the G161R-Ma variant in the pure form. 
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6.2 Recombinant purified G161S-Mi and G161C-Mi variants in the 
apo-form are unstable and prone to aggregation under physiological 
conditions 
Thermal denaturation studies have shown that both G161S-Mi and G161C-
Mi are characterized by a melting temperature (Tm) considerably lower 
than AGT-Mi and that the effect of the mutations on stability is exacerbated 
in the apo-form. In order to investigate if the lower Tm could reflect an 
instability of the variants under physiological conditions, the catalytic 
activity of AGT-Mi, G161S-Mi and G161C-Mi at 2 µM concentration in the 
holo- and in the apo-form has been monitored at 37°C, pH 7.4 and 150 mM 
ionic strength. No time-dependent inactivation can be observed for AGT-Mi 
in the holo- and apo-form nor for the Gly161 variants in the holo-form. On 
the contrary, the residual catalytic activity of the apo-forms of Gly161 
variants sharply decreases over time reaching at 180 min a value of ~25% 
and of ~5% for G161C-Mi and G161S-Mi, respectively (data not shown). 
Moreover, since the inactivation extent does not decrease with enzyme 
concentration, it can be affirmed that monomerization is not caused by the 
loss of activity.  
To test if protein aggregation is the cause of the thermal inactivation, we 
incubated G161C-Mi and G161S-Mi under physiological conditions 
monitoring turbidity changes of the solution over a 60 min time interval. As 
shown in Fig. 15A and B, the absorbance at 600 nm does not change for 
the variants in the holo-form, whereas a significant change in turbidity is 
observed for apoG161S-Mi and apoG161C-Mi, thus indicating an ongoing 
aggregation process. The aggregation extent is similar for the two proteins, 
even if in the case of the G161C-Mi variant a decrease in turbidity is 
observed after 40 min of reaction due to aggregates precipitation. Notably, 
the addition of excess exogenous PLP (100 µM) decreases the extent of 
aggregation of both G161S-Mi and G161C-Mi (Fig. 15). This result 
indicates that the binding of the coenzyme competes with the aggregation 
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process and is able to shift the equilibrium versus the non-aggregating 
holoenzymatic form.  
 
 
Fig. 15 : Time-dependent turbidity changes of G161S-Mi and G161C-Mi variants. 
Absorbance  changes at 600 nm as function of time of the variants at 2µM in the apo-forms 
(+), holo-forms (!) and apo-forms + 100 µM PLP (+) of Gly161 variants were monitored in 
60 mM potassium phosphate buffer, pH 7.4, at 37 °C. 
In order to characterize the species present in solution during incubation of 
G161S-Mi, G161C-Mi and AGT-Mi under physiological conditions, dynamic 
light scattering (DLS) studies were undertaken. Fig. 16A shows the time-
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dependence of the total count rate, a parameter that depends on both the 
size and the quantity of the particles, for the three enzymatic species in the 
holo- and apo-form. While the increase in the count rate is very slow for the 
holoenzymes and for apoAGT-Mi, a fast aggregation process can be seen 
for apoGly161 variants, with the count rate levelling off after ~20 and ~30 
min for apoG161S-Mi and apoG161C-Mi, respectively. 
!  
Fig. 16: Time-dependent aggregation of AGT-Mi and Gly161 variants: (A) total count 
rate (measured as kilo counts per second) of AGT-Mi and G161 variants as function of 
time. Color code: blue AGT-Mi; black G161S-Mi; red G161C-Mi. Open and closed 
symbols represent holo- and apo-form respectively. The other panels shown the time-
dependent  changes of the apparent diameter of (B) holo and apo-AGT-Mi, (C) holo and 
apo-G161S-Mi and (D) holo and apo-G161C-Mi. Symbol code: ! holo dimer; # apo 
dimer; # holo aggregates; $ apo aggregates. All measurements have been performed 
at 1 µM enzyme concentration, 37 °C, in 60 mM potassium phosphate buffer pH 7.4 
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The plots of the particle size against time reported in Fig. 16B, C and D 
show that, although small aggregates (from 200 to 600 nm) are formed 
upon incubation of holo- and apoAGT-Mi, holoG161S-Mi and holoG161C-
Mi, the signal of the dimer is continuously present. This means that the 
dimer is the most abundant species in solution, since the contribution to 
scattering from larger particles dominates the DLS signal being the 
scattering intensity proportional to the sixth power of a particle diameter. 
On the contrary, the signal of the dimer of apoG161S-Mi and apoG161C-Mi 
disappears after 5-10 min and aggregates of ~1500 nm are formed. 
Moreover, after ~40 min apoG161C-Mi forms a distinct population of high-
order aggregates (~5000 nm) that could explain the precipitation 
phenomenon seen in turbidimetry experiments (Fig. 15A). Finally, the 
aggregation extent increases as the protein concentration increases, thus 
indicating that the aggregation does not depend on protein monomerization. 
In order to define the aggregation mechanism of Gly161 variants and its 
possible correlation with the inactivation at physiological temperature, we 
followed the aggregation process by DLS and we measured the residual 
activity upon 1 h incubation at different ionic strengths (from 0.15 to 1.25 M). 
We found that the aggregation extent and the loss of activity of apoGly161 
variants increases as the ionic strength decreases (Fig. 17), thus indicating 
that electrostatic forces mediate the interaction between dimers of 
apoG161S-Mi and apoG161C-Mi and that the inactivation and aggregation 
processes are probably linked.  
The effect of Gly161 mutation on the stability of the dimeric structure of 
AGT in the apo-form was analysed by SEC under conditions in which no 
significant aggregation occurs, i.e. 0.1 M potassium phosphate buffer, pH 
7.4, 25°C. No peaks corresponding to monomeric species were detected 
down to 100 nM concentration for apoG161S-Mi and apoG161C-Mi, thus 
suggesting that the apovariants are not characterized by a dimeric structure 
significantly less stable with respect to apoAGT-Mi. However, the 
comparison of the spectral properties of apoG161C-Mi and apoG161S-Mi 
with those of apoAGT-Mi revealed that the variants in the dimeric form 
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display (i) a different near-UV dichroic spectrum, characterized by a 
decreased ellipticity at 288 nm and an increased ellipticity at 265 nm, and 
(ii) a 5 nm red-shift of the intrinsic fluorescence emission maximum(data 
not shown). Moreover, we found that the rate constant of association of 100 
µM PLP is equal to 0.28 ± 0.02 min-1, 0.18 ± 0.03 min-1 and 0.14 ± 0.01 min-
1, for apoAGT-Mi, apoG161S-Mi and apoG161C-Mi, respectively.  
Altogether, the obtained results indicate that the mutation of Gly161 to Ser 
or Cys on the background of the minor allele (i) makes AGT in the apo-form 
prone to a time-dependent inactivation and aggregation under physiological 
conditions, which is prevented by the binding of PLP, and (ii) changes the 
tertiary structure of apoAGT in the dimeric form and slows down PLP 
binding.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 17: Analyses of the aggregation and enzymatic activity of Gly161 variants at different 
ionic strength. Changes in the total count rate (measured as kilo counts per second) of 
G161S-Mi (A) and G161C-Mi (B) variants as function of time. Measurements performed at 1 
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µM enzyme concentration, 37 °C, in potassium phosphate buffer pH7.4 1.25 M (#), 0.5 M 
(%) and 0.15 M (!)ionic strength. (C) Histogram representative of the residual activity of 
G161S-Mi (filled bars) and G161C-Mi (empty bars) after 1h incubation at the indicated ionic 
strength. 
6.3 Gly161 variants show a reduced expression level and enzymatic 
activity in mammalian cells 
In order to investigate how the mutation of Gly161 could alter the 
expression and the activity of AGT in a cell environment, the G161R-Ma, 
G161S-Mi and G161C-Mi variants have been expressed in chinese 
hamster ovary (CHO) cells. We didn’t succeed in the generation of stable 
clones expressing the three Gly161 variants, as a consequence of the high 
mortality of the transfected cells probably caused by the accumulation of 
insoluble protein due to the expression of aggregation prone variants (see 
below). Thus, CHO cells transiently expressing AGT-Ma, AGT-Mi and the 
Gly161 variants were analysed for AGT enzymatic activity and expression 
level after 24h. While the transaminase activity of AGT-Mi is slightly lower 
with respect to AGT-Ma (310 ± 22 nmol pyruvate/min/mg lysate for AGT-
Ma and 267 ± 60 nmol pyruvate/min/mg lysate for AGT-Mi), that of Gly161 
variants is 0.6 ± 0.1, 1.2 ± 0.3 and 1.1 ± 0.2 nmol pyruvate/min/mg lysate 
for G161R-Ma, G161S-Mi and G161C-Mi, respectively. Moreover, Gly161 
variants have a reduced expression level as shown by the intensity of the 
specific band of immunoreactive AGT that is equal to 4% for G161R-Ma as 
compared with AGT-Ma, and to 12 % and 5% for G161S-Mi and G161C-Mi, 
respectively, as compared with AGT-Mi (Fig. 18). Thus, considering that 
the catalytic efficiency of the G161S-Mi and G161C-Mi variants in the 
purified form is similar to that of AGT-Mi, the very low AGT enzymatic 
activity of CHO cells expressing the variants can be attributed to their very 
low expression level.  
RT-PCR experiments have been conducted to rule out possible influences 
of the mutations at transcriptional level. No significant differences were 
observed in the levels of the mRNA transcripts for cells expressing AGT-
Ma, AGT-Mi, G161R-Ma, G161S-Mi or G161C-Mi (data not shown). 
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Therefore, the reduced expression of Gly161 variants originates at the 
protein level. 
 
6.4 Gly161 variants form cytosolic aggregates in mammalian cells 
Considering the aggregation propensity of G161S-Mi and G161C-Mi in the 
recombinant purified form, we investigated if aggregates of Gly161 variants 
are also formed inside the cell. For this purpose determined the amount of 
AGT present in the soluble and insoluble fraction of lysates of CHO cells 
expressing AGT-Ma, AGT-Mi and the Gly161 variants.  
!"
! " # $ % & ' ( ) !*+,+
,-.+
!!+
! " # $ % & ' ( ) !*+
!,!*%+
",!*%+
!,!*&+
",!*&+
-.
/0
+1
23
45
6+
*+
#,!*%+
0
100000
200000
1000000
2000000
!!+  
Fig. 18: Analysis of AGT expression in CHO cells expressing AGT-Ma, AGT-Mi and Gly161 
variants. 24 h after transfection CHO cells were harvested and lysed; 10 µg of cell lysate 
was subjected to SDS/PAGE, immunoblotted whit  anti-AGT from rabbit (1:2000) and than 
detected with a chemiluminescent substrate. (A) Immunoblot; (B) Histogram representative 
of the immunoblot bands volume. The immunoblot lanes and histogram bars are coded as 
follow: 1. soluble and 2. insoluble fraction of  CHO cell lysate expressing AGT-Ma, 3. soluble 
and 4. insoluble fraction of  CHO cell lysate expressing AGT-Mi, 5. soluble and 6. insoluble 
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fraction of  CHO cell lysate expressing G161R-Ma, 7. soluble and 8. insoluble fraction of  
CHO cell lysate expressing G161S-Mi, 9. soluble and 10. insoluble fraction of  CHO cell 
lysate expressing G161C-Mi, 11. whole cell lysate of untransfected CHO cells. Bar graphs 
represent the mean ± SEM. Data come from the mean of three different experiments. 
While in the case of AGT-Ma and AGT-Mi about 75-80% of the protein was 
present in the soluble fraction, in the case of G161R-Ma, G161S-Mi and 
G161C-Mi variants 93%, 84% and 91% of the protein, respectively, was 
present in the insoluble fraction  (Fig. 18). Although it should be noted that 
the total amount of protein (soluble plus insoluble fraction) present in the 
Gly161 variants is lower with respect to that of AGT-Ma or AGT-Mi, these 
data would suggest that the low expression level of the variants is mainly 
due to protein aggregation. In agreement with these results, two strong 
bands at 80-90 kDa, corresponding to the two structural isoforms of dimeric 
AGT [45], can be seen after cross-linking of lysates of cells expressing AGT-
Ma or AGT-Mi. On the other hand, cross-linking of lysates of cells 
expressing Gly161 variants lead to the appearance of a faint band at a 
molecular weight higher than 200 kDa, and to the almost complete loss of 
immunoreactive AGT, probably due to the formation of high-molecular 
weight aggregates that are unable to enter the gel (Fig. 19). In order to 
confirm the aggregation propensity of AGT induced by Gly161 mutation in 
the cellular system, lysates of CHO cells expressing AGT-Ma or the 
G161R-Ma variant were subjected to SEC and the fractions collected were 
analysed by western-blot to detect the presence of immunoreactive AGT 
(Fig. 20 A and B). As expected, AGT-Ma eluted between 15 and 16 ml, an 
elution volume identical to that of the active dimeric protein in the purified 
form, whereas the G161R-Ma variant mainly eluted in a broad peak from 7 
to 11 ml, consistent with the formation of a mixture of aggregates with 
apparent molecular weight from ~350 to more than 1000 kDa. 
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Fig. 19:  Cross-linking analyses of CHO cells expressing AGT-Ma, AGT-Mi and Gly161 
variants. 24 h after transfection CHO cells were harvested lysed and cross-linked with 
BS(PEG)5 at 50X molar excess; 10 µg of each mixture was subjected to SDS/PAGE, 
immunoblotted whit anti-AGT from rabbit (1:2000) and then detected with a 
chemiluminescent substrate. The immunoblot lanes are coded as follow: 1. untransfected 
CHO cells, 2. CHO cells  expressing AGT-Ma, 3. CHO cells expressing AGT-Mi, 4. CHO 
cells expressing G161R-Ma, 5. CHO cells expressing G161S-Mi, 6. CHO cells expressing 
G161C-Mi. 
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Fig. 20: Gel filtration analyses of CHO cells expressing AGT-Ma and the G161R-Ma variant. 
24 h after transfection CHO cells were harvested and lysed. (A) Size exclusion 
chromatography (SEC) elution profile of CHO cells expressing AGT-Ma (-), CHO cells 
expressing G161R-Ma(….) and recombinant purified AGT-Ma (--). (B) Western blot analyses 
of SEC fractions of CHO cells expressing AGT-Ma and G161R-Ma.  
Immunofluorescence microscopy studies were performed to define if the 
mutation of Gly161 could also affect the subcellular localization of AGT. 
Intracellular spots staining for AGT that do not colocalize neither with the 
peroxisomal nor with the mitochondrial marker were present in CHO cells 
transiently expressing G161R-Ma, G161S-Mi or G161C-Mi (Fig. 21). Only 
in the case of the G161S-Mi and G161C-Mi variants a qualitative analysis 
of the confocal images indicated a partial peroxisomal localization of AGT. 
On the other hand, as expected, a clear peroxisomal localization can be 
observed in CHO cells transiently expressing AGT-Ma or AGT-Mi (Fig. 22). 
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Notably, under these experimental conditions, no significant mitochondrial 
import of AGT-Mi, G161S-Mi and G161C-Mi can be seen (Fig. 21B). 
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Fig. 21: Subcellular distribution of Gly161 variants in CHO cells. 24 h after transfection cells 
were fixed and coloured as follow: (A) anti-AGT (green), anti-peroxisomal proteins (red); (B) 
anti-AGT (green), Mito Tracker (red). Nuclei were stained with Dapi (blue). Merge and single 
channel images come from a single z-plane. Scale bar: 10 µm. 
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Fig. 22: Subcellular distribution of AGT-Ma and AGT-Mi in CHO cells. 24 h after transfection 
cells were fixed and coloured as follow: (A) anti-AGT (green), anti-peroxisomal proteins 
(red); (B) anti-AGT (green), Mito Tracker (red). Nuclei were stained with Dapi (blue). Merge 
and single channel images come from a single z-plane. Scale bar: 10 µm. 
 
In agreement with immunofluorescence studies, IEM analyses revealed 
that AGT-Ma expressed in CHO cells is present in round or ovoid 
membrane organelles with electrone-dense interior whose shape, size and 
ultrastructural features were consistent with those of peroxisomes (Fig. 
23A). In contrast, the G161R-Ma signal was detected mainly in structures 
with irregular shape varying from 200-300 nm to several microns in size 
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(Fig. 23B). Importantly, these G161R-Ma positive structures lack external 
membrane, a feature consistent with the hypothesis of protein aggregates 
in the cytosol. 
Altogether, these data indicate that the mutation of Gly161 strongly induces 
the aggregation of AGT inside the cell, leading to the formation of high-
molecular weight cytosolic aggregates. 
 
!"
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Fig. 23: IEM analyses CHO cells expressing AGT-Ma or G161R-Ma. 24 h after transfection 
CHO cells expressing AGT-Ma (A) and the G161R-Ma (B) variant were stained with the 
anti-AGT antibody followed by protein A conjugated with 10 nm gold particles. Asterisks 
indicate mitochondria, arrows indicate peroxisomes and the circle indicates Golgi. Scale bar: 
150 nm. 
 
 
 
 
                                                                                   Results and discussion 
!*'!
6.5 Gly161 variants show a reduced half-life in mammalian cells 
Although protein aggregation is one of the features that distinguish Gly161 
variants, it does not completely account for their reduced expression level. 
Thus, we investigated if the mutation of Gly161 could affect the intracellular 
stability of AGT by determining the kinetics of expression of the protein (Fig. 
24). We found that while the expression of AGT-Ma and AGT-Mi is maximal 
at 24 h and remains stable up to 48 h, the expression level of Gly161 
variants shows its maximum level at about 8 h and then decreases with 
time, thus suggesting that the variants could be susceptible to intracellular 
degradation. Following this result, we determined the half-life of AGT-Ma, 
AGT-Mi and Gly161 variants expressed in CHO cells. The data reported in 
Fig. 25 clearly show that: (i) AGT-Ma and AGT-Mi are very stable, 
displaying half-lives of 29 ± 2 h and 27 ± 3 h, respectively, and (ii) the 
G161R-Ma, G161S-Mi and G161C-Mi variants show a lower intracellular 
stability with respect to AGT-Ma or AGT-Mi, displaying half-lives of <4 h, 13 
± 2 h, and 10 ± 1 h, respectively. Thus, the reduced expression level of the 
variants can be attributed not only to their aggregation propensity, but also 
to their greater susceptibility to intracellular degradation. 
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Fig. 24:  Time course of AGT-Ma, AGT-Mi and Gly161 variants expression in transiently 
transformed CHO cells. After transfection CHO cells were harvested at various times and 
lysed; 10 µg of cell lysate was subjected to SDS/PAGE, immunoblotted whit anti-AGT from 
rabbit (1:2000) and then detected with a chemiluminescent substrate. The immunoblot lanes 
are coded as follow: 1. untransfected CHO cells, 2. CHO cells expressing AGT-Ma, 3. CHO 
cells expressing AGT-Mi, 4. CHO cells expressing G161R-Ma, 5. CHO cells expressing 
G161S-Mi, 6. CHO cells expressing G161C-Mi. 
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Fig. 25: Measurement of the half-life of AGT-Ma, AGT-Mi, and Gly161 variants in CHO cells. 
Transiently transfected CHO cells were pulse labeled with 35S Cys-Met Mix and then 
incubated in complete DMEM for a chase time from 0 to 48 hrs. Cell lysates were 
immunoprecipitated with anti-AGT antibody and loaded on SDS-PAGE; signal of 
radiolabelled AGT was detected by autoradiography. 
 
6.6 Exogenous pyridoxine is able to partly rescue for the effect of 
Gly161 mutation 
100 µM pyridoxine, a vitamer of vitamin B6 known to be converted to PLP 
inside the cell [64], was added to the culture medium of CHO cells 
expressing AGT-Ma, AGT-Mi or the Gly161 variants. The specific activity of 
AGT-Ma and AGT-Mi drops to about 70% in the presence of exogenous 
coenzyme in the culture medium, a result very difficult to explain at present. 
On the other hand, the specific activity of G161R-Ma, G161S-Mi and 
G161C-Mi increases of 2.8, 3.1 and 2.1 fold, respectively, in the presence 
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of 100 µM pyridoxine (Fig. 26). Pyridoxine treatment does not change the 
total amount of protein of any of the analysed enzymatic species, but 
increases of 2.5, 3 and 2.8 fold the amount of protein present in the soluble 
fraction for G161R-Ma, G161S-Mi and G161C-Mi, respectively (Fig. 26). 
These results suggest that the action of the coenzyme is not due to an 
increased expression or to a decreased degradation of the variants, rather 
to a shift of the equilibrium from the apo to the holo-form of the variants, 
which partly prevented protein aggregation. 
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Fig. 26: Effect of pyridoxine on the expression level and specific activity of AGT-Ma, AGT-
Mi and Gly161 variants. Where indicated, CHO cells were treated with 100 µM pyridoxine 4h 
after transfection and, after 24h, were harvested and lysed. (A) 15 µg of cell lysate was 
subjected to SDS/PAGE, immunoblotted with anti-AGT from rabbit (1: 2000) and detected 
by chemiluminescence. (B) 100 µg of cell lysate was incubated with 0.5 M L-alanine and 10 
mM glyoxylate, and the amount of pyruvate produced after 30 min was determined .The 
immunoblot lanes and histogram bars are coded as follow: 1. untransfected CHO cells 2. 
CHO cells expressing AGT-Ma, 3. CHO cells expressing AGT-Mi, 4. CHO cells expressing 
G161R-Ma, 5. CHO cells expressing G161S-Mi, 6. CHO cells expressing G161C-Mi. Data 
are representative of three different experiments. Bar graphs represent the mean ± SEM. 
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6.7 Gly161 mutation causes a folding defect of AGT 
Previous data indicate that the mutation of Gly161 to either Ser or Cys 
does not compromise the enzymatic activity but strongly reduces the 
thermal stability of both the holo- and, to a higher extent, the apo-form of 
AGT[61]. Here, we show that: (i) the mutation of Gly161 strongly reduces the 
AGT expression level, both in E.coli and in a mammalian cellular model, 
and the reduction is not produced by differences at the level of transcription, 
(ii) under physiological conditions of temperature, ionic strength and pH, 
purified G161S-Mi and G161C-Mi variants in the apodimeric form are prone 
to inactivation and electrostatically-driven aggregation, (iii) when expressed 
in CHO cells, Gly161 variants form insoluble aggregates that localize in the 
cytosol, and (iv) the substitution of Gly161 strongly reduces the AGT 
intracellular half-life in the order G161R>G161C>G161S, in agreement with 
previous cell-free expression system studies indicating that the G161R-Ma 
variant is prone to proteasomal degradation [31]. All in all, these results 
indicate that Gly161 variants, although at different extents, are mainly 
characterized by a folding defect such that it is the inability of the mutated 
peptide chain to achieve or maintain a fully functional conformation, rather 
than the loss of protein function per se, that causes the disease. Therefore, 
the mutation is expected to induce a conformational change ultimately 
responsible for the propensity of the protein to both degradation and 
aggregation.  
In the absence of the crystal structure of Gly161 variants, it is unclear how 
the substitution of Gly161 with Arg, Ser or Cys could accelerate the 
degradation and the aggregation of AGT and whether the two processes 
are mutually related. Nevertheless, our data suggest that the defects of 
Gly161 variants are not due to a reduced stability of the dimeric structure. 
In fact, in line with Gly161 not being an interfacial residue, the purified 
G161S-Mi and G161C-Mi variants do not display an increased monomer-
dimer dissociation constant. Additionally, SEC analyses of lysates of CHO 
cells expressing G161R-Ma do not reveal the presence of monomeric AGT. 
Rather, DLS experiments show that the aggregation extent of the 
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apovariants is proportional to protein concentration and increases wiyh 
decreasing ionic strength.  
These data indicate that the variants in the dimeric form are prone to a self-
association process mediated by the electrostatic interaction between 
patches of opposite charge. AGT shows a highly positive charge 
distribution around its surface[40].  
On these bases, whatever the conformational change caused by Gly161 
mutation is, it can be hypothesized that it could lead to the exposure of 
negatively changed surfaces thus creating a dipole segregation of charges 
that leads to the electrostatic aggregation of the protein. A similar 
mechanism has been previously suggested for pathogenic variants of AGT 
bearing mutations at Gly41 [40]. Following this view, it is reasonable to think 
that the conformational change induced by Gly161 mutation could also 
cause the exposure of stretches susceptible to proteolytic degradation. 
Although this would explain the enhanced intracellular degradation of the 
variants, a direct evidence for this interpretation is lacking. 
 
6.8 The aggregation of Gly161 variants originates from the apo-form 
of the protein  
Our investigations on purified G161S-Mi and G161C-Mi variants suggest 
that (i) the mutation of Gly161 induce some structural changes in apoAGT 
that make it prone to aggregation under physiological conditions and (ii) the 
binding of PLP competes with protein aggregation by shifting the 
equilibrium toward the non-aggregating holo-form. A similar competition 
between aggregation and PLP binding is expected to occur also in the cell 
cytosol where the cytosolic aggregates formed by Gly161 variants primarily 
originate from the apo-form of the protein. Moreover, since the variants 
show a slower PLP binding than AGT-Mi, their apo-forms are expected to 
be more populated. On the basis of both this hypothesis and previous data 
on the response of AGT to chemical stress [29], a plausible model that 
explains the pathogenicity of Gly161 variants can be outlined. Figure 27A 
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and B compare the possible folding pathway of AGT-Ma and AGT-Mi in the 
cell cytosol with that of Gly161 variants. In both cases, the unfolded 
polypeptide chain (U) is expected to generate monomeric AGT (M) passing 
through a partly folded monomeric intermediate (M*). M can either bind 
PLP (MPLP) and then dimerize (DPLP), or dimerize (D) and then bind PLP 
(DPLP). In the case of AGT-Ma and AGT-Mi, most of the protein is converted 
to DPLP, which is readily imported to peroxisomes. 
On the contrary, the conformational change affecting Gly161 variants 
makes their apodimeric form (D) susceptible to a self-assembly process 
that competes with PLP binding. Thus, the molecular defect of Gly161 
variants seems to affect mostly the apo-form of the protein, similarly to 
other pathogenic AGT variants such as the more common G170R-Mi and 
the F152I-Mi [29, 39].  
The increased propensity to aggregation, in both non-cellular and cellular 
systems, is not a novelty in the array of enzymatic phenotypes leading to 
AGT deficiency [39, 40, 44, 45]. However, one distinctive feature of Gly161 
variants is that they form large aggregates in the cell cytosol, as revealed 
by immunofluorescence and electron microscopy analyses unlike, for 
instance G41R-Mi variant, which forms intraperoxisomal aggregates, as 
recently reported by Fargue S. et al[45].This different intracellular behaviour 
does not seem to depend on the inability of the variants to interact with the 
peroxisomal carrier Pex5p, as both G161S-Mi and G161C-Mi show a 
partial peroxisomal localization. It seems more likely that the aggregation of 
Gly161 variants occurs so rapidly that large aggregates unable to enter the 
peroxisome are formed before peroxisomal import can take place. In 
agreement with this view, the aggregation kinetics of purified apoG161S-Mi 
and apoG161C-Mi under physiological conditions is faster than that 
previously reported for the G41R-Mi variant[40]. This model can also explain 
the absence of a mitochondrial localization of G161S-Mi and G161C-Mi in 
our study. In fact, Fargue S. et al. [45] reported that some destabilizing 
mutations cosegregating with the minor allele polymorphism lead to a 
mitochondrial mistargeting of the protein stably expressed in CHO cells as 
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the result of a synergism between two different effects: the polymorphic 
P11L mutation unmasks a putative mitochondrial targeting sequence [27, 28], 
on the other hand the pathogenic mutations promote the accumulation of 
unfolded or partly folded monomeric species that are compatible with the 
mitochondrial import machinery. In the case of the G161S-Mi and G161C-
Mi variants, the pathogenic mutation does not seem to cause the 
accumulation of monomeric species and the consequent mitochondrial 
import. However, it cannot be excluded that the mitochondrial localization is 
prevented by the short-term expression of the protein that favours a 
peroxisomal localization[45].  
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Fig. 27: Proposed folding pathways of (A) AGT-Ma, AGT-Mi and (B) Gly161 variants. U, 
unfolded monomer, M*, partially folded monomer, M, folded monomer, MPLP, PLP-bound 
monomer, D, apodimer, DPLP, holodimer and AGGD aggregates of apodimer. 
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6.9 PLP is able to partly rescue for the effects of Gly161 mutation by 
reducing their aggregation extent 
Treatment with B6 is a common strategy for the therapy of many metabolic 
diseases caused by PLP-dependent enzymes. However, the degree of 
responsiveness is extremely variable depending on both the disease and 
the genotype of the patients. In the case of PH1, pyridoxine administration 
is effective in about 10-30% of the patients and clinical data suggest that 
the responsive mutations are associated with AGT mistargeting. Moreover, 
although it is known that pyridoxine administration increases the 
intracellular concentration of PLP, the molecular bases of the effect of the 
coenzyme are not fully understood. The evidences reported in this study 
suggest that PLP (i) reduces the aggregation extent of purified G161S-Mi 
and G161C-Mi variants by shifting the equilibrium from the apo- to the more 
stable holo-form, (ii) increases the specific activity of the variants 
expressed in the CHO cellular model system, likely by preventing protein 
aggregation and (iii) does not increase the total expression level of the 
variants. Thus, the coenzyme seems to essentially play a prostetic role 
facilitating the conversion of D to DPLP (Fig. 27). Although further studies 
will be required to establish the exact mechanism of action of exogenous 
coenzyme on Gly161 variants, our results suggest that pyridoxine 
administration should be regarded as a first line option for PH1 patients 
bearing mutations at Gly161. Considering the limited effect of pyridoxine on 
the specific activities of Gly161 variants, vitamin B6 administration should 
be associated with other molecules able to further stabilize Gly161 variants, 
such as compounds acting as pharmacological chaperones. 
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The molecular pathogenesis of PH1 is extremely varied, as several diverse 
enzymatic phenotypes, including loss of enzymatic activity, altered 
coenzyme binding affinity, folding defects, aggregation propensity, reduced 
intracellular stability and mislocalization can result in AGT deficiency. In this 
thesis is described the biochemical characterization of nine AGT variants 
(W108R-Mi, S158L-Ma, G161S-Mi, G161C-Mi, G161R-Ma, D183N-Ma, 
S187F-Ma, S218L-Ma, P319L-Ma and G350D-Mi) associated with PH1. 
Moreover a detailed analysis of the structural properties of the S187F-Ma 
variant and of the molecular and cellular properties of Gly161 variants is 
reported.  
Altogether, the obtained data have allowed us: 
1. to provide evidence for the structural and/or functional effects 
caused by each mutation on the protein and to define which form, 
holo- or apo-, and which part, active-site, large domain or small 
domain, of the enzyme is affected by the mutation.  
2. to reassess previous data obtained with crude cellular extracts in 
which all the analysed mutations were referred as causing loss of 
both immunoreactivity and catalytic activity.  
3. to indicate the suitable therapy, among those available, and to 
suggest new treatments strategies for patients bearing the analysed 
mutations. 
 
Thus, a multi-disciplinary approach comprising both studies on purified 
proteins and cellular biochemistry analyses should be applied to shed 
light on the molecular defect of pathogenic variants causing PH1. This 
would improve our understanding of the molecular pathogenesis of the 
disease and pave the way to define suitable therapies on the basis of the 
patient genotype.  
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S250F variant associated with aromatic amino acid 
decarboxylase deficiency: molecular defects and 
intracellular rescue by pyridoxine  
During the last year of my PhD I’ve been involved in the study of aromatic 
amino acid decarboxylase (AADC) deficiency, a rare neurometabolic 
disorder due to the absence of functional Dopa decarboxylase (DDC). DDC 
is a PLP-dependent enzyme responsible for the production of the 
neurotransmitters dopamine and serotonin. More than 50 patients with 
DDC deficiency have been tabulated on the BIOMDB database 
(http://www.biopku.org/biomdb/biomdb_start.asp), and 23 missense 
pathogenic mutations have been identified, half of which in homozygous 
patients. Although the clinical phenotype associated with the disease has 
been widely investigated [65, 66], the molecular effect(s) that each mutation 
induces on DDC is almost unknown. Nonsense and frameshifts mutations 
lead to the complete loss of the gene product, while missense point 
mutations cause the synthesis of an aberrant gene product which can be 
characterized by defects of enzymatic activity, PLP binding, protein stability 
and/or folding, protein half-life, etc. Current treatments for AADC deficiency 
include the administration of pyridoxine or PLP to increase the residual 
DDC activity, MAO-B inhibitors to minimize the dopamine degradation, or 
dopamine agonists to mime the action of the neurotransmitter [67]. The 
response to these therapies is variable, but the overall outcome is poor, 
probably reflecting the allelic heterogeneity. Moreover, since drugs are 
almost always given in combination, response is hardly ascribable to a 
single drug. In diseases related to protein malfunction it is diagnostically 
and therapeutically essential to understand the multiple mechanisms that 
relate the specific mutants with the pathology. Therefore, the knowledge of 
the structural and/or functional effect(s) that each amino acid substitution 
produces on DDC would be highly desirable. A first example of this 
approach is a recent study in which, by means of biochemical and 
bioinformatic analyses, the molecular defects of four recombinant purified 
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pathogenic variants whose mutations concern residues located at or near 
the active site have been identified. On these bases, a therapeutic 
treatment has also been proposed [68]. During my PhD the effects of the 
S250F mutation, the most frequent associated with AADC deficiency, have 
been defined by a combined analyses on the S250F variant both in the 
purified form and expressed in a cellular system. We found that Ser250 is 
not essential for the catalytic activity of DDC. However, its mutation to Phe 
causes a ~7-fold reduction of catalytic efficiency and a conformational 
change in the proximity of the mutated residue that is transmitted to the 
active site. In cellular extracts of E. coli and mammalian cells, both the 
specific activity and the protein level of the variant decrease with respect to 
the wild-type. The results with mammalian cells indicate that the mutation 
does not affect intracellular mRNA levels, and are consistent with a model 
where the S250F variant undergoes a degradation process via the 
proteasome, possibly through an ubiquitination process occurring faster 
than in the wild-type. Overall, biochemical and cell biology experiments 
show that loss of function of S250F occurs by two distinct but not exclusive 
mechanisms affecting activity and folding. Importantly, 4-phenylbutirric acid 
(4-PBA) or, to a major extent, pyridoxine increase the expression level and, 
in a dose-dependent manner, the decarboxylase specific activity of mutant-
expressing cells. This strongly suggests that 4-PBA and/or pyridoxine 
administration may be of important value in therapy of patients bearing the 
S250F mutation. 
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G41 is an interfacial residue located within the α-helix 34–42 of
alanine:glyoxylate aminotransferase (AGT). Its mutations on the
major (AGT-Ma) or the minor (AGT-Mi) allele give rise to the
variants G41R-Ma, G41R-Mi, and G41V-Ma causing hyperoxaluria
type 1. Impairment of dimerization in these variants has been sug-
gested to be responsible for immunoreactivity deficiency, intraper-
oxisomal aggregation, and sensitivity to proteasomal degradation.
However, no experimental evidence supports this view. Here we
report that G41 mutations, besides increasing the dimer-monomer
equilibrium dissociation constant, affect the protein conformation
and stability, and perturb its active site. As compared to AGT-Ma or
AGT-Mi, G41 variants display different near-UV CD and intrinsic
emission fluorescence spectra, larger exposure of hydrophobic
surfaces, sensitivity to Met53-Tyr54 peptide bond cleavage by pro-
teinase K, decreased thermostability, reduced coenzyme binding
affinity, and catalytic efficiency. Additionally, unlike AGT-Ma and
AGT-Mi, G41 variants under physiological conditions form insoluble
inactive high-order aggregates (∼5; 000 nm) through intermolecu-
lar electrostatic interactions. A comparative molecular dynamics
study of the putative structures of AGT-Mi and G41R-Mi predicts
that G41→ R mutation causes a partial unwinding of the 34–42
α-helix and a displacement of the first 44 N-terminal residues in-
cluding the active site loop 24–32. These simulations help us to en-
visage the possible structural basis of AGT dysfunction associated
with G41 mutations. The detailed insight into how G41 mutations
act on the structure-function of AGT may contribute to achieve the
ultimate goal of correcting the effects of these mutations.
dimer interface ∣ pathogenic variant ∣ protein aggregation ∣
pyridoxal 5'-phosphate
Alanine:glyoxylate aminotransferase (AGT) is a homodimericpyridoxal 50-phosphate (PLP) dependent enzyme which
catalyzes the interconversion of L-alanine and glyoxylate into
pyruvate and glycine. Human AGT has been cloned, expressed
in E. coli and purified. The enzyme crystal structure, complexed
with the competitive inhibitor amino-oxyacetic acid, was
determined at a resolution of 2.5 Å. Each subunit includes a
N-terminal extension (residues 1–21), a large N-terminal domain
(residues 22–282) containing the PLP-binding lysine (K209), and
a smaller C-terminal domain (residues 283–392) (1). Steady-state
and pre-steady-state kinetic studies featuring the AGT transami-
nation revealed high specificity for glyoxylate to glycine proces-
sing, consistent with a key role of AGT in glyoxylate detoxification
(2). The human liver-specific AGT is localized in the peroxisomal
matrix (3). The enzyme has been the focus of extensive clinical
research because its functional deficiency causes primary hyper-
oxaluria type 1 (PH1). PH1 is a rare autosomal recessive disorder
characterized by excessive synthesis and excretion of oxalate and
glycolate, and progressive accumulation of insoluble oxalate in
the kidneys and urinary tract (4). The AGT gene (AGXT) occurs
normally as one of the two allelic forms: the major (AGT-Ma) or
minor (AGT-Mi) alleles. The latter, comprising two coding poly-
morphisms, P11L and I340M, and a noncoding duplication in in-
tron 1 (5), has no dramatic effect on the properties of AGT. To
date, well over 100 pathogenic mutations associated to AGT-Ma
and/or AGT-Mi are known (6). Three categories of enzymatic
phenotypes causing PH1 can be identified: deficiency of AGT
catalytic activity but not AGT immunoreactivity, catalytic activity
and immunoreactivity deficiency, and mistargeting to mitochon-
dria (4, 7). Notably, clinical data for single PH1 AGT mutations
are generally limited to a small number of individuals, which may
interfere with identifying clear correlations between disease
characteristics and properties of mutant proteins. Currently,
the way of treatment of this progressive and potentially fatal
disease is poor, as the molecular bases of the effects of the various
disease-associated point mutations are unknown. In the last
years, a biochemical characterization of the pathogenic variants
G82E-Ma and F152I-Mi allowed us to correlate the clinical and
enzymatic phenotypes with the structural and functional proper-
ties of the corresponding variants (2, 8).
The G41 series of pathogenic mutations, including the G41R
encoded on the background of the major (G41R-Ma) and the
minor (G41R-Mi) alleles, and the G41V, which only cosegregates
with the major allele (G41V-Ma), is of special interest because
(i) G41 is an interfacial residue making van der Waals contacts
with the same residue of the other subunit and belongs to an
α-helix connected with the active site loop 24–32 (Fig. S1),
(ii) G41R mutation is more severe when it occurs on AGT-Mi
than on AGT-Ma (4), and (iii) responsiveness to pyridoxine ther-
apy for the patients bearing these mutations is so far unknown
(9). Previous clinical and cell biochemical studies suggested that
the weakening of the dimeric structure of AGT consequent to
G41 replacements could be responsible for depletion of immu-
noreactive AGT, its intraperoxisomal aggregation (4, 10), and
sensitivity to proteasomal degradation (11, 12). Because formal
proves of the effect of these mutations at the molecular level
are so far absent, we thought to provide insights into the mole-
cular basis of the G41 mutation’s pathogenicity. Biochemical data
indicate that G41 mutations, besides causing a weakening of the
intersubunit interaction, alter the conformational state of the
AGT dimeric form, reduce its resistance to thermal inactivation
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and unfolding, and induce susceptibility to proteolytic degrada-
tion and self-aggregation. Moreover, predictions of the structural
effects caused by G41 mutation by means of molecular dynamics
(MD) provide a possible interpretation and explanation of our in
vitro results.
Results
G41 Mutations Affect the Spectral Features and the Coenzyme Binding
Affinity. Like AGT-Ma and AGT-Mi, G41 variants bind 2 mol of
PLP per dimer, and exhibit visible absorbance and CD spectra
similar to those of AGT-Ma or AGT-Mi, even if their absorbance
and dichroic maxima are about 10–12 nm blue shifted (Fig. S2 and
Inset). TheKDðPLPÞ values for G41R-Ma,G41V-Ma, andG41R-Mi
were found to be 1.5# 0.4, 0.55# 0.1, and 6.0# 0.5 μM, respec-
tively, that are ∼6-, 2-, and 23-fold higher than that of AGT-Ma or
AGT-Mi (2, 8). Both AGT-Ma and AGT-Mi bind pyridoxamine
50-phosphate (PMP) with aKDðPMPÞ value≪0.1 μM, whereas even
a prolonged time of incubation of the apo forms of G41 variants
with PMP (up to 5 mM) does not result in a dichroic signal at
340 nm, typical of the AGT-PMP complex (2). Thus, G41 muta-
tions exert a decrease in the PLP binding affinity and a dramatic
reduction in thePMPbinding affinity. The comparisonof near-UV
CD spectra as well as of intrinsic and 1-anilinonaphthalene sulfo-
nic acid (ANS) fluorescence spectra of AGT-Ma, AGT-Mi, and
G41 variants provides evidence that a different conformation ex-
ists between each apoenzymatic form and the corresponding holo
form, and between the holo and apo forms of G41 variants
and the corresponding forms of AGT-Ma or AGT-Mi (Fig. S3A
and B). These data imply that (i) conformational changes seem
to accompany the apo to holo transition for each enzymatic form,
and (ii)G41mutations affect theoverall conformationof bothholo
and apo AGT.
The far-UV CD spectra of G41 variants have been compared
with those of AGT-Ma and AGT-Mi. All spectra exhibit minima at
210 and 222 nm, typical of proteins containing appreciable
amounts of α-helix. However, spectra deconvolution reveals that
AGT-Ma, AGT-Mi, and G41V-Ma have an identical composition
of the overall secondary structure, whereas both G41R-Ma and
G41R-Mi display about 5% less α-helical content.
G41 Mutations Slightly Affect the Kinetic Parameters. The kinetic
parameters of AGT-Ma, AGT-Mi, and G41 variants for the pair
alanine-glyoxylate are reported in Table S1. The Km values of
G41 variants for L-alanine and glyoxylate are not significantly
altered, whereas the kcat values decrease by 1.5–3.5-fold as
compared to those of the corresponding AGT-Ma and AGT-Mi.
Altogether, these data indicate that the G41 mutations slightly
affect the catalytic properties of AGT.
G41 mutations increase the dimer-monomer equilibrium dissociation
constant (Kd). As a first step to investigate the impact of G41 mu-
tations on the AGT dimeric structure, photo-induced cross-link-
ing experiments with Tris(2,20-bipyridyl) ruthenium(II) chloride
(TBPR) have been carried out at 1 μM enzyme concentration.
TBPR cross-linking is incomplete and also gives rise to the for-
mation of aggregates and intramolecular cross-linked monomers.
Nevertheless, it is possible to estimate the relative population of
chemically cross-linked dimer to monomer with similar results for
all the holo species, but lower for apo G41 variants than for
apoAGT-Ma and apoAGT-Mi (Fig. S4). To validate these data
we used the very accurate and sensitive size-exclusion chromato-
graphy (SEC) method. Holo and apo forms of AGT-Ma and
AGT-Mi as well as the holo forms of the G41 variants from 5
to 0.1 μM concentration (the latter value being the detection lim-
it), eluted as a single peak with a retention volume corresponding
to a dimer. Thus, the Kd values of these species must be
≪0.1 μM. On the other hand, the apo forms of G41 variants over
the range 50 − 0.1 μM enzyme concentration eluted as a single
peak whose position varied between the dimeric and the mono-
meric forms of the enzyme, indicating a rapid equilibrium pro-
cess. Plots of the percent dimer as a function of apoG41R-Ma
and apoG41R-Mi concentrations give hyperbolic-like curves,
the linear transformation of which yields the Kd values of 0.32#
0.05 and 1.8# 0.5 μM, respectively. In the case of apoG41V-Ma,
a decrease of the integrated peak area starts at 1.5 μM reaching at
0.1 μM a value about 30% of the one expected, possibly because
of monomerization followed by artefactual aggregation. A Kd va-
lue ranging from 1.5 to 0.1 μM can be estimated for this mutant.
The SEC results, consistent with those of cross-linking analyses,
do not allow to quantify the impact of G41 mutations on the Kd
value of holoAGT, but clearly indicate that the mutations increase
the Kd value of apoAGT.
G41 Mutations Induce Susceptibility to Proteinase K Digestion.
Limited proteolysis was used to further probe that replacements
of G41 change the overall conformation of AGT. AGT-Ma,
AGT-Mi, and the G41 variants in the holo and apo forms were
incubated in 100 mM potassium phosphate buffer, pH 7.4, at 25 °
C with proteinase K at different AGT/protease weight ratios
(from 5; 000∕1 to 100∕1). When aliquots of these reaction
mixtures were withdrawn at different times and subjected to
SDS-PAGE, it was observed that, although the size of the band
(∼42.7 kDa) corresponding to the intact holo or apo forms of
AGT-Ma and AGT-Mi remains unaltered even after a prolonged
time of incubation (Fig. S5A), that of G41 variants gradually de-
creases and simultaneously a faster migrating band (∼40.2 kDa)
appears. Both the 42.7 and 40.2 kDa bands stain with antibody
raised against the C-terminal hexahistidine tag, as revealed by
Western blot analysis, indicating that the cleavage occurs within
the N terminus. In fact, Maldi-mass spectrometry analysis yields a
molecular weight difference for the N terminus truncated
fragment of 5503# 15 atomic mass unit compared with the
full-length G41R mutant, compatible with a cleavage site located
at the peptide bond Met53-Tyr54. The effect of proteinase K on
holo G41R-Mi is shown in Fig. 1, and that on holo G41V-Ma in
Fig. S5B. The initial velocity values of the cleavage (expressed as
μg enzyme∕min ∕μg proteinase K) determined by measuring the
decrease of the intensity of the band corresponding to the intact
enzyme, are 4# 1, 530# 40, and 6# 1 for the holo forms of
G41R-Ma, G41R-Mi, and G41V-Ma, respectively, and 130# 30,
870# 90, and 30# 6 for the corresponding apo forms. The
proteolytic cleavage is accompanied by a time dependent loss of
transaminase activity occurring for holoG41R-Mi with an initial
velocity of 420# 50 μgmutant∕min ∕μg proteinase K , a value that
agrees with that of degradation. At a 10∕1 AGT/proteinase K
weight ratio, G41 variants are degraded in less than a half-hour
to low molecular weight peptides, whereas AGT-Ma and AGT-Mi
remain unaltered. Altogether these data indicate that, unlike
Fig. 1. Effect of proteinase K on holoG41R-Mi. HoloG41R-Mi (15 μM) was
incubated at 25 °C in 100 mM potassium phosphate buffer, pH 7.4, at a
1; 000∕1 ðwt∕wtÞ mutant/proteinase K ratio. At times indicated, aliquots
were removed, treated (seeMethods), and subjected to 12% SDS-PAGE. Plus
and minus signs indicate presence or absence of proteinase K.
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AGT-Ma and AGT-Mi, G41 variants undergo digestion and
concomitant inactivation more pronounced for their apo than for
the corresponding holo forms.
G41 mutations induce formation of high order inactive aggregates.
We noticed that, unlike AGT-Ma and AGT-Mi, holoG41 variants
at an ionic strength (I) value lower than 260 mM and/or at an
enzyme concentration higher than 10 μM form visible insoluble
aggregates. When these solutions are centrifuged, a yellow pellet
indicative of PLP-bound aggregates appears. The specific activity
of the precipitates resuspended in the assay buffer is <5% than
that of the supernatant containing the dimeric species. This ob-
servation, together with the documented presence of intraperox-
isomal aggregates in patients bearing G41R mutation (10), led us
to investigate in some detail this phenomenon by means of
turbidimetry and dynamic light scattering (DLS) studies under
physiological conditions, i.e., at 37 °C, pH 7.4 at I ¼ 150 mM.
As shown in Fig. 2, significant changes in turbidity began after
a lag phase ranging from 50 to 120 min for both the holo and
apo forms of G41R-Mi as well as for the apo forms of G41R-Ma
and G41V-Ma. No turbidity could be detected for these enzymatic
species at pH 7.4, and I ¼ 260 mM at either 25 °C or 37 °C at least
over a 5 h interval. Fig. 3A andB show plots of the total count rate as
a function of time for holo and apoenzymes of AGT-Ma, AGT-Mi,
and G41 variants. The increase in count rate for the holo and apo
forms of AGT-Ma and AGT-Mi is very slow, whereas the more
typical fast aggregation for G41 variants could be seen with the
count rate leveling off after ∼20–40 min. The decrease in the light
scattering intensity occurring for holoG41R-Mi and for the apo
forms of G41 variants is due to precipitation of the protein aggre-
gates. Altogether, the turbidity and DLS data indicate that (i)
replacements of G41 are responsible for the propensity of mutants
to self-association, the extent of which is more pronounced for the
apo forms than for the corresponding holo forms, and (ii) G41R-Mi
results the variant most prone to aggregation. The molecular size of
the species present in the enzymic solutions has been also evaluated.
The particle size of the dimeric form of AGT-Ma, AGT-Mi, and G41
variants, measured at 25 °C, pH 7.4, at I ¼ 260 mM, i.e., under con-
ditions of no detectable association, is about 10 nm. This value is
consistent either with that (9.32 nm) derived from the X-ray struc-
ture (1) or that (7# 2 nm) calculated by an appropriate empirical
equation (13). When the aggregation process occurring under the
physiological conditions mentioned above was followed by DLS,
the time dependence of the apparent particle size indicates that
the 10 nm species is always present for holo and apo AGT-Ma
and holoAGT-Mi, although small aggregates (100–800 nm) appear
after about 30 min (Fig. 4A and B). Considering that the scattering
intensity is proportional to the sixth power of the particle diameter,
the dimer must be in these species very abundant in number. In con-
trast, the dimer disappears over a 5–75 min time range, depending
on the enzymatic species, for AGT-Mi in the apo form and for G41
variants in both the holo and apo forms. Moreover, whereas only
small aggregates (100–800 nm) accumulate in apoAGT-Mi, in
G41 variants a distinct population of higher-order aggregates
(∼5; 000 nm), along with small aggregates, can be identified
(Fig. 4B–E). From these data it can be also envisaged that
(i) the turbidity is mainly associated to the presence of high-order
aggregates, and (ii) the lack of detectable turbidity for G41R-Ma
and G41V-Ma in the holo form could be ascribed to the very
low fractional contribution of the larger particles to the total scat-
tering intensity.
The effect of 200 mM trimethylamine-N-oxide (TMAO) or
100 mM betaine [two osmolytes known to suppress protein
aggregation (14)] on the aggregation process of holoG41R-Mi
has been followed by DLS. Either TMAO or betaine, although
unable to decrease the amount of and size of the aggregates
formed at equilibrium, as detected by the final count rate leveling
off, cause a slight increase in the lag time duration (from 10 to
20 min) and in the persistence of the dimeric species (from 35 to
70 min) in the aggregation kinetics.
Fig. 2. Time dependence of turbidity of AGT-Ma, AGT-Mi, and G41 variants.
Absorbance at 600 nm as a function of time of 4 μM apo forms of AGT-Ma (▪),
AGT-Mi (▾), G41R-Ma (▴), G41V-Ma (♦), and G41R-Mi (•) in potassium
phosphate buffer, pH 7.4, I ¼ 150 mM at 37 °C. Corresponding holoenzymes,
open symbols.
Fig. 3. Time-dependence of total count rate (measured as kilo counts
per second) of AGT-Ma, AGT-Mi, and G41 variants in the holo (A) and apo
(B) forms. Measurements performed at 4 μM enzyme concentration, 37 °C,
I ¼ 150 mM, pH 7.4. Color code: black, AGT-Ma; red, AGT-Mi; blue,
G41R-Ma; green, G41V-Ma; fuchsia, G41R-Mi.
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G41 Mutations Decrease Resistance to Thermal Denaturation and
Inactivation. A differential calorimetric study (DSC) was carried
out to reveal the impact of G41 mutations against thermal
denaturation. Thermal denaturation of holo and apo forms of
AGT-Ma, AGT-Mi, G41R-Ma, and G41V-Ma as well as of holo
form of G41R-Mi produces DSC profiles consisting of an en-
dothermic transition due to the protein denaturation followed
by a large exothermic transition due to the aggregation of the de-
naturated protein (Fig. S6), precluding the peaks deconvolution.
Thus, the maxima of the endothermic transitions of these species
represent apparent melting temperature (Tm) values. The Tm of
apoG41R-Mi could not be determined because of the lack of an
observable transition, possibly due to overlapping of the dena-
turation and aggregation processes (Table 1). The thermal effect
on the catalytic function of AGT-Ma, AGT-Mi, and G41 variants
was also measured, and the transition midpoints of thermal inac-
tivation (Ti) are reported in Table 1. The results indicate that
(i) holo AGT-Ma, AGT-Mi, and G41 variants display Tm and
Ti values higher than those of the corresponding apoenzymes,
which supports different conformational states of holo and apo
forms, (ii) AGT-Ma is more resistant than AGT-Mi, and (iii) G41
mutations decrease the thermal stability, being G41R-Mi the
most thermally instable variant.
MD studies.We examined in a comparative way the conformational
space sampled by the putative structures of AGT-Mi and G41R-Mi
by high-temperature (500 K) MD simulations with explicit water
solvation. Both AGT-Mi and G41-Mi reach an equilibrated state
after ∼100 ps (Fig. S7A), thereafter their global architecture re-
maining stable, as confirmed by the indicators commonly used
to analyze MD simulations (Fig. S7A–C). Unlike that observed
for AGT-Mi, a marked fluctuation can be observed for the region
spanning residues 1–44 of both monomers of G41R-Mi. This re-
gion comprises the active site loop (residues 24–32) and the α-helix
34–42 in which the G41R substitution takes place. In particular,
the MD simulation of G41R-Mi reveals that the N-terminal
α-helices (residues 34–42) undergo a progressive displacement
(Fig. S8), and a partial unwinding of the first and second turns
Fig. 4. Time dependence of the apparent diameters of AGT-Ma, AGT-Mi,
and G41 variants. Experimental conditions (see legend to Fig. 3). (A) holo
and apo AGT-Ma. (B) holo and apo AGT-Mi. (C) holo and apo G41R-Ma.
(D) holo and apo G41V-Ma. (E) holo and apo G41R-Mi. Color code: black, holo
dimer; green, apo dimer; red, holo small aggregates; blue, apo small aggre-
gates; cyan, holo high aggregates; fuchsia, apo high aggregates.
Table 1. Transition midpoints of thermal denaturation (Tm) and
inactivation (Ti) of AGT-Ma, AGT-Mi, and G41 variants
Enzyme Holo form Apo form Holo form Apo form
Tm*, °C Ti†, °C
AGT-Ma 77.3 62.4 77.4 59.1
AGT-Mi 73.2 55.6 72.6 52.2
G41R-Ma 60.3 57.6 57.7 53.0
G41R-Mi 53.7 ND 51.8 46.0
G41V-Ma 61.0 58.3 62.3 54.5
ND, not detectable.
*They represent apparent Tm values and are the mean of two independent
experiments. The error is within #0.3 °C error.
†Data inactivation points were subjected to nonlinear regression analysis and
Ti values were calculated. The data are the means of at least two
independent experiments. The standard error of the mean was less than
5% of the mean value in every case.
Fig. 5. Comparison of the initial 3D model of G41R-Mi (dark gray) with the
averaged structure obtained from MD simulation (light gray). Residues 1–46,
roughly corresponding to the N-terminal arm of G41R-Mi, are highlighted
in orange for the initial 3D model and in red for the averaged structure.
(Inset) Detail of the α-helix in which the G41R substitution takes place
(residues 34–42).
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of the helix (Fig. 5). It is likely that these events could be related to
the accommodation of the long side chain of Arg41.
Discussion
G41, located at the end of the α-helix 34–42 of AGT, is an inter-
facial residue which makes van der Waals contacts with the same
residue of the adjacent subunit (1). Thus, it is not surprising that
(i) the conversion of the small, uncharged Gly41 to the bulky,
charged Arg causes a ∼5% loss of α-helix content, while the
conversion to Val, a larger uncharged residue, does not have a
detectable effect on the overall secondary structure, and (ii) the
apo forms of G41 variants undergo reversible dissociation of the
subunits with Kd values from at least ∼3-fold to ∼20-fold higher
than that of apoAGT-Ma or apoAGT-Mi. Actually, we found that
G41 variants in the dimeric form differ from AGT-Ma or AGT-Mi
under many respects. Their structural conformation and stability
are altered, as detected by difference in the near-UV CD and
intrinsic emission fluorescence spectra, larger exposure of hydro-
phobic surfaces, sensitivity to proteinase K cleavage, and
decrease in Tm and Ti with respect to AGT-Ma and AGT-Mi.
Additionally, G41 variants show slightly altered visible spectro-
scopic features, a reduced steady-state catalytic activity, and a
decreased PLP binding affinity as well as a dramatic reduction
in the PMP binding ability.
A comparative study of the putative structures of AGT-Mi and
G41R-Mi by MD predicts that the G41R mutation would cause
the partial unwinding of the α-helix 34–42 as well as the displace-
ment of the N-terminal arm and its exposure to the environment.
Although these predictions are of course not an experimental
evidence of the structural effects caused by the mutation, they
are consistent with the in vitro data of G41R-Mi, i.e., the 5% loss
of the α-helix content and the susceptibility of the Met53-Tyr54
peptide bond to proteinase K cleavage. It is worth noting that,
although G41 is far from the active site, it is located in the α-helix
connected with the active site loop (residues 24–32) belonging to
the N terminus (Fig. S1). Therefore, we might speculate that the
alterations of the visible spectroscopic and catalytic features of
G41 variants could be due to the rearrangements occurring
around the mutated residue transmitted to the active site.
Another particularly interesting aspect is that, unlike AGT-Ma
and AGT-Mi, G41 variants spontaneously form insoluble inactive
high-order aggregates (∼5; 000 nm) under physiological condi-
tions of temperature, I and pH. The finding that the aggregation
extent greatly decreases as I increases may be ascribed to the
reduction in favorable attractive interactions due to screening
effects. This behavior indicates that aggregation is not due to hy-
drophobic interactions, in which case the addition of salt would
enhance aggregation and little effect would be seen at low I, but
rather to electrostatic intermolecular interactions arising from
protein charge heterogeneity. It is also worth noting that the ag-
gregation occurs at a pH value lower than pI, thus excluding an
isoelectric precipitation. Why are the G41 variants aggregation
prone? In the absence of the crystal structure of these variants,
the protein electrostatic potential distribution for AGT-Mi and
the 1–44 N-terminus lacking form of AGT-Mi has been calculated
by electrostatic computer modeling. The truncated form was
chosen for comparison because it would mimic the structure
of G41R-Mi upon the displacement of the N-terminal arm. As
shown in Fig. 6A and B, AGT-Mi displays a highly positive charge
distribution around its surface, whereas the truncated form exhi-
bits a clear dipole segregation of charges. In fact, the depletion of
the highly positively charged N-terminal arm of AGT-Mi leads to
the exposure of several negatively charged residues (Asp51,
Glu59, Glu62, Glu274, Glu281, Asp344, Glu346 of each mono-
mer), i.e., to a condition of electrostatically driven self-aggrega-
tion of AGT. Thus, one can reason out that the fluctuation of the
N terminus in G41R-Mi could cause the exposure of negative
charged residues similar to that observed for the truncated
AGT form. Although this could be a plausible explanation for
the propensity of G41 variants to aggregate spontaneously, a
conclusive evidence for this interpretation is lacking.
The finding that G41R-Mi displays structural and functional al-
terations more pronounced than G41R-Ma needs to be discussed.
The thermal unfolding data indicate that the instability of G41R-
Mi is due to the additive contribution of the polymorphic and
pathogenic mutations. The effect of the polymorphic substitutions
is possibly due to P11L in that Pro instead of Leu (i) contributes to
the increase of structural rigidity, (ii) exerts additional constraints
to the backbone, because the ring closure keeps its Φ angle value
almost fixed, and (iii) makes hydrophobic interactions with a
surface cavity surrounded by residues Leu14, Glu62, Gly63,
Tyr66, and Ala280.
Altogether, our data assist in assessing a picture of the G41
variants enzymatic phenotype more exhaustive than that pre-
viously proposed. The pathogenicity of G41 variants has been
until now related to a disruption of the interface and impairment
of dimerization resulting in formation of monomers with reduced
catalytic activity and prone to degradation and/or intraperoxiso-
mal aggregation (1, 4, 15). Our in vitro results would indicate not
only the impact of G41 mutations on the dimerization but also
provide evidence that G41 variants in the dimeric form are prone
to degradation and aggregation. The presence of aggregates only
within the peroxisomal matrix in patients bearing G41R mutation
(10) is consistent with this view in that the peroxisomal import
machinery acts on folded dimeric proteins. In any case, it will
be important to establish if the intraperoxisomal aggregates have
ultrastructure similarities with the aggregates spontaneously
formed in vitro. If this were the case, the electrostatically driven
protein aggregation between folded dimers could represent a un-
ique pathogenic mechanism by which G41 inherited mutations
would cause protein aggregation. Indeed, many disease-related
genetic mutations are known to alter the folding or stability of
proteins leading to intermediates in which hydrophobic patches
become exposed and prone to self-association.
Overall, our work improves the understanding of the correla-
tion between the genotype and the enzymatic phenotype, thus
allowing us to foresee the response to pyridoxine in patients car-
rying the G41 mutations. Administration of pyridoxine to these
patients is not sufficient to counteract the disease because the
molecular defects of these variants appear to be related to struc-
tural rearrangements yielding molecules that are both in the apo
and the holo forms prone to degradation and aggregation. A pro-
mising therapeutic strategy could be the administration of small
molecules able to stabilize the native state of the protein, thus
preventing degradation and aggregation. In this regard, our pre-
liminary results on the effects of osmolytes on the aggregation
behavior of G41 variants could be an encouraging perspective.
Fig. 6. Electrostatic potential surface maps of AGT-Mi and its truncated
form. Electrostatic gradient and map (kT∕e) of AGT-Mi (A), and 1–44
truncated form of AGT-Mi (B).
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Methods
Construction, Expression and Purification of G41 Variants. AGT-Ma and AGT-Mi
were prepared as reported (2, 8). Site-directed mutagenesis, expression, and
purification of G41 variants in the C-terminal His-tagged form were per-
formed using standard procedures as described in SI Text.
Enzyme Activity Assays. Pyruvate formation was measured by the spectropho-
tometric assay already reported (2). Kinetic parameters for the pair alanine/
glyoxylate of G41 variants were determined in the presence of 150 μM PLP by
varying the substrate concentrations at a fixed saturating cosubstrate
concentration. Data were fitted to the Michaelis–Menten equation. Thermal
inactivation experiments were performed as follows: enzyme (10 μM) was
incubated for 10 min in 100 mM potassium phosphate buffer, pH 7.4, at
different temperatures, and then chilled on ice. Transaminase activity was
measured as indicated above.
Binding Affinity for PLP. The KDðPLPÞ of G41 variants were determined by
measuring the PLP-induced changes either on the intrinsic fluorescence or
in the CD visible spectrum of the apoenzymes. The experimental conditions
and the relative data analysis are given in SI Text.
Cross-Linking and SEC Experiments. Photo-induced cross-linking with TBPR
was performed as previously described (7). SEC experiments were done on
an Akta FPLC system (GE Healthcare) using a custom packed Sephacryl
S-300 10∕600 column. The data were analyzed according to the method
of Manning et al. (16). Details are given in SI Text.
Proteinase K Digestion and Mass Spectrometry Analysis. Holo and apo AGT-Ma,
AGT-Mi, and G41 variants (15 μM) were treated with proteinase K in 100 mM
potassium phosphate buffer, pH 7.4, at 25 °C at various AGT/proteinase
K (wt∕wt) ratios. At various times, 15 μL-aliquots were withdrawn from the
reaction mixtures and subjected to enzymatic activity assay, SDS-PAGE, and
immunoblotting. The reaction was stopped by adding PMSF or EGTA to a final
concentration of 2 mM to each aliquot. After staining with Coomassie blue,
the band intensities were visualized and analyzed using ImageJ software
(Wajne Rasband). Immunoblotting was made as described in SI Text. Liquid-
chromatography/MS analyses of G41R-Mi were carried out with a model
Mariner Esi-Tof spectrometer from PerSeptive Biosystems, connected to a
C4 Grace-Vydac microbore column (1 × 50 mm). Column elution was carried
out with a CH3CN-1% HCOOH gradient from 1 to 80% in 30 min. Proteolysis
reaction of G41R-Mi with proteinase K was analyzed with a model 4800 Plus
Maldi-Tof-Tof instrument from Applied Biosystems. Samples were desalted on
a P10 C4 Zip-Tip, elutedwith a sinapinic acid (Sigma) saturated solution (2 μL) in
CH3CN∶H2O (60∶40 by vol). Details are given in SI Text.
Turbidimetry Measurements. The aggregation experiments were carried out
in potassium phosphate buffer, pH 7.4, at different I values and/or different
enzyme concentrations. The turbidity was monitored by measuring the ab-
sorbance at 600 nm as already reported (17).
DLS Measurements. DLS measurements were made on a Zetasizer Nano S
device from Malvern Instruments. The temperature of sample cell was
controlled by a thermostating system within #0.1 °C and 12.5 × 45-mm
disposable cells with stopper were used. To study the aggregation kinetics,
an aliquot of each enzymatic species was diluted to a final concentration of
4 μM in potassium phosphate buffer pH 7.4 at the desired I and temperature.
PLPwas added to the holoenzyme solutions to a final concentration of 60 μM.
The buffer was filtered immediately before use to eliminate any impurities.
TMAO or betaine were added to the buffer before the addition of G41R-Mi.
Spectroscopic Measurements. Absorption, fluorescence, and CD spectra were
performed as described in SI Text.
DSC. DSC experiments were conducted with a VP-DSC microcalorimeter
(Microcal) in the temperature interval from 20 to 90 °C, with a scan rate
of 90 °C∕h in 100 mM potassium phosphate buffer, pH 7.4, and at 5.5 μM
protein concentration.
Computational Analyses. MD simulations of the molecular models of AGT-Mi
and G41R-Mi, derived from the crystal structure of human AGT (1), down-
loaded from Brookhaven Protein Data Bank (18) were performed. A detailed
description of the generation of these structures and MD simulations is given
in SI Text. Electrostatic computations on AGT-Mi and its N terminus deleted
form were carried out by solving the nonlinear Poisson–Boltzmann equation,
one of the most popular continuum models for describing electrostatic inter-
actions between molecular solutes in salty, aqueous media. Adaptive Poisson
Boltzman Solver was used to this purpose (19), with a protein and solvent
dielectric of 2.0 and 80.0, respectively, and I ¼ 150 mM.
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a b s t r a c t
The sensitivity to denaturant stress of the major (AGT-Ma) and the minor (AGT-Mi) allele of alanine:-
glyoxylate aminotransferase and P11L mutant has been examined by studying their urea-induced
equilibrium unfolding processes with various spectroscopic and analytical techniques. AGT-Ma loses
pyridoxal 50-phosphate (PLP) and unfolds completely without exposing signiﬁcant hydrophobic clusters
through a two-state model (Cm w 6.9 M urea). Instead, the unfolding of AGT-Mi and P11L variant
proceeds in two steps. The ﬁrst transition (Cmw 4.6 M urea) involves PLP release, dimer dissociation and
exposure of hydrophobic patches leading to a self-associated intermediate which is converted to an
unfolded monomer in the second step. The unfolding pathways of apoAGT-Mi and apoP11L are similar to
each other, but different from that of apoAGT-Ma. Notably, the monomerization step in apoAGT-Mi and
apoP11L occurs with a Cm value (w1.6 M urea) lower than in apoAGT-Ma (w2.4 M urea). These data
indicate that Pro11 is relevant for the stability of both the dimeric structure and the PLP binding site of
AGT. Moreover, to understand the pathogenic consequences of G170R mutation on AGT-Mi at the protein
level, G170R-Mi has been characterized. HoloG170R-Mi exhibits spectroscopic and catalytic features and
urea unfolding proﬁles comparable to those of AGT-Mi, while the apo form monomerizes with a Cm of
w1.1 M urea. These biochemical results are discussed in the light of the characteristics of the enzymatic
phenotype of PH1 patients bearing G170R mutation in AGT-Mi and the positive response of these
patients to pyridoxine treatment.
! 2010 Elsevier Masson SAS. All rights reserved.
1. Introduction
Primary hyperoxaluria type 1 (PH1) is a rare autosomal recessive
disorder caused by a deﬁciency of the liver peroxisomal pyridoxal
50-phosphate (PLP)-dependent enzyme alanine:glyoxylate amino-
transferase (AGT). AGT catalyzes the transamination of the inter-
mediary metabolite glyoxylate to glycine, and its deﬁciency results
in the oxidation of glyoxylate to oxalate. Excessive oxalate synthesis
leads to the chronic deposition of insoluble calcium oxalate mainly
in the kidney and urinary tract. Following renal failure, the problem
of excessive oxalate synthesis is compounded by the inability to
remove it from the body and in some cases oxalate can deposit
almost anywhere in the body [1].
AGT is encodedby theAGXTgenewhich is locatedonchromosome
2q37.3, and comprises 11 exons spreading over 10 kB [2]. The atomic
resolution of the AGT structure complexed with the competitive
inhibitor aminooxyacetic acid has been reported [3]. The enzyme is
a dimer, and each monomer consists of a N-terminal arm, a large
N-terminal domain, and a small C-terminal domain. Two main
polymorphic variants havebeen identiﬁed. Theminorallele (AGT-Mi)
differs from the major allele (AGT-Ma) by the presence of 32C/ T
and 1020A/Gnucleotide substitutions,which lead to Pro11Leu and
Ile340Met amino acids replacements, respectively. In addition, the
minorAGXTallele contains a 74-bpduplication in intron 1 [4]. AGT-Mi
is not a variant disease-causing, even if its presence enables a small
amount (w5%) of AGT to be imported into the mitochondria [4] and
causes several biochemical effects, including an w15% decrease in
catalytic efﬁciency and a w5 !C reduction in the transition mid-
points of denaturation and inactivation [5,6]. Nevertheless, AGT-Mi is
deleterious when combined with certain additional mutations,
Abbreviations: AGT, alanine:glyoxylate aminotransferase; PLP, pyridoxal
50-phosphate; PH1, primary hyperoxaluria type 1; SEC, size exclusion chromatog-
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leading to impairments of the stability, localization, and/or dimer-
ization of the enzyme [7]. This is the case for G170R mutation, the
most common mutation found so far, accounting for about 25 to 30
per cent of the mutant alleles in European and North American
patients [4]. On the basis of the crystal structure of AGT and previous
biophysical studies in which both Pro10 and Pro11 were replaced by
Leu, it was suggested that the structural change occurring in the
N-terminal extension of AGT-Mi is the main determinant of the
decreased dimerization and mitochondrial mistargeting [8].
However, no reports providing experimental evidence for this
hypothesis are available so far. The clariﬁcation of this issue is
important in that it may help to understandwhy the P11L and I340M
polymorphisms sensitize AGT to the untoward effects of many
pathogenic mutations that are predicted to be innocuous in their
absence.
Recent studies have demonstrated that AGT-Ma and AGT-Mi
display the same overall conformation, spectroscopic features and
equilibrium dissociation constant for PLP, KD(PLP) (w0.3 mM) [6], as
well as a dimeremonomer equilibrium dissociation constant
<<0.1 mM [5]. Thus, since these results do not allow the identiﬁ-
cation of the structural elements distinguishing AGT-Mi from
AGT-Ma under native conditions, as a ﬁrst step we decided to
investigate and compare the stability of AGT-Mi with that of
AGT-Ma under stressed conditions. The urea denaturation proﬁles
of the two allelic forms of AGT indicate that they unfold through
a different mechanism, and that the dimeric structure of AGT-Mi is
less stable than that of AGT-Ma. In addition, the ﬁnding that the
urea-induced unfolding pathway of the P11L artiﬁcial mutant is
superimposable on that of AGT-Mi indicates that the P11L mutation
might be responsible for the signiﬁcant decrease in the stability of
the dimeric structure of AGT. This could be caused by the selective
destabilization of the interactions between the N-terminal arm of
one subunit and the opposite subunit. Moreover, we performed
urea and thermal denaturation experiments of the G170R patho-
genic variant associated with the minor allele (G170R-Mi). The
results obtained indicate that, unlike the holo dimer, the dimeric
apo form of G170R-Mi is more susceptible to dimer dissociation
than the corresponding apo form of AGT-Mi. These biochemical
characteristics are discussed in the light of previous data of the
enzymatic phenotype bearing G170R mutation on the minor allele.
2. Materials and methods
2.1. Materials
Urea, PLP, L-alanine, glyoxylate, isopropyl-b-D-thiogalactopyr-
anoside, and rabbit muscle L-lactic dehydrogenase were obtained
fromSigma. 8-Anilino-1-naphtalenesulfonic acid (ANS)wasobtained
fromMolecular Probes. All other chemicalswere of the highest purity
available.
2.2. Production and puriﬁcation of AGT-Ma, AGT-Mi, P11L
and G170R-Mi variants
The vectors coding for the P11L variant, the doublemutant P11L/
I340M (AGT-Mi) and the triple mutant P11L/I340M/G170R (G170R-
Mi) were obtained from the AGT-NoHis construct by using the
QuikChange II site-directed mutagenesis kit (Stratagene). The
oligonucleotides used for mutagenesis were as follows: P11L
forward primer, 50- GCTGCTGGTGACCCCCCTCAAGGCCCTGCTC
AAGC and its complement; I340M forward primer, 50- CATCGTCA
GCTACGTCATGGACCACTTCGACATTG and its complement; G170R
forward primer, 50- CCCCTTGATGGCTTCCGGGAACTCTGCCACAGG
-30, and its complement. The underlined codons indicate mutated
aminoacids. All mutations were conﬁrmed by DNA sequencing.
AGT-Ma and AGT-Mi as well as the P11L and G170R-Mi variants
were expressed and puriﬁed by the same procedure previously
described for AGT-NoHis [9,10]. The protein concentration was
determined by absorbance spectroscopy using an extinction coef-
ﬁcient of 9.7 # 104 M$1 cm$1 at 280 nm [9,10]. The PLP content was
determined by releasing the coenzyme in 0.1 M NaOH and by using
3 ¼ 6600 M$1 cm$1 at 388 nm.
2.3. Binding afﬁnity for PLP of G170R-Mi
The apo form of G170R-Mi was prepared as previously described
[9]. The KD(PLP) from G170R-Mi (0.1 mM) was determined by
measuring the quenching of the intrinsic ﬂuorescence of the
apoenzyme in the presence of PLP at concentrations ranging from
0.02 to 10 mM.
2.4. Denaturant-induced unfolding experiments
To determine the stability of AGT-Ma, AGT-Mi, P11L and
G170R-Mi variants toward denaturation by urea, stock solutions of
enzyme and 10 M freshly prepared urea, dissolved in 100 mM
potassium phosphate buffer, pH 7.4, were mixed to give the desired
concentration of enzyme and denaturant. Holoenzymes incubation
was performed in the presence of 10 mM exogenous PLP. Each
mixture was allowed to equilibrate at 25 !C for 3 h, which was
sufﬁcient to reach the limiting values for all enzyme properties
(catalytic activity, ﬂuorescence, visible and far-UV CD, and molec-
ular size) at each urea concentration used. The actual urea
concentration was checked using refractive index data [11].
2.5. Activity measurements
During the puriﬁcation of AGT enzymes, transaminase activity
assays were performed as previously described [9]. In the
experiments designed to determine the effect of various
concentrations of denaturant on transaminase activity, pyruvate
production was measured by an assay based on measuring the
2,4-dinitrophenylhydrazine derivative of pyruvate by HPLC as
reported previously [12].
2.6. Size-exclusion chromatography (SEC)
The molecular dimensions of 1 mM AGT-Ma, AGT-Mi, P11L and
G170R-Mi in the holo- and apo-form upon incubation for 3 h at
25 !C in the presence of varying urea concentrations, were deter-
mined by SEC. The mixtures were loaded on a custom packed
Sephacryl S-300 10/600 column equilibrated and runwith 100 mM
potassium phosphate buffer pH 7.4 containing the desired urea
concentration on an Akta FPLC system (GE Healthcare). The injec-
tion volume was 500 ml at a ﬂow rate of 0.4 ml/min with detection
at 280 nm. Three chromatography experiments were run per
sample, and the software Unicorn 5.01 (GE Healthcare) was used to
calculate the elution volume and the area of each peak. The
apparent hydrodynamic radius of the eluting species was calcu-
lated by comparing their elution volume to that of a set of molec-
ular weight standards under the same experimental conditions.
2.7. Fluorescence measurements
Fluorescencemeasurementswereperformedbyusing a1 cmpath
length quartz cuvette in a Jasco FP-750 spectroﬂuorimeter equipped
with a thermostatically controlled cell holder. Protein emission
spectra were taken from 300 to 450 nm (excitation at 280 nm) with
both the excitation and the emission slits set to 5 nm. The protein
concentration was typically 1 mM. All the spectra were corrected by
B. Cellini et al. / Biochimie 92 (2010) 1801e18111802
subtracting the emission spectrum of the buffer. Phase-diagrams
were obtained from the analysis of intrinsic ﬂuorescence emission
data by plotting ﬂuorescence intensity values measured at 365 nm
(I365nm) against the corresponding intensity values at 320 nm(I320nm)
according to the method of Kuznetsova et al. [13]. The dependence
I365nm¼ f (I320nm) is linear when changes in the protein environment
lead to the all-or-none transition between two different conforma-
tions. On the contrary, the nonlinearity of this function reﬂects the
sequential character of structural transformations, i.e., the population
of one or more intermediates.
ANS ﬂuorescence experiments were carried out as follows:
AGT-Ma, AGT-Mi or variants at 1 mM concentration were equili-
brated at the desired denaturant concentration for 3 h at 25 !C.
Then, 5 ml from a stock solution of 3 mM ANS were added to each
sample and incubated at 25 !C for 1 h. ANS excitation was done at
365 nm and the emissionwas monitored between 400 and 560 nm
using excitation/emission slit widths of 5 nm. The values were
normalized by subtracting the baseline recorded for the probe
alone under identical conditions.
2.8. CD measurements
Visible and far-UV CD were recorded on a Jasco J-710 spec-
tropolarimeter with 1 cm and 1 mm cell path length, respectively.
The enzyme concentration was 1 mM. The values obtained were
normalized by subtracting the baseline recorded of the buffer
having the same denaturant concentration. The thermal unfolding
of AGT-Mi and G170R-Mi was monitored by CD at 222 nm at
a concentration of 1 mM in 100mM potassium phosphate buffer, pH
7.4, with temperature increasing of 0.5 !C/min from 25 to 90 !C. CD
signals were ﬁtted either to two or three state unfolding mode
using Origin Pro7 software according to the method of Pace [11].
2.9. Dynamic light scattering (DLS)
Filtered stock solutions of AGT-Ma, AGT-Mi or G170R-Mi either
in the holo or in the apo-form, were diluted to 1 mM concentration
with various ﬁltered urea solutions in 100 mM potassium phos-
phate buffer pH 7.4. Each sample was incubated for 3 h at 25 !C and
DLS analysis was performed on a Zetasizer Nano S device (Malvern
Instruments) by using disposable 12.5 # 45-mm cells with stopper.
The appropriate viscosity and refractive index for each solutionwas
set and the temperature was kept at 25 & 0.1 !C during the
measurements.
2.10. Data analysis
The comparison of data collected with different methods was
made by normalising the data to Fu, the apparent fraction of
unfolded protein:
Fu ¼ ðY0 $ YnÞ=ðYu $ YnÞ (1)
where Y0 is the signal at a given urea concentration and Yn and Yu
are the observed values for the native and unfolded protein,
respectively.
The analysis of the equilibrium unfolding curves corresponding
to a two-state model ðN5UÞ was performed according to the
equation (2):
Y ¼ YN þ aNC þ ðYU þ aUCÞe
$mðCm$CÞ=RT
1þ e$mðCm$CÞ=RT (2)
where Y is the measured signal; YN and YU are the signal values
characteristic of the native (N) and fully unfolded (U) conforma-
tions, respectively; C denotes the urea concentration; aN and aU
represent the dependence on urea concentration of the signal of
the native and unfolded conformation, respectively; Cm is the
midpoint of urea required for unfolding and m stands for the slope
of the unfolding curve at Cm.
The urea-unfolding curves corresponding to a three-state
denaturation pathway (N 4 I 4 U, where I is the intermediate
state) or a four-state denaturation pathway (N 4 I1 4 I2 4 U)
were analyzed using equations (3) or (4), respectively:
Y ¼ YN$I½urea*
n1
Cn1m1½urea*n1
þ YI$U ½urea*
n2
Cn2m2 þ ½urea*n2
(3)
Y ¼ YN$I1 ½urea*
n1
Cn1m1½urea*n1
þ YI1$I2 ½urea*
n2
Cn2m2 þ ½urea*n2
þ YI2$U ½urea*
n3
Cn3m3 þ ½urea*n3
(4)
in which Cm1, Cm2 and Cm3 are the midpoint concentrations of urea,
YN 4 I (or YN 4 I1), Y I1 4 I2 and YI 4 U (or Y I2 4 U) represent the
change in the signal for the N4 I (or N4 I1), I14 I2 and I4 U
(or I24 U) transitions, respectively, and exponents n1, n2 and n3
reﬂect the steepness of the transition between states as a function
of urea concentration.
3. Results and discussion
3.1. AGT-Ma and AGT-Mi display a different sensitivity
to chemical stress
Under native conditions, both AGT-Ma and AGT-Mi exhibit an
emission spectrum (exc. at 280 nm) centered at 337 nm, which
reﬂects the average microenvironment of 6 tryptophan residues.
No gross differences in the secondary structure of AGT-Ma and
AGT-Mi are seen on far-UV CD. Upon denaturation at 10 M urea,
both proteins display a maximum ﬂuorescence emission at 352 nm
(Fig. 1 of SI) and a complete loss of far-UV CD signals. However,
signiﬁcant differences between AGT-Ma and AGT-Mi occur at
intermediate levels of urea. Indeed, Fig. 1A and B show that (i) the
transition curves for the urea-induced unfolding of AGT-Ma
monitored by far-UV CD (which reﬂects a-helix content) and
emission intensity as well as emission maximum tryptophan
ﬂuorescence (indicative of the microenvironment of the side chain
aromatic ring) describe a two-state process with a mid-point
transition ofw6.9 M urea (Table 1), and (ii) these curves for AGT-Mi
appear biphasic, suggestive of a three-state model between the
native dimeric state and the unfolded monomeric state. An inter-
mediate state appears to be stable at w5.5 M urea, and the tran-
sition midpoints were at about 4.6 M and 6.4 M for the ﬁrst and the
second transition, respectively (Table 1). While the ﬁrst step of the
unfolding proﬁle of AGT-Mi shifts to a higher denaturant concen-
tration and the intermediate appears to be more populated at 8 mM
than at 1 mM (Fig. 1B), the second transition is independent, within
the experimental error, on enzyme concentration. Thus, it is likely
that the ﬁrst transition includes the dimer to monomers dissocia-
tion, and that the signiﬁcant increase in ﬂuorescence intensity
observed during the ﬁrst transition may result from the loss of
quenching due to the release of PLP. In order to examine the
changes in ﬂuorescence in greater detail, we applied the phase
diagram analysis, which could illuminate populated intermediates
and their properties, to the emission ﬂuorescence spectra of
AGT-Ma and AGT-Mi at various urea concentrations. To this end, we
selected tryptophan ﬂuorescence at 320 nm and 365 nm that
reﬂect the amount of folded (blue-shifted) and unfolded (red-
shifted) states, respectively. When these parameters are plotted in
a xey graph, a straight line, typical for a two-state process, can be
observed in the diagram of AGT-Ma from 0 to 10 M urea. Two linear
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segments, 0e5.5 and 5.5e8 M urea, characterize instead the phase
diagram of AGT-Mi. They represent the existence of two indepen-
dent transitions separating three conformational states (insets of
Fig. 1A and B).
Table 1
Cm values for urea-induced unfolding of AGT-Ma, AGT-Mi, P11L and G170R-Mi in the holo and apo formsmonitored by various parameters at an enzyme concentration of 1 mM.
Probe HoloAGT-Ma HoloAGT-MI HoloP11L HoloG170R-Mi ApoAGT-Ma ApoAGT-Mi ApoP11L ApoG170R-Mi
Transaminase activity 6.7 & 0.2 4.4 & 0.1 4.4 & 0.2 4.4 & 0.1 n.m. n.m. n.m. n.m.
CD visible 6.7 & 0.1 4.35 & 0.06 4.65 & 0.3 4.3 & 0.1 e e e e
Tryptophan ﬂuorescence
Emission maximum 6.5 & 0.1 4.6 & 0.1 4.6 & 0.2 4.10 & 0.15 6.6 & 0.1 6.0 & 0.1 6.2 & 0.1 6.4 & 0.1
6.4 & 0.1 6.2 & 0.1 6.3 & 0.1
Relative intensity 4.7 & 0.1 4.5 & 0.1 4.56 & 0.03 2.37 & 0.03 1.74 & 0.01 1.4 & 0.1 1.17 & 0.06
3.0 & 0.04 3.2 & 0.1 3.0 & 0.1
Far UV CD 6.9 & 0.1 4.5 & 0.1 4.3 & 0.4 4.4 & 0.1 2.4 & 0.1 1.90& 0.03 1.66 & 0.2 1.10 & 0.03
6.4 & 0.1 6.6 & 0.2 6.4 & 0.2 6.4 & 0.1 2.7 & 0.1 2.9 & 0.1 2.7 & 0.04
6.4 & 0.2 6.2 & 0.1 6.5 & 0.1
Single, double and triple Cm values result from ﬁtting data to a two-state (eq. (2)), three-state (eq. (3)), and four-state (eq. (4)) process, respectively. n.m., not measurable since
one cannot distinguish between inactivation due to inhibitory or unfolding effects.
Fig. 2. Urea-induced unfolding equilibrium of holoAGT-Ma and holoAGT-Mi monitored
by catalytic activity and visible CD. Unfolding proﬁles of holoAGT-Ma (A) and hol-
oAGT-Mi (B) monitored by transaminase activity (-), and visible CD at 429 nm (,).
The fraction unfolded, Fu, was calculated using the observed activity or visible CD data
and eq. (1) as described under Materials and methods. The solid lines represent the
best ﬁt obtained to a two-state model (eq. (2)). The enzyme concentration was 1 mM.
Fig. 1. Urea-induced unfolding equilibrium of holoAGT-Ma and holoAGT-Mi monitored
by spectroscopic probes. Unfolding proﬁles of holoAGT-Ma (A) and holoAGT-Mi (B)
monitored by intrinsic ﬂuorescence intensity (-), emission maximum ﬂuorescence
(B), far-UV CD at 222 nm (,), and of NaBH4 reduced holoAGT-Ma (A) and holoAGT-Mi
(B) monitored by intrinsic ﬂuorescence intensity (:). In (B) is also reported the
unfolding proﬁle of 8 mM holoAGT-Mi monitored by intrinsic ﬂuorescence intensity
(6). The fraction unfolded, Fu, was calculated using the observed ﬂuorescence or CD
signals and eq. (1) as described under Materilas and methods. The solid lines represent
the best ﬁt obtained to a two-state (eq. (2)) or a three-state model (eq. (3)). Insets:
phase diagrams representing urea-induced unfolding of holoAGT-Ma (A) and hol-
oAGT-Mi (B). Each straight line represents an all-or none transition between two
conformers. The denaturant concentration values are indicated in the vicinity of the
corresponding symbol. Except where indicated, the enzyme concentration was 1 mM.
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As shown in Fig. 2A and B, AGT-Ma and AGT-Mi also differ for the
extent of PLP dissociation and loss of transaminase activity during
their urea-induced unfolding processes. The internal aldimine of
AGT-Ma and AGT-Mi exhibits an absorbance band at 423 nm, asso-
ciated with a positive dichroic band at 429 nm [9]. For both AGT-Ma
and AGT-Mi, the unfolding proﬁles monitored by CD visible and
enzymatic activity are coincident, and the data ﬁt a two-state model
with transition midpoints of about 6.7 and 4.4 M urea, respectively
(Table 1). From these data it can be concluded that (i) as expected, the
loss of PLP from AGT-Ma and AGT-Mi results in the loss of enzymatic
activity, and (ii) the loss of 429 nm dichroic band and enzymatic
activity takes place at a lower denaturant concentration for AGT-Mi
than for AGT-Ma. Moreover, the ﬁnding that the visible CD and
enzymatic activity Cm values for AGT-Ma are coincident with those
observed byﬂuorescence and far-UVCDmeasurements suggests that
PLP release for AGT-Ma occurs at a high denaturant concentration,
once the structure is sufﬁciently destabilized. On the other hand, the
coincidence of the Cm values (w4.4 M urea) measured by visible CD
and transaminase activity with those of the ﬁrst transition of AGT-Mi
observed by intrinsic ﬂuorescence and far-UV CD indicates that PLP
dissociation from AGT-Mi takes place at a low denaturant concen-
tration with a partial loss of tertiary and secondary structures.
It should also be noted that there is a slight steady decrease in the
CD visible signal and enzyme activity from 0 to 4 M for AGT-Ma and
from0 to 2Murea for AGT-Mi, i.e., within denaturant ranges inwhich
the intrinsic ﬂuorescence and far-UV CD signals of the two enzymatic
species remain unmodiﬁed. These pre-transition changes suggest
that urea might bind and act as an enzyme inhibitor. In fact, experi-
ments inwhich the kinetic parameters are determined in the absence
or presence of 1, 2, 3 and 4 M urea clearly demonstrate that urea is
responsible for amixed-type inhibition. This behaviour has been also
observed for other PLP-enzymes [14,15].
The difference of the effects that increasing levels of urea have on
AGT-Ma and AGT-Mi is further supported by ANS binding studies.
ANS is an anionic ﬂuorescent probe that binds to apolar surfaces and
exhibits a red shift in the emission maximum due to the changes in
hydrophobic patches on protein unfolding [16]. As previously
reported [17], upon the addition of native AGT-Ma or AGT-Mi in the
holo form to ANS, the ANS ﬂuorescence is characterized in both cases
by an emissionmaximumat 515 nmand a slight increase of emission
intensity. Fig. 3 shows the unfolding of AGT-Ma and AGT-Mi
monitored by ANS ﬂuorescence as a function of added urea. No
remarkable changes of ANS ﬂuorescence over the 0e8 M urea range
have been observed for AGT-Ma. On the other hand, in the 0e5 M
urea range there is a steady increase in ANS ﬂuorescence for AGT-Mi,
which reaches at 5 M urea a ﬂuorescence intensity w8-fold higher
than that observed in the absence of urea, as well as a shift of the
emission maximum from 515 to 489 nm. Further additions of urea
resulted in a decrease in ANS ﬂuorescence intensity and an increase
in the lmax consistent with dispersing the hydrophobic surface and
unfolding of the protein. These binding studies indicate that (i) no
signiﬁcant hydrophobic patches become exposed during the urea-
induced unfolding of holoAGT-Ma, and (ii) the unfolding interme-
diate observed by protein ﬂuorescence and far-UV CDemonitored
denaturation proﬁles of holo AGT-Mi is characterized by exposed
hydrophobic patches that are accessible to ANS. Such a change in
AGT-Mi structure may lead to its aggregation due to hydrophobic
interactions. This indeedwas supported by SEC andDLS experiments.
As shown in Fig. 4A and B, and insets, both the native dimer of
AGT-Ma and AGT-Mi in the holo form elute as a single peak from SEC
columnwith a retention volume of 31.5 ml (corresponding to that of
a dimer), and display a peak of about 10 nm on DLS consistent with
the hydrodynamic diameter of the molecule determined by X-ray
crystallography [17]. Analyses of the chromatograms indicate that (i)
while AGT-Ma elutes as a peakwhose total area does not signiﬁcantly
change over 0e8 M urea range, AGT-Mi elutes as a peak whose
Fig. 3. ANS ﬂuorescence of holoAGT-Ma and holoAGT-Mi at various urea concentra-
tions. ANS emission ﬂuorescence intensity at 515 nm in the presence of holoAGT-Ma
(-) and holoAGT-Mi (,) as a function of urea concentrations (exc. at 365 nm). Inset,
changes in emission maximum of holoAGT-Ma (-) and holoAGT-Mi (,) as a function
of urea concentrations. The enzyme concentration was 1 mM.
B
A
Fig. 4. Urea-induced changes in molecular dimension of holoAGT-Ma and holoAGT-Mi.
Size distribution from chromatographic proﬁles on SEC of holoAGT-Ma (A) and holoAGT-
Mi (B) at the indicated urea concentration. Insets, size distribution on DLS at 0 and 6 M
urea of holoAGT-Ma (A) and holoAGT-Mi (B). The enzyme concentration was 1 mM.
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integrated area begins to decrease at 2 M, reaches at 5 M urea
a minimum value of about 40% relative to the native protein, and
then gradually regains the total integrated area when the urea
concentration is further increased, and (ii) both AGT-Ma and AGT-Mi
elutewith a decreased retention volume (up to 29ml) between 0 and
5 M urea, and from 5 to 10 M urea are gradually converted into the
unfolded monomer characterized by a further decrease in the
retentionvolume of the peak. DLSmeasurements indicate that at 6M
urea AGT-Ma shows a peak at 14 nm, possibly due to an expanded
dimeric structure, whereas AGT-Mi exhibits a peak at 25e30 nm,
which suggests aggregate species (insets of Fig. 4A and B).
Altogether these data provide evidence that the unfolding of
AGT-Ma occurs via a single transition in which only native and
denaturated molecules are populated, while that of AGT-Mi
proceeds through a three-state process (Scheme 1). The ﬁrst step of
AGT-Mi unfolding, associated with PLP release, concomitant inac-
tivation and monomerization, yields an intermediate which lacks
PLP. This intermediate is signiﬁcantly populated at w6 M urea. It
retains w40% of the native CD signal and w60% of the native
ﬂuorescence, and consists of 25e30 nm aggregates, which are
converted into a completely unfolded monomer during the second
transition (Fig. 1B and inset of Fig. 4B). The kinetics of the changes
of the 429 and 222 nm dichroic signals of AGT-Mi at 6 M urea
reveals that they occur with similar rate constants
(0.0240 & 0.0001 min$1), thus suggesting that PLP release and loss
of secondary structure are concerted events. It is reasonable to
hypothesize that the different unfoldingmechanism of AGT-Ma and
AGT-Mi in the holo form could be attributable to the fact that PLP
release and monomerization take place in AGT-Mi at urea
concentration lower than in AGT-Ma. Thus, to elucidate the stabi-
lizing effect of the cofactor on AGT-Ma and AGT-Mi, the urea-
mediated denaturation of the NaBH4-reduced forms of AGT-Ma and
AGT-Mi, in which the coenzyme is irreversibly bound to the
proteins was studied. The tryptophan ﬂuorescence data following
urea denaturation indicate that both reduced AGT-Ma and AGT-Mi
are unfolded in a single enzyme concentration independent step
with urea concentration at mid-denaturation of w8.1 and 5.9 M,
respectively (Fig. 1A and B). Additionally, neither the presence of
aggregates nor changes in ANS ﬂuorescence can be seen during the
urea-mediated unfolding of the NaBH4 reduced forms of both the
enzymatic species. Thus, the reductive trapping of the cofactor as
a nondissociable derivative converts the unfolding proﬁle of AGT-
Mi from a three-state to a two-state model by preventing the
formation of an aggregated intermediate. Moreover, the different
resistance of the reduced forms of AGT-Ma and AGT-Mi to chemical
stress strongly suggests that the difference in stability between
holoAGT-Ma and holoAGT-Mi is an intrinsic structural feature of the
two apoproteins. The results on the irreversibly bound PLP forms of
AGT lead us to investigate the stability of the apo forms of AGT
against urea denaturation. Their ﬂuorescence and far-UV CD
Scheme 1. Urea-induced equilibrium unfolding pathway of AGT-Ma (DPLP / U) and
AGT-Mi (DPLP/ IAggr/ U), where DPLP and U indicate the native holodimer and the
unfolded monomer, respectively, M* represents a transient partially unfolded mon-
onmeric species, and IAggr the insoluble PLP-unbound aggregates.
Fig. 5. Urea-induced unfolding equilibrium of apoAGT-Ma, apoAGT-Mi and apoG170R-
Mi. Unfolding proﬁles of apoAGT-Ma (A), apoAGT-Mi (B) and apoG170R-Mi (C) moni-
tored by intrinsic ﬂuorescence intensity (-), emission maximum ﬂuorescence (:) and
far-UV CD at 222 nm (,). The fraction unfolded, Fu, was calculated using the observed
ﬂuorescence or CD signals and eq. (1) as described under Materials and methods. The
solid lines represent the best ﬁt obtained to a two-state (eq. (2)) or a three-state
(eq. (3)) or a four-state model (eq. (4)). The enzyme concentration was 1 mM.
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properties under denaturation conditions are presented in Fig. 5A
and B, and the Cm values are reported in Table 1. The denaturation
curves of apoAGT-Ma monitored by intrinsic ﬂuorescence and far-
UV CD ﬁt a biphasic model. The ﬁrst transition, which is not asso-
ciated with a lmax shift, is enzyme concentration dependent with
a midpoint ofw2.3 M urea, followed by a transition concentration
independent with Cm value of w6.3 M urea (Table 1). An inactive
intermediate state appears to be stable from w3 to 5.5 M urea in
a conformation able to bind ANS, as revealed by the maximum
emission wavelength at 482 nm and a 5-fold increase in the ANS
ﬂuorescence intensity relative to the native protein (Fig. 6).
Evidence for the formation of aggregates over this urea range is
provided by a signiﬁcant decrease in the total peak area on SEC
(Fig. 2A of SI), and conﬁrmed by the presence ofw30 nm particles
seen by DLS experiments (Fig. 7). At urea concentrations +5.5 M
aggregates are gradually converted into soluble unfoldedmonomer,
as revealed by a gradual shift of the peak on SEC toward lower
retention volume (Fig. 2A of SI). The unfolding pathway of apo AGT-
Mi is more complex than that of apo AGT-Ma. A look at the varia-
tions of intrinsic ﬂuorescence and far-UV CD with urea concentra-
tions reveals some interesting features. As presented in Fig. 5B,
increasing urea concentration induces a decrease in both the
ﬂuorescence intensity and far-UV CD signal between 1 and 2 M.
This transition (Cm w 1.7 M urea) (Table 1) is highly cooperative,
characterized by a loss of about 70% and 50% of the secondary and
tertiary structures, respectively, and leads to an inactive interme-
diate. Above 2 M urea, ﬂuorescence intensity and ellipticity at
222 nm begin to rise, and they reach a maximum at w3.5 M
remaining unchanged up to 5.5 M. Obviously, this complex pattern
needs further explanation. The ﬁrst transition is not associatedwith
a lmax shift, as shown in Fig. 5B. Therefore, it is probably not caused
by changes in the hydratation of tryptophans but rather by an
increase in quenching of these residues, possibly due to confor-
mational changes. This idea is supported by several observations.
First, the ﬁndings that this transition is dependent on protein
concentration and that the elution proﬁle on SEC of 2 M-treated
apoAGT-Mi (Fig. 2B of SI) reveals a mixture of a dimeric and
a monomeric species strongly suggest that this step is linked to
a dissociation event. Since the retention volume of the monomeric
species is 33.1 ml (Fig. 2B of SI), a value slightly lower than the
theoretical one of a folded monomer (33.3 ml), it is reasonable to
think that the dissociation gives rise to a partially unfolded
monomer. Second, the ANS ﬂuorescence proﬁle of apoAGT-Mi
treated with increased urea concentrations reveals a w13-fold
increase in emission intensity and a blue shift in the emission
maximum (from 507 to 481 nm) from 1 to 2 M urea (Fig. 6). This
suggests that clusters of hydrophobic residues become exposed
during this transition, and they are possibly susceptible to aggre-
gation. This interpretation gains support from SEC and DLS exper-
iments on apoAGT-Mi as a function of urea concentration:
a consistent decrease of the peak area (Fig. 2B of SI) and the
formation of approximately 3500 nm particles (Fig. 7) can be seen
in the 1e2.5 M range. On the basis of this ﬁnding, the observed loss
of the intensity ﬂuorescence and far-UV CD signal over this range
could be due to light scattering effects of these high-order aggre-
gates. The second transition, characterized by a gradual decrease in
the molecular dimensions of apoAGT-Mi (Fig. 7) and a concomitant
increase in the ﬂuorescence intensity and 222-nm ellipticity
without any detectable change in emission maximum (Fig. 5B),
describes a conversion from high-order to low-order aggregates.
The latter populate the intermediate extending from 3.5 to 5.5 M
urea, and are then converted to the completely unfolded monomer
with a Cm transition ofw6.2 M urea.
On the basis of all the above data, it can be concluded that P11L
and I340M substitutions characterizing AGT-Mi (i) result in
a decreased stabilization of the dimeric form of apoAGT, and (ii)
convert the overall process of urea unfolding of apoAGT from
a three-state (native dimer / low order aggregates / unfolded
monomer) into a four state (native dimer/ high-order aggregates
derived from a partially unfolded monomer / low-order aggre-
gates/ unfolded monomer).
3.2. P11L mutation is responsible for the urea sensitivity of AGT-Mi
The sensitivity of P11L mutant to urea stress has been evaluated
by monitoring its urea unfolding in the holo and apo forms by
visible, far-UV CD and intrinsic ﬂuorescence as well as by ANS
binding, activity, and SEC measurements under equilibrium
conditions. The results (data not shown) obtained for all these
probes are identical to the corresponding of AGT-Mi in the holo and
apo forms (Table 1). Thus, the presence of a leucine residue at
position 11 decreases the stability of the dimeric structure of AGT.
Fig. 6. ANS ﬂuorescence of apoAGT-Ma, apoAGT-Mi and apoG170R-Mi at various urea
concentrations. ANS emission ﬂuorescence intensity at 507 nm in the presence of
apoAGT-Ma (-), apoAGT-Mi (,) and apoG170R-Mi (:) as a function of urea
concentrations (exc. at 365 nm). Inset, changes in the emission maximum of apoAGT-
Ma (-), apoAGT-Mi (,) and apoG170R-Mi (:). The enzyme concentration was 1 mM.
Fig. 7. DLS measurements of size of apoAGT-Ma, apoAGT-Mi and apoG170R-Mi at
various urea concentrations. DLS measurements of apoAGT-Ma (-), apoAGT-Mi (B)
and apoG170R-Mi (;) as a function of urea concentration. The data points represent
values averaged over 20 acquisitions, depending on the quality of the data; bars
indicate standard deviations. The enzyme concentration was 1 mM.
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3.3. Unfolding of AGT-Ma and AGT-Mi in correlation with
their structural features
We tried to explain all the above results by looking at the
structure of the enzyme. The AGTase dimeric interface is very large
(w23% of the solvent accessible area), and is composed of inter-
actions across the two large domains as well as contacts between
the N-terminus of one subunit and the large domain of the adjacent
subunit. Thus, as already suggested [3], the N-terminal segments
are probably relevant for dimer formation. Inspection of the crystal
structure of AGT reveals that Pro11, belonging to the N-terminus,
not only contributes to the increase in the structural rigidity, but
also exerts additional constraints to the backbone, since the ring
closure keeps its V angle value almost ﬁxed. In addition, this
residue makes hydrophobic interactions with a surface cavity sur-
rounded by residues Glu62, Gly63, Tyr66 and Ala280 of the oppo-
site subunit. Therefore, it is likely that replacement of Pro11 by Leu
could destabilize the interactions between the N-terminus of one
subunit with the large domain of the adjacent subunit. This
observation provides an explanation for why the monomerization
of holo and apo AGT-Mi occurs at lower urea concentration than the
monomerization of AGT-Ma. However, it does not explain why the
complete release of PLP in AGT-Ma requires a higher degree of
structural destabilization than in AGT-Mi. The lower destabilization
observed for AGT-Mi as compared with AGT-Ma suggests that the
substitution of Pro11 by Leu could result in an altered sensitivity to
urea stress of the PLP-bound state. In the native AGT-Ma dimer [3]
PLP is located in a wide catalytic cleft that is assembled by residues
from both subunits and its phosphate group entails two interac-
tions with Tyr260 and Thr263 of the adjacent subunit. Moreover,
Lys209, the PLP binding residue, is held in place by an active site
loop (residues 24e32) directly connected with the N-terminal
extension. In fact, as shown in the inset A of Fig. 8, the hydroxyl side
chain of Ser31 is at an appropriate distance to make hydrogen
bonds with the peptide carbonyl groups of Gln208 (3.34 Å) or
Lys209 (3.27 Å) or with the Nd2 of Asn212 (2.92 Å). In addition, the
peptide NH of Ser31might interact with the peptide carbonyl group
of Gln208 (3.12 Å). Based on these observations, it seems reason-
able to suggest that the perturbation at the N-terminus caused by
P11L mutation could be transmitted through the active site loop to
the PLP binding site. This could explain why PLP release takes place
in AGT-Ma at urea concentrations higher than in AGT-Mi. All of this
considered, it can be proposed that Pro11 in AGT may be conserved
in order to optimize not only the global stability of the dimeric
structure but also the local stability of the PLP binding site.
3.4. Refolding trials of AGT-Ma and AGT-Mi
AGT enzymatic activity can be restored after treatment with
denaturant providing that the initial urea concentrations are <6
and <2 M for AGT-Ma and AGT-Mi, respectively, i.e., at denaturant
concentrations lower than those at which monomerization occurs.
At higher concentrations of denaturant, the refolding of these
enzymatic species is largely irreversible. Neither quick or step
dialysis, nor different initial (from 1 to 100 mM) or ﬁnal (from 0.02
to 5 mM) concentration of the enzyme, had any effect on the degree
of reactivation. The addition of non-ionic detergent, dithiothreitol,
alanine, the use of different pH values in the reactivation mixture,
or a variation of the time allowed for reactivation all failed to
restore transaminase activity.
When fully denatured samples of AGT-Ma or AGT-Mi were
brought by quick dilution (100-fold) in the absence or presence of
PLP (from 0.01 to 1 mM) to an urea concentration that would be
expected to support native enzyme, only about 20 and 5% of activity
was recovered for AGT-Ma and AGT-Mi, respectively. These refolded
species eluted on SEC as dimers but their integrated peaks area are
Fig. 8. Ribbon diagram of the crystal structure of AGT. Ribbon diagram of the crystal structure of AGT (PDB code 1H0C): the two subunits are coloured yellow and violet; the
N-terminus (residues 1e40) of the yellow subunit, represented as ribbons/sticks, is orange; PLP, represented as sticks, is green; Gly170 of the violet subunit is yellow. Inset A: detail
of the active site loop of the yellow subunit. The positions of the residues Ser31, Lys209, Gln208, and Asn212 are indicated. Black bars represent the possible hydrogen bonds
involving Ser31. Inset B: detail of the region in which Gly170 is located (violet ribbons) compared with the same region in which the G170R mutation takes place (green ribbons)
(PDB code 1J04). Gly170, Arg170, Arg197 and Lys5* are labelled. Black bars represent the possible hydrogen bonds involving Arg197.
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about 20 and 5% of those expected, thus indicating that during the
refolding the majority of the protein forms insoluble aggregates. All
these data suggest that in both the allelic forms of AGT the bimo-
lecular reaction corresponding to themonomeredimer transition is
impaired, at least under the experimental conditions tested. The
refolding efﬁciency of AGT was also studied starting from fully
denatured enzyme in 6M guanidine hydrochloride. The recovery of
enzyme activity was comparable to that obtained from 8 M-urea
treated enzyme. This result is in apparent contrast with what
previously reported by Coulter-Mackie et al. [18]. These authors
stated that denaturation and refolding of the overexpressed AGT
after guanidine hydrochloride treatment of the inclusion bodies
produces high yield of biologically active protein and that
successful folding of AGT was independent on the presence of PLP.
This apparent contradiction can be understood by the following
considerations. The ﬁnding that both soluble and insoluble frac-
tions contain AGT enzymatically active, even if the speciﬁc activity
in the untreated insoluble fraction is about 10% that in the soluble
fraction, indicates that AGT is not completely unfolded in the
inclusion bodies. In addition, since the unfolding has been carried
out on the pellet of inclusion bodies in the presence of 6 M
guanidine hydrochloride for 1 h at 4 !C, it can be hypotesized that
these experimental conditions could be sufﬁcient to extract AGT
from the inclusion bodies but possibly not strong enough to
completely unfold AGT.
Recently, Albert et al. [19] have solved the three-dimensional
structure of a complex between the bacterial chaperonine GroEL
and a folding intermediate of the I244T variant associated with the
minor allele of AGT by cryo-electron microscopy. These results
show that the assisted folding of this mutant is driven through the
forced unfolding of a quasi-native state of the protein. Based on this
ﬁnding, together with the very low refolding yield of AGT-Ma and
AGT-Mi obtained in our “in vitro” refolding experiments, it can be
suggested that a molecular chaperone system is vital for guiding
AGT to its native state.
3.5. Sensitivity of G170R-Mi to urea and thermal stress
Cell biology studies have indicated that G170R mutation asso-
ciated with the minor allele causes the aberrant localization of AGT
to mitochondria instead of peroxisomes [20]. It has been hypoth-
esized, but not proved, that an alteration of dimerization during the
folding pathway could be the cause of the mistargeting of this
variant [21]. In order to understand the biochemical effects of this
mutation, G170R-Mi has been constructed, puriﬁed and charac-
terized. The puriﬁed variant was homogenous as indicated by
a single band on SDS-PAGE with a mobility identical to that of
AGT-Ma and AGT-Mi. The yield of this variant after the standard
puriﬁcation was about 20% with respect to that of AGT-Mi. Like
AGT-Ma and AGT-Mi, G170R-Mi variant binds 2 mol of PLP per
dimer with a KD(PLP) of 0.4 & 0.1 mM, a value comparable to that of
AGT-Mi, and exhibits visible absorbance and CD spectra similar to
those of AGT-Ma or AGT-Mi (data not shown). Again, the kinetic
parameters of this variant for the pair alanine/glyoxylate
(kcat ¼ 34 & 3 s$1, KmL-ala ¼ 36 & 2 mM, Kmglyox ¼ 0.4 & 0.1 mM) do
not signiﬁcantly differ from the corresponding ones of AGT-Mi [6].
The urea unfolding proﬁles of holoG170R-Mi have been monitored
by intrinsic ﬂuorescence, far-UV CD and catalytic activity, and the
Cm values are reported in Table 1. Data from these experiments as
well as those from SEC and DLS studies are essentially equivalent to
those of holoAGT-Mi (data not shown). Therefore, the G170R
mutation on the minor allele of the holoform (i) does not affect
either the spectroscopic or, in contrast with previous reports
[22,23], the catalytic features, and (ii) does not alter the sensitivity
to the urea stress. Moreover, since the unfolding proﬁle of
apoG170R-Mi monitored by far-UV CD, intrinsic (Fig. 5C) and ANS
ﬂuorescence (Fig. 6), and DLS experiments (Fig. 7) appears quali-
tatively comparable to that of apoAGT-Mi, it can be described by
a four-state model in which the following transitions occur: native
dimer / high-order aggregates / low-order
aggregates / unfolded monomer. Since, like in apoAGT-Mi, the
ﬁrst transition of the unfolding pathway of apoG170R-Mi is protein
concentration dependent, it is reasonable to suggest that mono-
merization gives rise to exposure of hydrophobic surfaces and
aggregation. Nevertheless, it is of interest to point out that while
the Cm values of the second and third transitions of apoG170R-Mi
are similar to those of apo AGT-Mi, the Cm value of the ﬁrst tran-
sition (w1 M urea) is lower than that of apoAGT-Mi (Cm ¼w1.7 M
urea) (Table 1). This could indicate an higher instability of the apo
dimeric structure of G170R-Mi with respect to the corresponding of
AGT-Mi, thus suggesting that G170R mutation alters the
dimeremonomer dissociation of apoAGT-Mi.
The impact of the G170R mutation on the stability of AGT-Mi in
the holo and apo forms was further investigated through moni-
toring the sensitivity of AGT-Mi and G170R-Mi to thermal dena-
turation. We performed far-UV CD-monitored heating scans of
these proteins at a rate scan of 0.5 !C/min (Fig. 3 of SI). A single
transition is observed for both holoenzymes with similar Tm values
(72.4 & 0.1 !C and 72.5 & 0.1 !C for AGT-Mi and G170R-Mi,
respectively). On the other hand, the thermal unfolding of the
apoenzymes is a two-step process with two apparent Tm: 51.
1 & 0.1 !C and 64 & 1 !C for apoAGT-Mi, 48.2 & 0.1 !C and 64 & 1 !C
for apoG170R-Mi. In both cases, the amplitude is of about 80% and
20% for the ﬁrst and the second transition, respectively. Altogether
these data indicate that G170R mutation only affects the stability of
apoAGT-Mi, and are consistent with those obtained by urea
unfolding experiments.
It is not easy to explain why G170R mutation decreases the
stability of the dimeric structure of AGT-Mi in the apo formwithout
any apparent effect on the holo form. Recently, Djordjevic et al. [24]
solved the crystal structure of the major allelic form of human AGT
containing the G170R mutation. The authors found that this variant
has an overall structural architecture and a spatial conﬁguration of
the active site microenvironment similar to those of AGT-Ma. Thus, it
is not surprising that holoG170R-Mi displays spectroscopic and
catalytic properties indistinguishable from those of holoAGT-Mi.
Nevertheless, signiﬁcant local structural changes are seen in the
vicinity of the G170Rmutation (inset B of Fig. 8). Gly170 is located in
the ﬁrst turn of helix 168e175, and its replacement by an arginine
side chain causes a conformational change leading to a 1Å translation
in the position of the Ca of residue Asp167 as well as an approxi-
mately 30! turn along the helical axis. The consequences of this
helical displacement are (i) a 1.5Å change in the CapositionofGly170
and roughly a half peptide bond turn of the helix, and (ii) the
breakdown of a salt bridge betweenHis174 and Asp201 aswell as the
rotation of His174 toward solvent. It is alsoworth pointing out that in
AGT-Ma Arg197 forms a hydrogen bond to the carbonyl O atom of
Lys5 from the adjacent subunit, while the predominant rotamer of
Arg197 in the G170R structure impairs the formation of this inter-
action. This is possibly due to change of the position of the a-helix
168e175 relative to that of the loop 184e201. On the basis of these
crystallographic data, it can be speculated that the decreased stability
under urea stress of the dimeric form of apoG170R-Mi compared to
that of AGT-Mi could be due mainly to the loss of intersubunit
hydrogen bond between Arg197 and Lys5*. The ﬁnding that the holo
form of G170R-Mi exhibits dimer stability comparable to that of
AGT-Mi is likely due to compensatory hydrogen bonds between PLP
of one subunit and residues of the opposite subunit. However, the
determination of the 3D structure of both the apo forms of AGT-Mi
and G170R-Mi would be necessary to verify this interpretation.
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We tried to correlate our “in vitro” results on the functional
features of G170R-Mi variant with the observed enzymatic
phenotype associated with this mutation. The possible folding
pathway of AGT has been taken into consideration, even if we are
aware that the partial reversibility of the unfolding process based
on an equilibrium process does not allow a thermodynamic model
to be deﬁned. As shown in Scheme 2, the pathway a/ b/ c/ d
foresees the conversion of the unfolded monomer (U) to a partially
unfolded monomer (M*), and then to a folded monomer (M) which
dimerizes giving the apodimeric species (D). Upon PLP binding D is
converted into the catalytically active dimer (DPLP). In the alterna-
tive pathway a/ b/ e/ f, after the conversion of U to M* and of
M* to M, M would bind PLP leading to MPLP which dimerizes
generating DPLP. On the basis of the different requirements of the
protein for mitochondria or peroxisomes import, it can be postu-
lated that unfolded (U) or loosely folded (M*) monomeric species
are compatible with the mitochondrial import machinery, while
folded monomeric (M and MPLP) and dimeric (D and DPLP) species
are compatible with the peroxisomal import machinery. However,
it cannot be excluded that the M* species could be also imported to
the peroxisome. The route a/ b/ c/ d should be the preferred
one in that (i) the concentration of vitamin B6 in whole blood with
normal dietary intake is expected to be 1.6e2 mM (with about
0.1 mM in plasma) [25], (ii) even if not yet measured, the KD(PLP)
value of M is expected to be higher than that of D. Since G170R
mutation associated with the minor allele is responsible for the
mistargeting of 90e95% of AGT from its normal location in the
peroxisomes to the mitochondrial matrix, the G170R-Mi variant
should not follow the a / b / c / d route, and its dimeric
structure should not form. This is supported by the following
results and considerations. Our ﬁnding that the holodimeric form of
G170R-Mi is catalytically equivalent to that of AGT-Mi indicates
that, if it formed in the liver cytosol, it would be imported in the
peroxisomes, and would not be pathogenic. Moreover, the
G170R-Mi variant displays a PLP binding afﬁnity comparable to that
of AGT-Mi, thus implying that the responsiveness to vitamin B6 of
PH1 patients carrying this mutation [26,27] could not be ascribed to
the conversion of D to DPLP. On this basis, and taking into account
that the D species of G170R-Mi is more destabilized than the D
species of AGT-Mi, it is reasonable to suggest that during the folding
process of G170R-Mi the step c should be altered. As a consequence,
since the formation of D is greatly impaired, the formation of
monomeric forms (M* and M) could prevail. While M could
undergo aggregation either in the peroxisome or in the cytosol, M*
could be imported into mitochondria, possibly with a rate higher
than that of its conversion to M. Following this view, and consid-
ering that the dimeric structure of AGT-Mi and P11Lmutant is more
destabilized than that of AGT-Ma, it can be suggested that P11L
mutation itself could affect step c, even to a lower extent thanwhen
it is associated with G170R mutation. Indeed, only 5% of AGT-Mi is
mistargeted to mitochondria. Thus, the functional synergism
between the P11L polymorphism and the G170R mutation appears
to be related to their combined effect on dimer stability. It has been
previously proposed that the effect of G170R mutation on AGT-Mi
consists in the retardation of dimerization in the cytosol [21]. In
addition, it has been reported that treatments, known as being able
to increase non-speciﬁcally the stability of proteins, correct the
intracellular targeting of G170R-Mi in COS cells [26]. Although
these data are in line with our results and interpretation, a ther-
modynamic and kinetic analysis of the monomer/dimer associative
process of AGT-Ma, AGT-Mi and G170R-Mi would be necessary to
clarify this issue. To this end, studies to engineer a folded monomer
of AGT by site-directed mutagenesis are in progress.
Nevertheless, the molecular mechanism by which the vitamin
B6 therapy is able to counteract the effects caused by G170R
mutation associated to the minor allele remains to be established.
Based on our results, it can be argued that the effect of increasing
PLP concentration (about 100e500-fold with respect to normal
daily intake [23]) could result in binding of the coenzyme to the M
species able to generate DPLP through the route a/ b/ e/ f. It is
also possible that PLP could bind to M* leading to MPLP and then to
DPLP. In the ﬁrst case, PLP would play a prosthetic role, while in the
second case it would play both conformational and prosthetic roles.
The role of PLP as pharmacological chaperone in AGT folding has
been already raised [22,27], even if it needs to be proved.
4. Conclusions
Our studies on the sensitivity to urea stress of AGT-Ma, AGT-Mi
and P11L variant point out that the dimeric structure and the PLP
binding site of AGT-Mi are destabilized with respect to AGT-Ma, and
that these destabilizing effects are due to the P11L mutation. It has
been proposed that this mutation is responsible for the loss of some
intersubunit contacts between the N-terminus of one subunit and
the large domain of the opposite subunit as well as for the pertur-
bation transmitted from the N-terminus through the active site loop
to bound-PLP. In addition, we attempted to identify the molecular
basis of the impact of G170Rmutation associated to the minor allele.
Thismutation, themost common in PH1, is responsible for aw90% of
AGT mistargeting from its usual peroxisomal location to mitochon-
dria [20]. Administration of vitamin B6 has a beneﬁcial therapeutic
effect in patients carrying this mutation [27,28]. The biochemical
characterization of recombinant G170R-Mi has allowed us to estab-
lish that the holoform exhibits spectroscopic and catalytic features as
well as sensitivity to urea and chemical stress indistinguishable from
those of AGT-Mi. However, evidence is provided for a stability of its
apodimer dimeric structure lower than that of apoAGT-Mi. These
ﬁndings suggest that it is the dimer-monomer dissociative process to
be affected in apoG170R-Mi, and that pharmacological doses of
vitamin B6 allow binding of PLP to the monomeric species and
rescue the variant from being targeted to mitochondria. To our
knowledge, this study is the ﬁrst report of the biochemical impact of
G170Rmutation on AGT-Mi, thus allowing to correlate themolecular
defect with the pathogenic consequences of this variant.
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Scheme 2. Proposed pathways of AGT folding. U, unfolded monomer, M*, partially
folded monomer, M, folded monomer, MPLP, PLP-bound monomer, D, apodimer, DPLP,
holodimer and PLP (C). The arrows (.) indicate the import of different AGT species to
mitochondrion or to peroxisome, the arrow (- - -) indicates the possible import of M*
to peroxisome.
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Primary Hyperoxaluria Type I (PH1) is a disorder of glyoxylate metabolism caused by mutations in the human
AGXT gene encoding liver peroxisomal alanine:glyoxylate aminotransferase (AGT), a pyridoxal 5′-phosphate
(PLP) dependent enzyme. Previous investigations highlighted that, although PH1 is characterized by a signiﬁ-
cant variability in terms of enzymatic phenotype, the majority of the pathogenic variants are believed to
share both structural and functional defects, as mainly revealed by data on AGT activity and expression level
in crude cellular extracts. However, the knowledge of the defects of the AGT variants at a protein level is still
poor. We therefore performed a side-by-side comparison between normal AGT and nine puriﬁed recombinant
pathogenic variants in terms of catalytic activity, coenzyme binding mode and afﬁnity, spectroscopic features,
oligomerization, and thermal stability of both the holo- and apo-forms. Notably, we chose four variants in
which the mutated residues are located in the large domain of AGT either within the active site and interacting
with the coenzymeor in its proximity, andﬁve variants inwhich themutated residues are distant from the active
site either in the large or in the small domain. Overall, this integrated analysis of enzymatic activity, spectroscopic
and stability information is used to (i) reassess previous data obtained with crude cellular extracts, (ii) establish
which form(s) (i.e. holoenzyme and/or apoenzyme) and region(s) (i.e. active site microenvironment, large
and/or small domain) of the protein are affected by each mutation, and (iii) suggest the possible therapeutic ap-
proach for patients bearing the examined mutations.
© 2011 Elsevier Inc. All rights reserved.
1. Introduction
Primary Hyperoxaluria Type I (PH1) is a human metabolic disease
whose principal hallmark is the formation of calcium oxalate stones at
ﬁrst in the kidneys and urinary tract and then, should renal failure
occur, in the whole body [1]. Although the ﬁrst clinical manifestations
are related to renal dysfunction, the cause of the disease is the deﬁcien-
cy of an hepatic peroxisomal protein, namely alanine:glyoxylate amino-
transferase (AGT) [2]. AGT is a pyridoxal 5′-phosphate (PLP)-dependent
enzyme that converts L-alanine and glyoxylate into pyruvate and gly-
cine. In the absence of AGT, the oxidation of glyoxylate by lactate dehy-
drogenase results in the synthesis of oxalate with the consequent
formation and deposition of insoluble calcium oxalate crystals [1].
AGT is encoded by the AGXT gene [3], which is present in humans as
two polymorphic variants, the “major allele” (AGT-Ma) and the less
common “minor allele” (AGT-Mi). AGT-Mi differs from AGT-Ma by a
74-bp duplication in intron 1 and by two mutations leading to the
P11L and I340M amino acid substitutions, respectively [4,5].
PH1 is characterized by a remarkable heterogeneity in terms of en-
zymatic phenotypes. Among the more than 150 pathogenic mutations
in the AGXT gene identiﬁed so far [6], missense mutations are the
most common type and lead to AGT deﬁciency by a variety of different
mechanisms. Indeed, some mutations reduce AGT catalytic activity,
others affect either protein folding, stability or localization inside the
cell, while others, that represent the vast majority, inﬂuence at varying
degrees both AGT catalytic activity and folding. Moreover, some muta-
tions cosegregate and functionally interact with the minor allele poly-
morphism [7–9]. It should be pointed out that the effects of most
pathogenic mutations have been identiﬁed by measuring the AGT
transaminase activity (expressed as speciﬁc activity) and/or the protein
expression level in crude cellular extracts or cell-free expression sys-
tems [9–16]. However, in cases of low speciﬁc activity and low expres-
sion level, this approach does not allow one to assess if a mutation
exerts a structural and/or a functional impact. Since in diseases related
to protein malfunction it is diagnostically and therapeutically essential
to understand themultiplemechanisms that relate the speciﬁcmutants
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with the pathology, the knowledge of the structural and/or functional
effect(s) that each amino acid substitution produces on AGT would be
highly desirable. A relevant step in this direction has been the resolution
of the crystal structure of AGT in complex with the inhibitor aminoox-
yacetic acid [17]. The structure revealed that AGT is dimeric and belongs
to the aspartate aminotransferase family of PLP-dependent enzymes.
Each subunit is comprised of an N-terminal extension (residues 1–21)
that wraps over the surface of the other subunit, a large domain (resi-
dues 22–282) containingmost of the active site and thedimerization in-
terface, and a C-terminal domain (residues 283–392) containing the
peroxisomal targeting information (Fig. 1A). As in all PLP-enzymes,
the cofactor is covalently bound to the apoprotein by a Schiff base link-
age with a lysyl residue which is at position 209 in AGT. The analysis of
the crystal structure of AGT not only provided information on the active
site topography and on the residues involved in binding of coenzyme
and substrates but also allowed one to rationalize and interpret the im-
pact of some disease-speciﬁc mutations in terms of their likely
effects on AGT tertiary and quaternary conformation [17]. Indeed, in
the last 5 years, biochemical and bioinformatic investigations on
several pathogenic variants in the recombinant puriﬁed form have un-
covered their molecular defects. In particular, it has been demonstrated
that (i) the dramatic loss of catalytic activity of the G82E-Ma variant is
related to its inability to undergo an efﬁcient transaldimination [18] rath-
er than to an impaired PLP binding, as previously suggested [9], and (ii)
the decreased catalytic activity and immunoreactivity of Gly41 variants
are not primarily due to the destabilization of the dimeric structure, as
previously reported [9,17,19], but to the propensity of these variants in
the dimeric form to undergo aggregation and degradation [20]. Addition-
ally, evidence has been provided that the defect of G170R-Mi [21] and
F152I-Mi [22] consists of a reduced dimer stability of their apo-forms. In
this regard, it must be pointed out that, although the crystal structure of
apoAGT is not available yet, near-UVCDandﬂuorescence spectra strongly
suggest a different conformationbetween the apo- andholo-formsof AGT
[20]. Importantly, the identiﬁcation of the mechanism(s) leading to AGT
loss of function in these variants has allowed to predict that patients car-
rying mutations at Gly82 or Gly41 will be unresponsive to pyridoxine
treatment and to explain why patients bearing the G170R and F152I mu-
tations have been found to be responsive to B6 therapy [23–25]. Follow-
ing these considerations, it would be desirable to extend the analysis on
the structural and functional properties to as many puriﬁed recombinant
pathogenic variants as possible in both the holo- and apo-forms.
To this aim, we decided to elucidate the molecular basis underlying
AGT loss of function in a subset of known pathogenic mutations spread
over the structure of AGT. Speciﬁcally, we chose mutations affecting
(i) residues at the active site directly interactingwith the PLP coenzyme
(Trp108, Ser158 and Asp183), (ii) a residue located in the large domain
of AGT in the proximity of the active site (Ser218), and (iii) residues
located far from the AGT active site either in the large (Gly161,
Ser187) or in the small domain (Pro319 and Gly350) (Figs. 1A and B).
Enzyme activity, PLP binding mode and afﬁnity, oligomerization, and
thermal unfolding were analyzed for each of these variants in its puri-
ﬁed holo- and apo-forms. The integrative analysis of the kinetic, spec-
troscopic and thermostability data allows one to (i) establish that, in
contrast with previous data obtained on crude lysates, not all the vari-
ants have both structural and functional defects, (ii) deﬁne if amutation
causes a structural defect limited to the active site or extended to the
large and/or the small domain of AGT, and (iii) suggest the treatment
that could be effective for patients carrying the examined mutations.
2. Materials and methods
2.1. Materials
PLP, SYPRO orange, L-alanine, sodium glyoxylate, pyruvate, rabbit
muscle L-lactic dehydrogenase, and isopropyl β-D-thiogalactopyrano-
side were all purchased from Sigma. All other chemicals were of the
highest purity available.
2.2. In silico analyses
In silico mutagenesis analyses were performed by means of the
software PyMol [26] (DeLano Scientiﬁc) starting from the three-
dimensional structure of AGT (pdb ﬁles 1H0C_A and 1H0C_B).
2.3. Site-directed mutagenesis
The polymorphic and pathogenic variants of AGT were constructed
starting from the pAGT-His construct that contains the complete open
reading frame of AGT cloned in a pTrcHis2A expression plasmid [9].
The mutations were introduced by using the QuikChange site-directed
mutagenesis kit (Stratagene) and the oligonucleotides used for muta-
genesis are reported in Supplementary Table 1. All the mutations
were conﬁrmed by the entire DNA sequence analysis.
2.4. Protein expression and puriﬁcation
Mutant enzymes in their histidine-tagged form were expressed in
E. coli and puriﬁed with the procedure already described [18]. The apo-
form of each variantwas prepared as previously described [18]. The pro-
tein concentration in the AGT samples was determined by absorbance
spectroscopy using an extinction coefﬁcient of 9.54×104 M−1 cm−1
at 280 nm [18]. The PLP content of the holoenzymes was determined
by releasing the coenzyme in 0.1 M NaOH and by using an εM=
6600 M−1 cm−1at 388 nm.
Fig. 1. 3D representation of the AGT structure (PDB ﬁle 1H0C). (A) Overall structure
of the AGT dimer. One monomer is colored gray, while in the opposite monomer the
N-terminus, the large domain and the small domain are colored magenta, blue and
green, respectively. PLP is represented as yellow sticks. Pro11 and Ile 340 are repre-
sented as red sticks, while Gly161, Ser187, Pro319 and Gly350 are represented as
magenta sticks. (B) The AGT active site is shown. PLP is represented as yellow sticks.
Residues directly interacting with PLP are represented as dark gray sticks or, if their
mutation is analyzed in this study, as orange sticks. Ser218 is represented as magen-
ta sticks. The dotted lines indicate possible hydrogen bond interactions. The ﬁgure
was rendered using PyMol [26].
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2.5. Determination of the equilibrium dissociation constants of the
variants for PLP
The equilibrium dissociation constant for PLP (KD(PLP)) of G161C-
Mi, G161S-Mi, P319L-Ma and G350D-Mi variants was determined
by measuring the quenching of the intrinsic ﬂuorescence of the apo-
enzymes (0.1 μM) in the presence of PLP at a concentration range of
0.01–10 μM. In the case of W108R-Mi, S158L-Ma, D183N-Ma and
S218L-Ma variants, the KD(PLP) was determined by measuring the CD
signal at 430 nm of the apo forms at a concentration of 10 μM in the
presence of PLP at concentrations ranging from 5 to 300 μM. All the
experiments were carried out in 100 mM potassium phosphate buff-
er, pH 7.4. The KD(PLP) values for the mutant–coenzyme complexes
were obtained by using the following equation:
Y ¼ Ymax
E½ #t þ PLP½ #t þ KD PLPð Þ−
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
Eð #t þ PLP½ # þ KD PLPð Þ
h "2−4 E½ #t PLP½ #tr
2 E½ #t
where [E]t and [PLP]t represent the total concentrations of the mutant
and PLP, respectively, Y refers to either the intrinsic ﬂuorescence
quenching or the 430 nm dichroic signal changes at a PLPt concentra-
tion, [PLP], and Ymax refers to the aforementioned changes when all
enzyme molecules are complexed with coenzyme.
The KD(PLP) for the S187F-Ma variant has been estimated as the
upper limit value by the following procedure: samples of holo- and
apo-S187F-Ma at various protein concentrations (from 0.01 to 1 μM,
being 0.01 μM the detection limit) were incubated overnight at
25 °C in 100 mM potassium phosphate buffer, pH 7.4. The intrinsic
ﬂuorescence emission at 336 nm of each sample was registered and
the percentage of ﬂuorescence quenching at each protein concentra-
tion was then calculated.
2.6. Enzyme activity measurements
The kinetic parameters for the overall transamination reaction for
the pair alanine/glyoxylate of the AGT variants (0.1–10 μM) were
determined in the presence of saturating PLP concentration by vary-
ing the substrate concentration at a ﬁxed saturating co-substrate con-
centration. For the G161C-Mi, G161S-Mi, S218L-Ma, P319L-Ma and
G350D-Mi variants pyruvate formation was measured by a spectro-
photometric assay using the coupled lactate dehydrogenase system
previously described [18], while for the W108R-Mi, S158L-Ma,
D183N-Ma and S187F-Ma variants a more sensitive assay based on
measuring the 2,4-dinitrophenylhydrazine derivative of pyruvate by
HPLC analysis was used [27]. Data of initial velocity as a function of
substrate concentration were ﬁtted to the Michaelis–Menten
equation.
2.7. Dynamic light scattering (DLS)
Stock solutions of all AGT variants, either in the holo- or the apo-
form, were diluted to 10 μM concentration with 100 mM potassium
phosphate buffer, pH 7.4. PLP at saturating concentrations was
added to the holoenzyme solutions. Each sample was incubated for
10 min at 25 °C and DLS analysis was performed on a ZetasizerNano
S device (Malvern Instruments) by using disposable 12.5×45-mm
cells with stopper. The temperature was kept at 25±0.1 °C during
the measurements by a Peltier temperature controller.
2.8. Thermostability
The thermostability studies on puriﬁed AGT variants in the holo-
(in the presence of saturating PLP) or the apo-form were performed
by both CD-monitored thermal unfolding and differential scanning
ﬂuorimetry (DSF). In the ﬁrst method, the CD signal at 222 nm of
AGT variants at 10 μM concentration in 100 mMpotassium phosphate
buffer, pH 7.4, was registered with temperature increasing from 25 to
90 °C at a heating rate of 1.5 °C/min. For the holo-forms the PLP disso-
ciation during thermal unfolding was also monitored by measuring
the CD signal at 430 nm under the same experimental conditions
reported above. Calculation of the melting temperatures (Tm) was
carried out by ﬁtting the CD signal either to a two or a three state
unfolding model using the Origin Pro7 software according to the
method of Pace [28]. The rates of PLP dissociation and loss of second-
ary structure at the melting temperature for both AGT-Ma and AGT-
Mi were measured by monitoring the CD signal at 430 and 222 nm
with time, and ﬁtting the data to a single exponential curve.DSF
experiments were performed with puriﬁed AGT variants at the
concentration of 1 μM in 100 mM potassium phosphate buffer pH
7.4 containing 5× SYPRO orange, according to the method of Nielsen
et al. [29]. Considering the high background ﬂuorescence of the holo-
and apo-forms of W108R-Mi at 25 °C, the SYPRO orange ﬁnal concen-
tration was 2.5×. Proteins were subjected to a ramp of 2.15°C/min in
a Mastercicle EP Realplex 4 (Eppendorf) at a temperature gradient
from 25°C–90°C. Graph generation and calculation of Tm were carried
out by using the Realplex software.
2.9. Spectroscopic measurements
Absorption measurements were made with a Jasco V-550 spectro-
photometer with a 1 cm path length quartz cuvette at a protein con-
centration of 1–10 μM. Visible and far-UV CD spectra were recorded
on a Jasco J-710 spectropolarimeter equipped with a thermostatically
controlled compartment at 25 °C, by using 1 cm path-length quartz
cuvettes. The enzyme concentration was 1–10 μM and the spectra of
the holoenzymes were recorded in the presence of saturating PLP
concentrations. Routinely, three spectra were recorded at a scan
speed of 50 nm/min−1 with a bandwidth of 2 nm and averaged auto-
matically. Intrinsic ﬂuorescence emission spectra were recorded on a
Jasco FP-750 spectroﬂuorometer equipped with a thermostatically
controlled cell holder.
3. Results
3.1. In silico analyses
To investigate the possible local effect of each of the studied amino
acid substitutions on AGT we mapped them onto the available crystal
structure of the enzyme in its major allelic form [17] and performed
in silico mutagenesis by the software PyMol [26]. The location of the
residues whose mutation has been analyzed in this work is shown
in Figs. 1A and B. Trp108, Ser158 and Asp183 are active site residues
that directly interact with the coenzyme. The side chain of Ser158 is
hydrogen-bonded to the 3′ hydroxyl group of PLP, the indolic ring
of Trp108 forms a base-stacking interaction with the pyridine ring
of the coenzyme, and the carboxylic group of Asp183 forms a salt-
bridge with the positive pyridine nitrogen of PLP. Thus, it can be pre-
dicted that the W108R, S158L and D183N mutations could have a
functional effect on AGT, by possibly altering the binding of the coen-
zyme and/or the catalytic properties of the enzyme. Ser218, a residue
located near the active site, does not interact with the coenzyme, and
is located at the end of the strand 6 of the β-barrel. Since its hydroxyl
group could interact with the peptydic oxygens of Ser81, Gly80 and
Ile78, this residue might be involved in the proper positioning of
the helix 4 that also comprises Gly82, a residue hydrogen-bonded to
the PLP phosphate. The S218L mutation is predicted to have a local
structural effect on the large domain, possibly resulting in the distor-
tion of the coenzyme binding cleft. Gly161 and Ser187 are two large
domain residues located far from the active site. Gly161 is located at
the interface between the large and the small domain and the in silico
analysis predicts that both G161C and G161S mutations would alter
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the inter-domain contacts of the AGT subunit. Ser187 is located in a
random coil region on the re face of the coenzyme and its substitution
with a phenylalanine residue would possibly change the positioning
of the loop 154–169 comprising Gly161, thus indirectly affecting the
large domain/small domain contacts. Finally, Pro319 and Gly350
belong to two random coil regions of the small domain. It can be pre-
dicted that the P319L mutation could have a structural effect on the
small domain by leading to a mispositioning of the helix 11 located
on the surface of the protein. Gly350 faces the active site on the si
side of the coenzyme and the Gly350-to-Asp substitution could
induce steric clashes of the small domain, in particular of the loop
343–357.
3.2. E. coli expression and puriﬁcation
E. coli expression vectors encoding for the selected pathogenic vari-
antswere constructed by site-directedmutagenesis. Eachmutationwas
inserted on the backgroundof themajor or theminor allele according to
the genotype of the PH1 patients in whom themutation was identiﬁed.
Then, by a previously developed protocol [18], the nine AGT variants
were expressed and puriﬁed to homogeneity, as indicated by a single
band on SDS–PAGE at an apparent molecular weight of about 45 KDa
(data not shown). The majority of the mutant proteins was present in
good amounts in the soluble extract as compared to AGT-Ma or AGT-
Mi, except Gly161 variants whose yield is ~10% that of AGT-Mi. The
far-UV CD spectrum of each variant in the apo-form was registered
and found to be identical to that of apoAGT-Ma or apoAGT-Mi, thus in-
dicating that the mutations do not introducemajor changes on the sec-
ondary structure of the protein. Moreover, the molecular dimensions of
the variants in both the holo- and apo-forms have been determined by
DLS. For each protein at 10 μM concentration in 100 mM potassium
phosphate buffer pH 7.4, a peak with a size ranging from 9.2 to
10.8 nm, corresponding to that of a dimer, could be seen. This indicates
that the dimer is the most abundant species in solution, given that the
intensity of the signal on DLS varies with the sixth power of a particle
diameter. However, the presence of low amounts of small aggregates
(100–400 nm) could be noticed for W108R-Mi, S218L-Ma, S187F-Ma,
G161C-Mi, G161S-Mi and P319L-Ma in both the holo- and apo-forms
as well as for G350D-Mi in the apo-form (data not shown).
3.3. PLP binding mode and afﬁnity
The equilibrium dissociation constants (KD(PLP)) for the complexes
between PLP and the variants were determined by titrating the apo-
form of each enzymatic species with increasing concentrations of PLP
and by ﬁtting the data to the appropriate equation. The obtained KD
(PLP) values are reported in Table 1 alongwith the previously determined
KD(PLP) values for AGT-Ma and AGT-Mi [18,22]. Basing on these data, it
can be observed that: (i) W108R-Mi, S158L-Ma, D183N-Ma and S218L-
Ma, even if at different extents, show a signiﬁcantly reduced afﬁnity for
the coenzyme while (ii) G161C-Mi, G161S-Mi, P319L-Ma and G350D-
Mi display an unaltered or even increased afﬁnity for PLP. In the case of
S187F-Ma, the enzyme concentration required for ﬂuorescence mea-
surements far exceeds the KD(PLP), which precludes the determination
of a precise value for KD(PLP). Thus, only an upper limit of 0.01 μM has
been estimated for the KD(PLP) of the S187F-Ma variant.
Coenzyme binding to AGT gives rise to typical absorbance bands at
430 and 340 nm associated with positive and negative dichroic sig-
nals, respectively [18]. In order to deﬁne if the analyzed PH1-causing
mutations could alter the AGT coenzyme binding mode, the UV–
visible absorbance and CD spectrum of each enzymatic species at
10 μM concentration has been registered in the presence of saturating
PLP concentrations (Fig. 2), and the corresponding optical activity
(expressed as millidegrees/absorbance at 410–430 nm) has been
calculated (Table 1). The results indicate that, at varying degrees,
only the W108R,G161C, G161S, S158L and S218L mutations decrease
the optical activity with respect to that of AGT-Ma or AGT-Mi, thus in-
dicating that these mutations cause a change in the microenviron-
ment of the internal aldimine. It is worth noting that, although the
S187F-Ma variant does not show an altered value of the optical activ-
ity, its internal aldimine is characterized by about 6 nm-blue shifted
absorbance and dichroic maxima (Fig. 2A). This ﬁnding, along with
the increase of at least about 27-fold in the KD(PLP) value, suggests
that the mutation should induce some local structural changes at
the AGT active site.
3.4. Enzymatic activity
The steady-state kinetic parameters of the overall transamination of
the alanine-glyoxylate pair were measured on the variants and com-
pared with those of either AGT-Ma or AGT-Mi. A summary of the
resulting steady-state parameters is listed in Table 2. The kcat/Km
value of D183N-Ma vs AGT-Ma and W108R-Mi vs AGT-Mi is
decreased by ~23,000- and 30,000-fold, respectively. The reduction in
the catalytic efﬁciency is mainly driven by the decrease in the kcat
value, being about 0.02% and 0.04% that of AGT-Ma and AGT-Mi, re-
spectively. Both S158L and S218L mutations do no signiﬁcantly change
the Km values, but reduce the kcat values of AGT-Ma by ~100-fold and
~16-fold, respectively, thus causing a reduction in the catalytic efﬁcien-
cy. As for S187F-Ma, the Km and the kcat values decrease by ~2- and
360-fold, respectively, as compared to AGT-Ma. Taken together, these
results agree with those previously obtained on both puriﬁed proteins
[13] and crude bacterial extracts [12]. On the other hand, a moderate, if
any, reduction of the kcat value (≥50% residual activity) has been ob-
served for the P319L-Ma variant (vs AGT-Ma) and for the G161C-Mi,
G161S-Mi, and G350D-Mi variants (vs AGT-Mi). This is in contrast
with previous reports showing that the speciﬁc activity of Gly161 var-
iants and G350D-Mi in crude cellular extracts was less than 1% [12] and
2.9% [30], respectively, that of AGT-Ma. However, the subsaturating
substrate concentration used in these studies (150 mM L-alanine, by
comparison see the Km values for L-alanine listed in Table 2) coupled
with the low expression level of these variants might explain this
discrepancy.
3.5. Thermal stability studies
To investigate whether the analyzed PH1-associated mutations
could affect the stability of AGT, which could give information about
the steady-state amount of active enzyme, we compared the thermal
unfolding proﬁles of the puriﬁed variants with those of AGT-Ma or
AGT-Mi.
Thermal protein denaturation was studied either by monitoring the
decrease of the dichroic signal at 222 nm and 430 nm, which are indic-
ative of the loss of the protein secondary structure and of the PLP-bound
Table 1
Equilibrium dissociation constants for PLP (KD(PLP)) and optical activity of AGT-Ma,
AGT-Mi and pathogenic variants.
Enzymatic species KD(PLP) (μM) Optical activity
AGT-Ma 0.27±0.03a 97 mdeg/Abs 420 nma
AGT-Mi 0.26±0.02b 97 mdeg/Abs 420 nmb
W108R-Mi 96±19 4.73 mdeg/Abs 434 nm
S158L-Ma 272±47 45 mdeg/Abs 430 nm
G161S-Mi 0.46±0.07 66 medeg/Abs 430 nm
G161C-Mi 0.56±0.09 57 mdeg/Abs 414 nm
D183N-Ma 2.1±0.1 84 mdeg/Abs 430 nm
S187F-Ma b0.01 103 mdeg/Abs 414 nm
S218L-Ma 24.2±0.1 31 mdeg/Abs 428 nm
P319L-Ma 0.19±0.04 88 mdeg/Abs 420 nm
G350D-Mi 0.031±0.005 88 mdeg/Abs 420 nm
a From Cellini B. et al. [18].
b From Cellini B. et al. [22].
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content, respectively, or by differential scanning ﬂuorimetry (DSF), that
allows one to monitor unfolding events by measuring the exposure of
hydrophobic groups of the denaturing protein [29]. This analysis was
performed both in the holo- and apo-forms of each enzymatic species
and the obtained results are listed in Tables 3 and 4, respectively. The
far-UV (222 nm) (Fig. 3) and the visible (430 nm) CD-monitored heat-
ing scans as well as the DSF experiments reveal that the holo-forms of
AGT-Ma andAGT-Mi are denatured and release PLP in a single-step pro-
cess with melting temperatures at about 78 °C and 74 °C, respectively.
This is in agreement with previous results obtained by differential scan-
ning calorimetry [20] and thermal inactivation experiments [22]. In
order to assess whether the loss of secondary structure and the PLP re-
lease are concerted events in these enzymatic species, the kinetics of
changes of the 430 nm and 222 nm have been measured at their Tm
values. We found that while the rate constant of the loss of the
430 nm dichroic signal is 0.0042±0.0001 s−1 and 0.0057±0.003 s−1
for AGT-Ma and AGT-Mi, respectively, that of the loss of the 222 nm di-
chroic band is 0.0024±0.0001 s−1 and 0.0021±0.001 s−1. These data
provide evidence for a higher local stability of the PLP binding site in
AGT-Ma than in AGT-Mi, in linewith the higher sensitivity to urea stress
of the PLP-bound state of the latter form [21]. They also indicate that
both the allelic forms of AGT release the coenzyme before losing their
secondary structure, as corroborated by the ﬁnding that, when the co-
enzyme is covalently bound to the protein by NaBH4-reduction, the
mid-point transition of AGT-Ma and AGT-Mi is at 85.6 °C and 79.1 °C,
respectively.
Like holoAGT-Ma and holoAGT-Mi, the nine pathogenic variants in
the holo-form display a single thermal transitionwith the Tmholo values,
derived from the 222 nmCD andDSFmeasurements, comparable to the
corresponding resulting from the 430 nm CD measurements (TmPLP).
The D183N mutation appears to exert a stabilizing effect, while the
S187F, G350D and P319L mutations do not exert any effect on protein
stability. For all the remaining variants the transition from the native
state to the unfolded state occurs at temperatures lower than the corre-
sponding wild-type, i.e. AGT-Ma or AGT-Mi. The variants W108R-Mi
and S218L-Ma show the most pronounced alteration with Tmholo of
54° and 57 °C, respectively. However, it should be noted that W108R-
Mi displays a considerably (~10-fold) elevated ground state ﬂuores-
cence signal at 25 °C in comparisonwith AGT-Mi, thus suggesting an in-
creased hydrophobicity due to partial protein unfolding even without
the application of the thermal stress.
Interestingly, the apo-forms of AGT-Ma and AGT-Mi display a ﬁrst
unfolding phase with a mid-denaturation at 61 °C and 53 °C for AGT-
Ma and AGT-Mi, respectively, and then a second unfolding transition
with a mid-denaturation at 66 °C for both AGT-Ma and AGT-Mi
(Fig. 3). In order to deﬁne the impact of the nine pathogenic mutations
on the intrinsic stability of AGT, the thermal unfolding of the apo-form
of each variant has been measured by far-UV CD (Supplementary
Fig. 1) and DSF experiments. Apo-S158L-Ma unfolds in a single-step
process with a Tmapo value identical to that of the high-temperature
transition (Tm2apo) of apoAGT-Ma, thus suggesting that this large do-
main mutation does not signiﬁcantly affect the Tm2apo value. On the
other hand, the small domain mutations G350D and P319L, associated
with the major and the minor alleles, respectively, cause the complete
loss of the high-temperature transition (Tm2apo) without affecting the
low-temperature transition (Tm1apo). All together, these ﬁndings indi-
cate that the mutations of residues located in the large or in the small
domain only affect the Tm1apo or the Tm2apo values, respectively.
Distinct alterations of thermal unfolding parameters were observed
for the variants S187F-Ma, G161C-Mi and G161S-Mi in the apo-form.
These residue replacements in the large domain give rise to a single
thermal transition with a mid-point at temperatures lower than those
of the Tm1apo of AGT-Ma or AGT-Mi. On the other hand, a two step pro-
cess was observed for apo-S218L-Ma and apo-W108R-Mi with both
transition left-shifted, and Tmapo values lower than those of apoAGT-
Ma and apoAGT-Mi, respectively. These data suggest that these large
domain mutations not only exert destabilizing effects of the domain in
which they are located but also inﬂuence the structural stability of the
region responsible for the high-temperature transition.
It should be noted that the analysis of apo-W108R-Mi performed
using DSF, unlike that performed using CD, reveals a single Tmapo
value similar to the Tm2apo measured by CD. This could be explained
by the fact that this apovariant has a ground state ﬂuorescence 100-
fold higher than that of apoAGT-Mi, reﬂecting an increased hydro-
phobicity due to partial protein unfolding of the native apoprotein.
4. Discussion
To date, about 150 point mutations leading to PH1 have been iden-
tiﬁed that span throughout all the 11 exons of the AGXT gene and
about half of them are missense mutations [6]. While prediction of
the effect of splice-site mutations, premature stop-codon insertion
and major deletions is straightforward, missense point mutations or
small insertions/deletions are more dubious and suitable instruments
should be available to evaluate their consequences on the AGT struc-
tural and/or functional properties. Until now, the effect of many PH1-
causing mutations has been evaluated by either the analysis of patient
liver samples or by eukaryotic and/or prokaryotic cell expression
Fig. 2. CD spectra of AGT-Ma, AGT-Mi and pathogenic variants. (A) CD spectra of AGT-
Ma (black), S158L-Ma (red), D183N-Ma (blue), S187F-Ma (violet), S218L-Ma (green)
and P319L-Ma (orange).(B) CD spectra of AGT-Mi (black), W108R-Mi (green), G161C-
Mi (fucsia), G161S-Mi (blue) and G350D-Mi (orange). All CD spectra are registered in
the presence of saturating PLP concentrations in 100 mM potassium phosphate buffer,
pH 7.4, at an enzyme concentration of 9 μM.
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experiments [9,11–13,15,16,19,31–35]. These studies led to classify all
the known pathogenic mutations according to their effect on the AGT
catalytic activity and/or immunoreactivity [7,9,36]. During the last
years, however, a more detailed biochemical and bioinformatic char-
acterization of several puriﬁed recombinant pathogenic variants in
both the holo- and apo-forms allowed identiﬁcation of their defect
(s) at a molecular level [18,20–22]. A more complex scenario of the
pathogenic mechanisms responsible for AGT deﬁciency has emerged,
thus highlighting that the heterogeneity of the PH1-causing enzymatic
phenotypes could be even wider than previously thought and sub-
stantiating the idea that a deﬁnition of the defect of the AGT variants
at molecular level would be highly desirable.
On these bases, we have explored the structural and functional
properties of nine pathogenic variants by using in silico predictions
based on the available crystal structure of the protein [17] and by de-
ﬁning some biochemical properties of the variants in their holo- and
apo- recombinant puriﬁed forms. Each mutation was inserted on
the background of either the major or the minor allele on the basis
of the genotype of PH1 patients. We report the consequences of
each amino acid substitution on: (i) the coenzyme binding mode
and afﬁnity and the catalytic activity, which are indicative of the
effect of a mutation on the AGT functional properties, and (ii) the
quaternary structure and the thermal stability of the protein in the
holo- and apo-forms, which together are indicative of the structural
effects of a particular mutation and of the possible role of the coen-
zyme on protein stability.
The ﬁrst observation that comes from our data concerns the ther-
mostability of AGT-Ma and AGT-Mi in the holo form measured either
by the loss of secondary/tertiary structure or by the PLP release. Inter-
estingly, in both of these species (i) the Tmholo and TmPLP values are
identical, (ii) the rate of PLP release is higher than that of the global
unfolding, and (iii) the Tmholo is lower than the mid-point transition
of the NaBH4-reduced form. Thus, since a conversion from the holo-
to the apo-form occurs during the thermal transition, the Tmholo
values are affected by the sensitivity of the active site to the thermal
stress. Nevertheless, our results clearly show that, in agreement
with previous studies [21,37], AGT-Ma and AGT-Mi in the apo-form
are signiﬁcantly less stable than the corresponding holo-forms. In ad-
dition, while a single transition occurs during the thermal unfolding
of the holo-proteins, two transitions with melting temperatures
(Tm1apo and Tm2apo) lower than the corresponding Tmholo characterize
the thermal unfolding of the apoproteins. Taken together, these data
Table 4
Tmapo values of AGT-Ma, AGT-Mi and pathogenic variants.
Enzymatic species Tm1apoa(°C)
CD 222 nm
Tm2apoa (°C)
CD 222 nm
Tm1apoa (°C)
DSF
Tm2apoa (°C)
DSF
AGT-Ma 61.1 66.4 61.9 67.3
AGT-Mi 53.1 66 54.2 66.5
W108R-Mi 48.9 54 53.3
S158L-Ma 65.9 64.3
G161S-Mi 46.8 46.5
G161C-Mi 51.1 51.3
D183N-Ma 70.2 70.3
S187F-Ma 48.2 45.3
S218L-Ma 50.9 57.8 47.2 55.7
P319L-Ma 61.6 60.1
G350D-Mi 53.6 52.5
a They represent Tm values and are the mean of two independent experiments. The
error is within ±0.3 °C.
Table 2
Steady-state kinetic parameters of AGT-Ma, AGT-Mi and pathogenic variants for the pair alanine-glyoxylate.
Enzymatic species Substrate Cosubstrate kcat (s−1) Km L-alanine(mM) Km Glyoxylate (mM) kcat/Km (s−1/mM−1)
AGT-Maa L-Alanine Glyoxylate 45±2a 31±4a 1.4±0.2a
Glyoxylate L-Alanine 45±2a 0.23±0.05a 196±4a
AGT-Mib L-Alanine Glyoxylate 33±5b 28±2b 1.2±0.2b
Glyoxylate L-Alanine 37±1b 0.22±0.01b 168±8b
W108R-Mi L-Alanine Glyoxylate 0.0013±0.0003 36±3 0.00004±0.00001
Glyoxylate L-Alanine n.d. n.d. n.d.
S158L-Ma L-Alanine Glyoxylate 0.41±0.03 25±6 0.016±0.001
Glyoxylate L-Alanine 0.41±0.04 0.35±0.09 1.2±0.3
G161S-Mi L-Alanine Glyoxylate 55±2 70±9 0.8 ±0.1
Glyoxylate L-Alanine 58±2 0.63±0.07 92±2
G161C-Mi L-Alanine Glyoxylate 36.1±0.7 103±6 0.35±0.02
Glyoxylate L-Alanine 36.6±0.7 0.21±0.02 174±1
D183N-Ma L-Alanine Glyoxylate 0.008±0.003 140±17 0.00006±0.00001
Glyoxylate L-Alanine n.d. n.d. n.d.
S187F-Ma L-Alanine Glyoxylate 0.13±0.01 12±2 0.0108±0.0002
Glyoxylate L-Alanine 0.12±0.01 0.13±0.04 0.92±0.09
S218L-Ma L-Alanine Glyoxylate 2.7±0.1 29±6 0.09±0.02
Glyoxylate L-Alanine 2.95±0.08 0.19±0.02 15±2
P319L-Ma L-Alanine Glyoxylate 27.5±0.8 44±5 0.63±0.01
Glyoxylate L-Alanine 26.2±0.7 0.11±0.02 238±44
G350D-Mi L-Alanine Glyoxylate 15.0±0.7 328±51 0.046±0.007
Glyoxylate L-Alanine 15±1 0.29±0.04 52±7
n.d. not determined because the rate of glyoxylate half-transamination is comparable to that of PMP dissociation/PLP association at sub-saturating glyoxylate concentrations.
a From Cellini B. et al. [18].
b From Cellini B. et al. [22].
Table 3
Tmholo and TmPLP values of AGT-Ma, AGT-Mi and pathogenic variants.
Enzymatic species Tmholoa(°C)
CD222 nm
TmPLPa(°C)
CD420 nm
Tmholoa(°C)
DSF
AGT-Ma 77.5 78 78.6
AGT-Mi 73.6 73.6 74.1
W108R-Mi 54.1 53.4 53.9
S158L-Ma 67 64 64.7
G161S-Mi 62.5 62.8 61.8
G161C-Mi 64 64.2 63.8
D183N-Ma 80.8 79.6 80.1
S187F-Ma 76.7 74.4 73.6
S218L-Ma 57.8 57.9 56
P319L-Ma 77.9 76.3 77.5
G350D-Mi 73.5 73.7 72.6
a They represent apparent Tm values and are the mean of two independent experi-
ments. The error is within ±0.3 °C.
137E. Oppici et al. / Molecular Genetics and Metabolism 105 (2012) 132–140
indicate that (i) PLP located at the interface between the two subunits
is responsible for the higher stability of holoAGT-Ma and holoAGT-Mi
with respect to the corresponding apo-forms, and (ii) the large and
small domains unfold in a concerted and cooperative way in the
holo-forms, while appear to be differentially stabilized in the apoen-
zymes. Considering that PLP makes several contacts with the large
domain only [17], it can be speculated that in the apoenzymes, but
not in the holoenzymes, the large domain could be less stable than
the small one. Accordingly, the three state model of thermal denatur-
ation of apoAGT can be described as a process in which a low-temper-
ature transition (Tm1apo), that represents the unfolding of the large
domain, is followed by a high-temperature transition (Tm2apo), that
represents the unfolding of the small domain, and by irreversible pro-
tein denaturation. This interpretation might explain the reason why
the two polymorphic mutations typical of the minor allele induce a
~8 °C reduction only in the Tm1apo. Previous evidences have indicated
that the reduced stability of AGT-Mi might depend on a distortion of
the N-terminal arm of the protein caused by the P11L substitution
that, in turn, likely destabilizes the dimeric structure of AGT [21].
Since the N-terminal arm wraps over the surface of the opposite sub-
unit that interacts with the large domain, it follows that the distortion
of the N-terminus could speciﬁcally destabilize the large domain of
AGT.
In Table 5 the major defect(s) of the nine pathogenic variants ana-
lyzed on crude lysates and on recombinant puriﬁed protein are listed.
On the basis of the functional and structural features of the pathogenic
variants in the holo-form, it can be inferred that (i) D183N-Ma, G350D-
Mi and S187F-Ma display exclusively a functional defect. It is reason-
able that Asp183, in analogy with what observed upon replacement
of Asp222 with asparagine in E. coli aspartate aminotransferase [38],
plays a role in stabilizing the positive charge at N(1) of PLP, thus en-
hancing the electronwithdrawing capacity of the coenzyme. Moreover,
the functional defect of G350D-Mi, that could be ascribed to as one pos-
sible cause of its pathogenicity, might be its high Km L-alanine value.
According to the in silico analysis, the substitution of Gly350 with an
aspartate residue changes the conformation of the loop 343–357 at
the entrance of the AGT active site, thus possibly affecting substrate
binding. On the other hand, considering that Ser187 is a residue far
from the active site, the features of S187F-Ma in terms of speciﬁc activ-
ity, PLP binding afﬁnity and mode are unexpected and difﬁcult to ex-
plain. (ii) W108R-Mi, S158L-Ma and S218L-Ma are characterized by a
functional defect (decreased catalytic activity and PLP binding afﬁnity
as well as altered coenzyme binding mode) associated with an in-
creased sensitivity to thermal stress limited to the active site microen-
vironment. This is not surprising, taking into account that Ser158,
Ser218, and Trp108, residues belonging to the large domain, interact
directly or indirectly with functional groups of PLP. (iii) HoloGly161
variants show exclusively a structural defect consisting in a decreased
thermostability of their active site, and (iv) P319L-Ma in the holo
form appears to display neither a functional nor a structural defect. No-
tably, by looking at the thermal unfolding proﬁles of these variants in
the apo-form, a more detailed and enlightening picture of their molec-
ular defects comes out. Unlike AGT-Ma and AGT-Mi, all the apo forms
of the examined variants, except S218L-Ma and W108R-Mi, exhibit a
single transition. Based on the Tmapo values reported in Table 4, and
considering the thermal unfolding model proposed for apoAGT-Ma
and apoAGT-Mi, it can be deduced that the large domain D183N and
S158L mutations do not decrease AGT stability, being the Tmapo values
of S158L-Ma and D183N-Ma similar to or higher than the Tm2apo of
AGT-Ma. On the other hand, the large domain G161S, G161C, S187F,
W108R, and S218L mutations cause a destabilizing effect not limited
to the large domain but extended to the small domain. In fact, the
Tmapo values of S187F-Ma and Gly161 variants are lower than the
Tm1apo of AGT-Ma and AGT-Mi, respectively, and both the Tm1apo and
the Tm2apo of S218L-Ma and W108R-Mi are lower than the
Table 5
Major defect(s) of AGT pathogenic variants analyzed on crude lysates and on recombinant puriﬁed proteins.
Analysis on crude lysates Analysis on puriﬁed proteins
AGT variants Speciﬁc
activity
Expression
level
PLP binding
afﬁnity
PLP binding
mode
Speciﬁc
activity
Tmholo and
TmPLP
Tmapo Functional (F)
and/or
strucural (S) defect
Suggested therapy
W108R-Mi Decreaseda Decreaseda Decreased Altered Decreased Decreased Decreased F+S ?
S158L-Ma Decreasedb Decreasedb Decreased Altered Decreased Decreased Slightly
increased
F+S ?
G161S-Mi Decreasedb Decreasedb Slightly
decreased
Altered Sligthy
decreased
Decreased Decreased S Pyridoxine+chemical
chaperones
G161C-Mi Decreasedb Decreasedb Slightly
decreased
Altered Slightly
decreased
Decreased Decreased S Pyridoxine+chimica
chaperones
D183N-Ma Decreaseda Decreaseda Decreased Slightly
altered
Decreased Slightly
increased
Slightly
increased
F ?
S187F-Ma Decreaseda Decreaseda Increased Unaltered Decreased Unaltered Decreased F+S ?
S218L-Ma Decreased Decreased Decreased Altered Decreased Decreased Decreased F+S Chemical chaperones
P319L-Ma ? ? Slightly
increased
Slightly
altered
Slightly
decreased
Unaltered Slightly
decreased
S Pyridoxine
G350D-Mi Decreasedc ? Increased Slightly
altered
Decreasedf Unaltered Decreased F+S L-Alanine+pyridoxine
a From Coultier-Mackie MB et al. [13].
b From Williams E. et al. [12].
c From von Schnakenburg C. et al. [30].
f Mainly due to the high Km L-alanine value.
Fig. 3. Far-UV CD-monitored heating scans of AGT-Ma and AGT-Mi. Far-UV CD changes
of holoAGT-Ma (black curve, straight line) and holoAGT-Mi (gray curve, straight line)
in the presence of 10 μM exogenous PLP, and of apoAGT-Ma (black curve, dotted
line) and apoAGT-Mi (gray curve, dotted line). The enzyme concentration was 10 μM,
and the buffer was 100 mM potassium phosphate, pH 7.4.
138 E. Oppici et al. / Molecular Genetics and Metabolism 105 (2012) 132–140
corresponding of AGT-Ma and AGT-Mi, respectively. While this ﬁnding
is not easy to explain forW108R-Mi and S218L-Ma, it is consistent with
the in silico analysis in the case of Gly161 variants and S187F-Ma. In
fact, Gly161 is just located at the interface between the large and
small domains, and the bulky hindrance of the side chain of phenylal-
anine at position 187 could cause a mispositioning of the loop 154–
168 involved in interdomain interactions. Finally, the small domain
P319L and G350D mutations have essentially a structural effect limited
to the small domain, being the Tmapo values of the P319L-Ma and
G350D-Mi similar to the Tm1apo of AGT-Ma and AGT-Mi, respectively.
Overall, with respect to the analysis performed on crude lysates
[9–13,15,16,33,34], the data obtained on puriﬁed recombinant vari-
ants make clear the diversity of the effect(s) caused by each mutation
and strength the importance of looking at both holo and apo forms of
pathogenic variants. Finally, the new insights into the molecular basis
of the defects of the examined AGT pathogenic variants could be in-
strumental in suggesting possible therapeutic approaches (Table 5).
B6 supplementation is expected to be beneﬁcial for those patients
carrying the P319L mutation on the major allele. Since the major im-
pact of this mutation is on the thermostability of the apo-form of AGT,
the coenzyme is expected to shift the equilibrium toward the holo-
form. Patients with G161 mutations on the minor allele could beneﬁt
by pyridoxine treatment in association with chemical chaperones be-
cause these mutations reduce the thermostability of both the holo
and apo-forms of G161 variants. In the case of patients bearing the
G350D mutation on the minor allele, a combination of L-alanine and
pyridoxine could be suggested to overcome the reduced afﬁnity for
the substrate and the reduced thermal stability of the apo form.
Again, the administration of molecules acting as chemical chaperones
could be effective for patients harboring the S218L mutation on the
major allele, considering that the S218L-Ma variant has a reduced
thermal stability in both the holo and apo forms and retains a rather
signiﬁcant speciﬁc activity. On the other hand, no suggestions can be
advanced for a pharmacological treatment of patients carrying the
W108R mutation on the minor allele or the S158L, D183N and
S187F mutations on the major allele.
5. Conclusions
In conclusion, our characterization of the AGT variants in their re-
combinant puriﬁed form provided evidence for structural and/or
functional defects of each enzymatic species. The in vitro approach
presented in this study permits to: (i) reassess previous data obtained
in crude cellular lysates, (ii) deﬁne whether the impact of each muta-
tion is limited to the active site microenvironment or extended to the
large and/or the small domain, thus posing itself as a valid instrument
to shed light on the molecular defects of other PH1-causing variants
and (iii) suggest possible treatments for patients bearing the exam-
ined mutations.
Supplementary materials related to this article can be found
online at doi:10.1016/j.ymgme.2011.09.033
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Abstract Defects in liver peroxisomal alanine:glyoxylate
aminotransferase (AGT), as a consequence of inherited
mutations on the AGXT gene, lead to primary hyperoxaluria
type I (PH1), a rare metabolic disorder characterized by the
formation of calcium oxalate stones at first in the urinary
tract and then in the whole body. The curative treatments
currently available for PH1 are pyridoxine therapy, effective
in only 10–30 % of the patients, and liver transplantation, an
invasive procedurewith potentially serious complications. A
valid therapeutic option for PH1 patients would be the
development of an enzyme administration therapy. How-
ever, the exogenous administration of the missing AGT
would require the crossing of the plasma membrane to
deliver the protein to liver peroxisomes. In this study, we
constructed, purified and characterized the fusion protein
of AGT with the membrane-penetrating Tat peptide
(Tat-AGT). Although Tat-AGT shows subtle active site
conformational changes as compared with untagged AGT, it
retains a significant transaminase activity. Western-blot
analyses, enzymatic assays and immunofluorescence studies
show that active Tat-AGT can be successfully delivered to a
mammalian cellular model of PH1 consisting of chinese
hamster ovary cells expressing glycolate oxidase (CHO-GO),
whereas untagged AGT cannot. Moreover, the intracellular
transduced Tat-AGT makes CHO-GO cells able to detoxify
endogenously produced glyoxylate to an extent similar to that
of CHO-GO cells stably expressing AGT. Altogether, these
results show that the Tat peptide is capable of delivering a
functional AGT to mammalian cells, thus paving the way for
the possibility to use Tat-AGT as an enzyme replacement
therapy to counteract PH1.
Keywords Primary hyperoxaluria type I ! Rare disease !
Pyridoxal 50-phosphate ! Tat peptide !
Enzyme administration therapy ! Protein delivery
Abbreviations
PH1 Primary hyperoxaluria type I
AGT Alanine:glyoxylate aminotransferase
PLP Pyridoxal 50-phosphate
CD Circular dichroism
DLS Dynamic light scattering
GO Glycolate oxidase
CHO-GO Chinese hamster ovary cells expressing
glycolate oxidase
CHO-GO-AGT Chinese hamster ovary cells expressing
glycolate oxidase and AGT
Introduction
Primary hyperoxaluria type I (PH1) (OMIM 259900) is a
rare disorder of metabolism characterized by the overpro-
duction and excretion of oxalate resulting in recurrent
urolithiasis and nephrocalcinosis, a condition leading to
systemic oxalosis with calcium oxalate precipitation in
several body areas (Danpure 2005). The disease is caused by
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mutations in the AGXT gene encoding liver peroxisomal
alanine:glyoxylate aminotransferase (AGT), a pyridoxal
50-phosphate (PLP)-dependent enzyme that catalyses the
conversion of alanine and glyoxylate to pyruvate and gly-
cine (Danpure and Jennings 1986). The loss of functional
AGT in PH1 leads to the oxidation of increased amounts of
glyoxylate to oxalate by lactate dehydrogenase, thus causing
the formation and deposition of calcium oxalate crystals.
PH1 is a very heterogeneous disease. Genetic analyses
have identifiedmore than 150 different pathogenicmutations
on the AGXT gene including nonsense, frameshift and the
most common missense mutations (Williams et al. 2009).
Moreover, missense mutations can cause AGT deficiency by
a number of different mechanisms spanning from functional
(loss of catalytic activity or reduced affinity for the PLP
cofactor) to structural effects (loss of immunoreactivity,
reduced stability, aggregation propensity, aberrant intracel-
lular localization) (Cellini et al. 2007, 2009, 2010a, b;
Coulter-Mackie and Lian 2006, 2008; Coulter-Mackie et al.
2008; Danpure et al. 1989, 1994; Hopper et al. 2008; Lumb
and Danpure 2000; Pittman et al. 2012).
A variety of therapeutic approaches for PH1 have been
developed. Classical treatments are aimed at increasing the
solubility of the urinary calcium oxalate, removing the
stones once formed, and dealing with renal failure by
dialysis and kidney transplantation (Danpure 2005). All of
these approaches, however, are symptomatic and do not
address the cause of the disease. Another current thera-
peutic approach is the administration of pharmacological
doses of pyridoxine (Vitamin B6), a precursor of the
essential cofactor of AGT, but only a minority (10–30 %)
of patients is responsive to this therapy (Monico et al.
2005). The only curative approach available for PH1
patients unresponsive to pyridoxine is liver transplantation,
which reintroduces most of the body’s requirements of
active AGT. However, it represents a very invasive and
wasteful intervention because an entire organ is used to
replace only one defective gene (Cochat et al. 2012).
Therefore, a novel pharmacological treatment for PH1
addressing the causes of the disease, but with limited side-
effects, is urgently required. Since the disease is caused by
the deficit of a single gene, an enzyme administration
therapy could be a valid therapeutic option.
AGT is dimeric and belongs to the Fold Type I family of
PLP-dependent enzymes. Each subunit is made up of (i) a
large domain, comprising most of the active site and the
dimerization interface, (ii) an N-terminal extension that
wraps over the surface of the neighbouring subunit and is
important for the preservation of the correct conformation
and activity (Montioli et al. 2012), and (iii) a small domain,
containing regions that mediate the peroxisomal import of
the protein (Fodor et al. 2012; Zhang et al. 2003). Although
AGT can be easily purified both in its histidine-tagged and
untagged forms and is highly resistant to thermal and
chemical denaturation (Cellini et al. 2007, 2008), a major
obstacle for the development of an enzyme administration
therapy is the passage through the hepatocyte plasma
membrane required for the localization to liver peroxi-
somes, where AGT should be efficiently directed once
released into the cytosol via its C-terminal targeting signal.
During the last years, it has been shown that the 11-resi-
dues domain rich in basic amino acids of the HIV-1 Tat
protein, along with similar domains found in VP22 from the
herpes simplex virus and Antennapedia from Drosophila,
possesses the ability to traverse biological membranes in a
process termed protein transduction (van den Berg and
Dowdy 2011; Fittipaldi and Giacca 2005; Schwarze et al.
1999). Although the exact transduction mechanism is con-
troversial, it is clear that the internalization does not occur
through a receptor-, transporter-, or endosome-mediated
fashion. The Tat basic peptide has been employed as a carrier
to direct the uptake of various heterologous proteins into
living cells, including for therapeutic applications (Vyas
et al. 2012; Rapoport et al. 2011; Toro andGrunebaum 2006;
Toro et al. 2006). In this study, we have generated, purified
from Escherichia coli and characterized a fusion protein
made up of the HIV-1 Tat protein transduction domain and
AGT (Tat-AGT). Tat-AGT internalized into mammalian
cells retains catalytic activity and prevents glyoxylate
accumulation in a cellular model of PH1. These data suggest
that AGT delivery through the Tat peptide is feasible and
could represent an important step toward a new therapeutic
approach for the disease.
Materials and Methods
Plasmid Construction
The pTrcTat-AGT plasmid containing the Tat-AGT coding
sequence has been constructed by means of PCR amplifi-
cation adding the Tat derived cell penetrating peptide
(CPP) coding sequence (amino acids 49–57) at the 50 end
of the native AGT cDNA. For cloning purposes, consensus
sequences of NcoI/HindIII restriction enzymes were added
to the 50 and 30 ends respectively. The native AGT start
codon was deleted and replaced by an ATG sequence in the
30 NcoI consensus sequence. Four subsequent PCR ampli-
fications were required to generate the appropriate sequence.
The first PCR was performed by using the AGT cDNA as
template, the forward primer Fw1 (50 CGT CGC GGT GCC
TCT CAC AAG CTG CTG 30) and the reverse primer Rw1
(50 GGTCTGG AAG CT TCA CAG CTT CTT CTT
GGGGC 30). The succeeding PCR runs have been performed
with the same reverse primer of the first reaction and with the
following forward primers: Fw2 (50 CGG CAA CGC CGT
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CGC GGT GCC T CT C 30), Fw3 (50 CGC AAG AAA CGT
CGG CAA CGC CGT CGC 30), Fw4 (50 GAT ACC ATG
GGC CGC AAG AAA CGT CGG CAA C 30). In each run,
the purified PCR product of the previous amplification round
has been used as template. The final PCR product has
been digested with NcoI and HindIII restriction enzymes
(Fermentas) and cloned into the pTrcHis2 expression vector.
Protein Expression and Purification
Escherichia coli JM109 cells transformed with the plasmid
pTrcTat-AGTwere grown in 4.5 l ofLuria broth at 37 "C to a
turbidity of 0.4–0.6 at 600 nm as previously described
(Cellini et al. 2008). Briefly, expression was induced with
0.1 mM isopropyl-D-thiogalactopyranoside for 15 h at
30 "C. Cells were harvested and resuspended in 10 mM
sodium phosphate buffer pH 7.2 containing 2 mM EDTA,
0.1 mM dithiothreitol and 0.1 mM PLP. Lysozyme was
added to a concentration of 0.2 mg/ml and the culture was
incubated for 15 min at room temperature. After a freeze–
thaw, leupeptin (0.5 g/ml) and pepstatin (0.7 g/ml) were
added and the suspension was centrifuged at 30,0009g for
30 min at 4 "C. The cleared lysate was diluted to about
20 mg/ml, adjusted to pH 7.2 and then loaded on a DEAE
Sepharose FF 26/20 column (GE Healthcare) equilibrated
with 10 mM sodium phosphate buffer pH 7.2 and washed
with the same buffer. A linear gradient (600 ml) from 10 to
200 mM sodium phosphate buffer, pH 7.2, was then applied.
Under these conditions, Tat-AGT elutes between 100 and
130 mM sodium phosphate. Active fractions were pooled
and concentrated using an Amicon Ultra 15 unit (Millipore)
to around 50 ml and extensively dialysed versus 1 M
potassiumphosphate pH7.4. The protein solutionwas loaded
into a Phenyl-Sepharose column previously equilibrated
with 1 M potassium phosphate pH 7.4. Tat-AGT was eluted
with a linear gradient from 1 to 0.05 M potassium phosphate
pH 7.4. Active fractions elute between 0.25 and 0.2 M
potassium phosphate. The apoenzyme of Tat-AGT was
prepared as previously described (Cellini et al. 2007).
Spectroscopic Measurements
Absorption measurements were made with a Jasco V-550
spectrophotometer with 1 cm path-length quartz cuvettes at
a protein concentration of 5 lM. Visible and far-UV cir-
cular dichroism (CD) spectra were recorded on a Jasco
J-710 spectropolarimeter equipped with a thermostatically
controlled compartment at 25 "C, by using 1 cm path-
length quartz cuvettes. The enzyme concentration was
5 lM. Routinely, three spectra were recorded at a scan
speed of 50 nm/min with a bandwidth of 2 nm and averaged
automatically. Dynamic light scattering (DLS) analyses
were performed as previously described (Oppici et al.
2012). Intrinsic fluorescence emission spectra were recor-
ded on a Jasco FP-750 spectrofluorometer equipped with a
thermostatically controlled cell holder. The equilibrium
dissociation constant for PLP (KD(PLP)) of Tat-AGT was
determined by measuring the quenching of the intrinsic
fluorescence of the apoenzyme at 0.1 lM concentration in
the presence of PLP at a concentration range of 0.03–5 lM
as previously described (Daidone et al. 2012).
Cell Culture, Transduction and Lysis
Chinese hamster ovary cells stably expressing glycolate
oxidase (CHO-GO) and double stable clones expressing
both AGT and GO (CHO-GO-AGT) (kindly provided by
Prof. C.J. Danpure, University College London) were cul-
tured at 37 "C under O2/CO2 (19:1) in Ham’s F12 Glutamax
medium (Invitrogen) supplemented with 10 % (v/v) fetal
calf serum, 100 units/ml penicillin and 100 lg/ml strepto-
mycin. CHO-GO cells were cultured in the presence of
400 lg/ml zeocin, while CHO-GO-AGT cells were cul-
tured in the presence of 400 lg/ml zeocin and 1 mg/ml
G-418, as previously reported (Behnam et al. 2006; Mont-
ioli et al. 2012). CHO-GO cells were seeded in a 6-well
plate at 2.5 9 105 cells/well. After 24 h the medium was
replaced with fresh Ham’s F12 medium containing Tat-
AGT at a concentration range of 1.5–15 lM. After 24 h
cells were extensively rinsed with PBS, trypsinized and
lysed according to (Montioli et al. 2012). Protein concen-
tration of the cell lysate was determined with a modified
Lowry Assay protein determination kit (Biorad).
Activity Assays
The AGT enzymatic activity of E. coli and CHO-GO lysates
and of purified Tat-AGT was determined by measuring
pyruvate production using a spectrophotometric assay cou-
pled with lactate dehydrogenase as previously described
(Behnam et al. 2006; Cellini et al. 2007). The kinetic param-
eters for the overall transamination reaction for the pair ala-
nine/glyoxylate of 0.1 lM Tat-AGT were determined in the
presence of 100 lM exogenous PLP by varying the substrate
concentration at a fixed saturating co-substrate concentration.
Data of initial velocity as a function of substrate concentration
were fitted to the Michaelis–Menten equation.
Western-Blot Analyses
5 lg of theCHO-GOcell lysatewere loaded into each lane of
a polyacrylamide gel. Upon transfer on an ImmobilonP
membrane (Millipore), the filter was incubated with the
purified antiAGT IgG from rabbit serum (kindly provided by
Prof. C.J. Danpure, University College London) at a dilution
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1:2,000. After extensive washing, the filter was incubated
with a peroxidase-conjugated anti rabbit secondary antibody
(GE Healthcare) at a 1:2,000 dilution and the signal was
detected using a chemiluminescent detection system (ECL,
Millipore). Blotted proteins were detected using the Chem-
iDoc XRS Imaging System (BioRad, Hercules, CA) and
quantified by the Quantity One software.
Immunofluorescence Studies
CHO-GO cells on glass coverslip were fixed in 4 % (w/v)
paraformaldehyde, permeabilized with 0.3 % Triton X-100
in PBS plus 3 % bovine serum albumin followed by im-
munolabelling. Rabbit polyclonal anti-human glycolate
oxidase (GO) (kindly provided by Dr. G. Rumsby, Uni-
versity College Hospital, London) and guinea-pig poly-
clonal anti-AGT human (kindly provided by Prof. C.J.
Danpure, University College London) were used as primary
antibodies (Behnam et al. 2006), followed by Alexa Fluor-
conjugated antibodies (Life Technologies). The images
were captured using a Leica SP5 confocal laser-scanning
fluorescence microscope (Leica Microsystem, Manheim,
Germany) at 639 magnification and processed using Image
J (Rasband, W.S., ImageJ, U.S. NIH, Bethesda, Maryland,
USA) and Adobe Photoshop softwares.
Glycolate Toxicity Assay
Cells were plated at 7,000 cells/well in a 96 wells plate. The
day after cells were treatedwith Tat-AGT as explained above.
Upon 1 h incubation, glyoxylate production was induced by
the addition of Hepes buffered glycolate pH 7.0 at final con-
centration of 1 mM. Cell viability was evaluated after 24 h
incubation using the crystal violet staining (Sigma). Cells
were rinsed with PBS, incubated at room temperature for
5 min with 4 % formaldehyde ? 0.5 % Crystal Violet solu-
tion to perform fixing and staining. The cells were then
extensively washed with distilled water to remove the excess
of dye. Cells were finally lysed with 1 %SDS in PBS to allow
for crystal violet solubilization and quantification. The
absorbance at 595 nm, which is proportional to the number
of viable cells, has beenmeasuredwith aTECANplate reader.
Six replicates were performed for each assay condition.
Statistic analysis was performed with GraphPad Prism
Version 5.0 (GraphPad software, San Diego, CA, USA).
Results
Construction, Expression and Purification
of the Tat-AGT Fusion Protein
As a first step to produce a cell-permeable AGT, we con-
structed the pTrcTat-AGT expression vector, which con-
tains the HIV-1 Tat basic domain (Tat49–57) at the 5
0 end of
the cDNA sequence encoding AGT. A nucleotide triplet
encoding a glycine residue was inserted between the
sequence of the Tat peptide and that encoding AGT to
minimize any possible effect of the N-terminal Tat peptide
on the folding and the conformational stability of the
protein (Montioli et al. 2012).
Recombinant Tat-AGT overexpressed in E. coli was
purified from the soluble fraction of the bacterial lysate as
detailed in Table 1. This method yields about 4 mg of pure
protein per litre of bacterial culture and gives a 62-fold
purification with 57 % recovery of the initial enzyme units.
As expected, purified Tat-AGT migrates as a single band on
SDS-PAGE with an apparent molecular mass slightly
higher than untagged AGT (Supplementary Fig. 1).
Unfortunately, we didn’t succeed in the determination of
the molecular mass of Tat-AGT because the protein
aggregates at the almost null saline concentration required
for the analysis. Considering that perturbations of the
N-terminus make AGT prone to an electrostatically-driven
aggregation (Cellini et al. 2010b; Montioli et al. 2012), the
behaviour of Tat-AGT could be due to subtle conforma-
tional changes of the N-terminal arm induced by the pres-
ence of the Tat peptide (see below).
Spectroscopic and Kinetic Properties of Tat-AGT
All the spectroscopic and kinetic experiments are per-
formed in 0.1 M potassium phosphate buffer pH 7.4. The
CD spectrum of purified recombinant Tat-AGT in the far-
UV region, reflecting the secondary structure composition
of the protein, is identical to that of untagged AGT.
Moreover, DLS analyses indicate that the protein has a
hydrodynamic diameter of about 10 nm, as previously
found for untagged AGT (Cellini et al. 2010b). Thus, the
addition of the Tat peptide at the N-terminus does not alter
the gross conformation and the dimeric structure of AGT.
Table 1 Summary of the
purification of the Tat-AGT
fusion protein expressed in
E. coli
Volume
(ml)
Protein
(mg)
Total
activity
(units)
Specific
activity
(units/mg)
Yield
(%)
Purification
(fold)
Cleared lysate 160 1,936 500,800 259 – –
DEAE-FF 180 133 367,000 2,759 73 11
Phenyl Sepharose 91 17.8 284,000 15,955 57 62
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As in all PLP-dependent enzymes, AGT binds the
cofactor via a Shiff base linkage between the carbonyl group
of the coenzyme and an active site lysine residue (Lys209 in
AGT) forming a complex called internal aldimine (Zhang
et al. 2003). Purified Tat-AGT binds two molecules of PLP
per dimer. The absorbance and visible CD spectra of the
protein were compared with those of untagged AGT (Fig. 1
and inset). Tat-AGT displays two absorbance maxima at 419
and 331 nm, attributable to the ketoenamine and enolimine
tautomers of the internal aldimine, respectively, whose rel-
ative intensity is different from untagged AGT. Moreover,
although the CD spectra of the two proteins are qualitatively
similar, the magnitude of the positive band at 430 nm is
lower in Tat-AGT with respect to the untagged protein. Tat-
AGT in the apo-form does not show any absorbance and CD
signal in the visible region. The intrinsic fluorescence
emission spectrum of apoTat-AGT shows an about 2.5-fold
higher intensitywith respect to the holo-form. The difference
is due to the quenching of a substantial fraction of the tryp-
tophan emission fluorescence by the bound coenzyme.
Titration of apoTat-AGT with PLP and analysis of the
quenching of intrinsic fluorescence as a function of coen-
zyme concentration (Supplementary Fig. 2) yields a KD(PLP)
value for the PLP-Tat-AGT complex equal to 243 ± 7 nM, a
value comparable to that of untagged AGT (Cellini et al.
2008). Altogether, these results indicate that, although the
presence of the Tat peptide could induce some small struc-
tural changes at the active site of the protein affecting the
coenzyme bindingmode, it does not alter the affinity of AGT
for the PLP coenzyme.
The steady-state kinetic parameters for the overall
transamination reaction of the alanine/glyoxylate pair cat-
alyzed by Tat-AGT have been measured and compared
with those of untagged AGT. As reported in Table 2,
although Tat-AGT displays a kcat value equal to *40 %
compared to untagged AGT and a 2-fold higher Km for the
two substrates, it retains a significant catalytic activity.
Transduction of Tat-AGT into Mammalian Cells
In order to test the ability of Tat-AGT to be internalized
into mammalian cells, we used a cellular model of PH1
consisting of CHO cells stably transfected with GO (CHO-
GO). When these cells are treated with glycolate, a phys-
iological precursor of peroxisomal glyoxylate, the activity
of GO converts it to glyoxylate. In the absence of AGT, the
accumulating and highly reactive glyoxylate cannot be
detoxified to glycine and becomes toxic for CHO-GO cells
(Behnam et al. 2006). Thus, the ability of CHO-GO cells to
survive when treated with glycolate is an indirect measure
of the presence of functional AGT inside the cells.
As a first step, we evaluated the transduction ability of
Tat-AGT by adding the fusion protein to the culture
medium of CHO-GO cells and determining the level of
transduced AGT into the cells by western-blot analysis
after 24 h. Neither Tat-AGT nor untagged AGT at 60 lM
concentration were toxic for CHO-GO cells. As shown in
Fig. 2, Tat-AGT is successfully delivered to CHO-GO cells
whereas untagged AGT is not. The extent of the trans-
duction of Tat-AGT into cultured cells is linear in the range
0.1–3 lM, reaches it’s maximum at 7.5 lM and does not
increase further by increasing the concentration of the
fusion protein. In this regard, it should be noticed that the
plateau seen between 7.5 and 60 lM is not due to a satu-
ration of the chemiluminescence signal, as we checked by
loading the gel with two different amounts of protein.
Moreover, it can be observed that the levels of intracellular
AGT in CHO-GO cells treated with 7.5–15 lM Tat-AGT
are very similar to those present on CHO-GO cells stably
transfected with AGT (CHO-GO-AGT).
The restoration of the catalytic activity of the transduced
protein in cells is a key issue in the application of the
protein transduction technology for therapeutic use.
Therefore, we determined the transaminase activity of
Fig. 1 Spectral properties of untagged AGT and Tat-AGT. Absorp-
tion and CD spectra (inset) of 5 lM untagged AGT (dotted line) and
Tat-AGT (dark line). In each case the buffer was 0.1 M potassium
phosphate pH 7.4
Table 2 Steady-state kinetic parameters of Tat-AGT and untagged
AGT in 0.1 M potassium phosphate buffer pH 7.4 at 25 "C
Substrate Cosubstrate kcat (s
-1) Km (mM)
Untagged
AGT
Alanine Glyoxylate 50 ± 5a 35 ± 4a
Glyoxylate Alanine 42 ± 4a 0.11 ± 0.02a
Tat-AGT Alanine Glyoxylate 17 ± 1 74 ± 9
Glyoxylate Alanine 16.1 ± 0.4 0.26 ± 0.03
a From Cellini et al. (2007)
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AGT in CHO-GO cells treated with Tat-AGT. Cells treated
with untagged AGT as well as CHO-GO-AGT cells were
used as negative and positive control, respectively. While
untransduced CHO-GO cells and CHO-GO cells treated
with untagged AGT do not show any detectable AGT
transaminase activity, CHO-GO cells transduced with 1.5 lM
Tat-AGT for 24 h display a transaminase activity of
19 ± 1 nmol pyruvate/min/mg protein and CHO-GO-AGT
cells display a transaminase activity of 42 ± 2 nmol
pyruvate/min/mg proteins. This result indicates that the Tat
peptide has a specific effect on protein internalization and
that the transaminase activity is not due to residual AGT
from the culture medium non-specifically bound to the cell.
Thus, these data demonstrate that Tat-AGT is efficiently
transduced into mammalian cells and that the delivered
protein maintains its catalytic activity.
To determine the cellular localization of the transduced
fusion protein, CHO-GO cells treated with Tat-AGT were
analysed by immunofluorescence staining and compared
with CHO-GO-AGT cells. As expected, no AGT fluores-
cence signal was present in CHO-GO cells treated with
untagged AGT and, as shown in Fig. 3a and b, AGT
co-localizes with the peroxisomal marker GO in CHO-GO-
AGT cells. The analysis of cells treated with Tat-AGT
indicates that the fusion protein is able to cross the plasma
membrane, thus confirming the efficacy of the transduction
process. However, as shown in Fig. 3c and d, the AGT
fluorescence is localized into discrete compartments in the
cytoplasm and does not superimposes with the GO fluo-
rescence. Although this result suggests that Tat-AGT is
retained in intracellular vesicles, it cannot be excluded that
a very small fraction of the protein could be soluble in the
cytoplasm or correctly imported into peroxisomes but the
signal is too low to be detected by the microscope.
Fig. 2 Analyses of AGT expression in CHO-GO cells treated with
Tat-AGT. AGT expression of CHO-GO cells after 24 h treatment
with Tat-AGT at different concentrations. 5 lg of whole cell lysates
were subjected to SDS/PAGE electrophoresis and immunoblotted
against anti-AGT as described under the Materials and Methods
section. The total AGT expression of CHO-GO-AGT cells is shown
for comparison. a Immunoblot, b Histogram representative of the
immunoblot bands volume. The immunoblot lanes and the histogram
are coded as follow: 1 CHO-GO, 2 CHO-GO treated with 60 lM
untagged AGT, 3 CHO-GO treated with 0.1 lM Tat-AGT, 4 CHO-
GO treated with 0,2 lM Tat-AGT, 5 CHO-GO treated with 0.5 lM
Tat-AGT, 6 CHO-GO treated with 1 lM Tat-AGT, 7 CHO-GO
treated with 1.5 lM Tat-AGT, 8 CHO-GO treated with 3 lM Tat-
AGT, 9 CHO-GO treated with 7,5 lM Tat-AGT, 10 CHO-GO treated
with 15 lM Tat-AGT, 11 CHO-GO treated with 30 lM Tat-AGT, 12
CHO-GO treated with 60 lM Tat-AGT, 13 CHO-GO-AGT. Data
come from the mean of three different experiments
Fig. 3 Immunofluorescence analysis of CHO-GO-AGT cells (a,
b) and CHO-GO cells transduced with Tat-AGT (c, d). CHO-GO-
AGT cells and CHO-GO cells after 24 h incubation with 1.5 lM Tat-
AGT were fixed on glass coverslips, permeabilized and stained as
described in the Materials and Methods section. Polyclonal antibodies
were used to detect AGT (green) and GO (red). The small rectangles
in panels a and c indicate the areas shown in close-up in panels b and
d, respectively. In panels b and d the original image and the
individual split channels are shown (Color figure online)
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Effect of Transduced Tat-AGT on Cell Viability Upon
Glycolate Treatment
We then evaluated whether transduced Tat-AGT protects
CHO-GO cells from glycolate-induced toxicity, as an
indication that transduced Tat-AGT is functionally active
inside the cell. As a first step we determined that the
addition of either Tat-AGT or untagged AGT to the culture
medium of CHO-GO cells does not have any effect on cell
viability. Then, CHO-GO cells pretreated with Tat-AGT or
untagged AGT were exposed to 1 mM glycolate and their
viability was compared with that of CHO-GO cells stably
expressing AGT under identical experimental conditions.
As shown in Fig. 4, in the presence of glycolate the via-
bility of the cells pretreated with Tat-AGT significantly
increases in a dose-dependent manner, while untagged
AGT fails to rescue the cells from the toxic effect of gly-
oxylate, thus indicating that Tat-AGT has a specific effect
on glyoxylate detoxification. Notably, the transduction of
CHO-GO cells with 15 lM Tat-AGT gives a protection
similar to that provided by the stable expression of AGT.
This could suggest that once transduced inside the cell,
Tat-AGT is able to detoxify glyoxylate to an extent similar
to that of the endogenously produced protein.
Discussion
A wide range of disorders are known that involve PLP-
dependent enzymes spanning from metabolic (Cellini et al.
2012; Ferreira 1993; Zhu et al. 2008), neurologic (di Salvo
et al. 2012; Giardina et al. 2011; Montioli et al. 2011), and
infectious diseases (Bertoldi et al. 2002; Muller et al.
2009). While in many cases enzyme inhibitors are likely
therapeutic options (Daidone et al. 2012; Pegg et al. 1995;
Wu et al. 2011), in some cases, when the disease is caused
by inherited mutations of a gene leading to an enzymatic
deficit, the rescue of the catalytic activity of the lacking
enzyme is necessary. To this aim, several strategies are
currently being developed, including enzyme enhancement
therapies (Ringe and Petsko 2009), effective for mutations
that affect protein folding, and gene therapy (Humbert et al.
2012), whose safety is questioned by the use of viral vec-
tors. An alternative approach is represented by the enzyme
administration therapy. Although the potential immuno-
genicity of the administered protein should not be under-
estimated (Deegan 2012), the reversibility of the treatment
and the control over the levels of protein in the cell should
guarantee lower side effects. PH1 is a very good candidate
for the development of an enzyme administration therapy
because it is a single gene disorder caused by the deficit of
AGT that is almost only expressed in liver peroxisomes
(Motley et al. 1995). However, one of the limiting factors
of an efficient protein administration is the crossing of the
plasma membrane for the intracellular delivery (Fittipaldi
and Giacca 2005; van den Berg and Dowdy 2011). During
the last years, the discovery of protein transduction
domains, small cationic peptides able to penetrate the
cellular membrane, has opened the door to the possibility
to deliver macromolecular drug conjugates for a variety of
diseases including cancer, ischemia and neurodegenerative
disorders (van den Berg and Dowdy 2011). Although an
enzyme replacement therapy based on the use of Tat-fusion
proteins has been recently exploited for the treatment of
inherited metabolic diseases (Rapoport et al. 2011; Toro
et al. 2006; Vyas et al. 2012), this approach has not been
attempted until now for PH1.
In this study, we describe for the first time a protein
transduction approach to deliver recombinant AGT to
mammalian cells. The gene encoding AGT was fused with
a gene fragment encoding the Tat protein basic domain in a
bacterial expression vector to produce the Tat-AGT fusion
protein. Moreover, a protocol has been developed to obtain
in a short time a significant amount of pure protein.
The biochemical characterization of Tat-AGT reveals
that the protein has no gross conformational differences
with respect to untagged AGT and is able to catalyse the
overall transamination reaction. This is a relevant finding
because represents a promising starting point for the use
of Tat-AGT for an enzyme replacement therapy for PH1.
However, it should be noted that Tat-AGT is endowed
with a lower catalytic activity and a slightly different
coenzyme binding mode with respect to untagged AGT.
A recent study has demonstrated that the N-terminus
plays an essential role for the maintenance of the AGT
functionality, probably as a consequence of the presence
of the loop 24–32 that faces the active site of the enzyme
(Montioli et al. 2012). It is possible to hypothesize that
Fig. 4 Glycolate cytotoxicity assay of CHO-GO cells transduced
with Tat-AGT. The histogram is representative of the cell viability
after 24 h treatment with 1 mM glycolate measured by the crystal
violet colorimetric assay and expressed as absorbance at 595 nm.
Data are representative of three different experiments. Bar graphs
represent the mean ± SEM *P\ 0.05; ***P\ 0.001
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the presence of the Tat tag at the N-terminus could
slightly change the conformation of this loop, thus
inducing small conformational changes at the AGT active
site that could account for the observed effects on activity
and coenzyme binding mode. In this regard, a future
optimization of Tat-AGT should involve the insertion of a
linker between the Tat peptide and the N-terminus of
AGT in order to minimize the effects of the tag on the
active site integrity.
In our study we showed that the administration of Tat-
AGT to CHO-GO cells, which represent a cellular model of
PH1, is not toxic for the cells and results in the presence of
intracellular catalytically active AGT. It should be noted
that CHO-GO cells transduced with 1.5 lM Tat-AGT and
CHO-GO-AGT cells display a transaminase activity of
19 ± 1 and 42 ± 2 nmol pyruvate/min/mg proteins,
respectively. Considering that the kcat of purified Tat-AGT
is about 40 % that of untagged AGT, this result would
indicate that the amount of AGT present in CHO-GO cells
transduced with 1.5 lM Tat-AGT is similar to that of
CHO-GO-AGT cells. This is apparently in contrast with
the results shown in Fig. 2, where the amount of total AGT
of CHO-GO cells transduced with 1.5 lM Tat-AGT is
about 50 % that of CHO-GO-AGT cells. This can be
explained by considering that while activity assay only
measures the amount of active protein, western-blot anal-
yses are performed under denaturing conditions and mea-
sure the total amount of protein including aggregated and
misfolded species. Thus, it is possible to speculate that
about 50 % of AGT in CHO-GO-AGT cells, being
endogenously produced and not exogenously transduced,
could be in a misfolded and/or inactive conformation.
We found that transduced Tat-AGT is able to catalyse
peroxisomal glyoxylate detoxification similar to stably
expressed untagged AGT. Since glycolate treatment of
CHO-GO cells induces the production of glyoxylate in
peroxisomes by peroxisomal GO, the protective effect of
Tat-AGT would suggest that the delivered protein is cor-
rectly localized to peroxisomes. However, our immuno-
fluorescence studies indicate that AGT appears localized in
discrete cytosolic vesicles that do not overlap with per-
oxisomes. A similar localization has been reported for
other Tat-fusion proteins (Caron et al. 2004; Gump and
Dowdy 2007; Sloots and Wels 2005; Fittipaldi et al. 2003)
and might be related to the Tat peptide-mediated protein
transduction. Although the exact mechanism has been a
matter of debate and is still not completely clarified, many
studies indicate that the internalization does not occur
through clatrin-mediated endocytosis followed by fusion
with lysosomes (Fittipaldi and Giacca 2005). Indeed, the
transduction appears to be a multi-step process that
involves the binding of the TAT peptide to the cell surface,
the uptake of the cargo by macropinocytosis and the release
of the cargo into the cytoplasm. The latter step seems to be
stimulated by the decrease of pH inside the vesicle or by a
membrane perturbation induced by the Tat peptide.
Although a similar transduction mechanism might operate
for AGT internalization into CHO-GO cells, the question
of how the protein is able to detoxify peroxisomal gly-
oxylate remains. A first possibility is that a very small
percentage of the protein is imported into peroxisomes and
is sufficient to catalyse glyoxylate detoxification but is not
detected due to the low signal. This would be possible
because the peroxisomal targeting machinery act on the
protein once folded and the targeting information is located
at the C-terminus of AGT (Motley et al. 1995; Rucktaschel
et al. 2011). A second possibility is that glyoxylate
detoxification is performed by cytosolic AGT, even though
inside vesicles. Indeed, it is known that in the absence of
AGT, glyoxylate escapes peroxisomes and can be metab-
olized to either oxalate or glycolate by the cytosolic
enzymes lactate dehydrogenase (LDH) and glyoxylate
reductase (GRHPR). On the basis of the kinetic properties
of the enzymes involved in glyoxylate metabolism, it has
been proposed that the fate of glyoxylate depends on the
ambient conditions within the cell, including the relative
abundance of enzymes and substrates (Mdluli et al. 2005).
Considering that the catalytic efficiency of Tat-AGT is
similar to that of LDH and GRHPR, it is possible to
speculate that in CHO-GO cells transduced with Tat-AGT
a significant amount of glyoxylate could be converted to
glycine in the cytosol, thus accounting for the higher sur-
vival of the cells in the presence of glyoxylate.
In conclusion, our results not only demonstrate that the
AGT delivery to mammalian cells through the Tat peptide is
feasible, but also suggest that this approach could allow to
rescue for the enzymatic deficit of PH1. Many reports have
been published in the last years describing the application of
protein transduction approaches to various diseases and the
Tat-fusion delivered proteins have been tested both in ani-
mal and in cellular disease systems (Rapoport et al. 2011;
Toro and Grunebaum 2006; van den Berg and Dowdy 2011;
Vyas et al. 2012). Further studies will be necessary to
establish the efficacy and potential use of Tat-AGT as
therapeutic strategy for PH1. In particular, we plan to
deeply investigate the fate of Tat-AGT inside the cell as
well as its possible effects in an animal model of PH1
previously described (Salido et al. 2006) or in hepatic cell
lines derived from PH1 patients once they will be available.
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Treatment of Dopa Decarboxylase-Related Diseases: An Overview 
"#$%#$#!&'(()*)+,!-)..#$/0!10*2)0(),!3()4#!566).),!#*/!&#$(#!"0$$)!70(2#220$*)+!
Department of Life Sciences and Reproduction, Section of Biological Chemistry, University of Verona, Italy 
Abstract: 806#!/'.#$%09:(#4'!;88&<!)4!#!6:$)/09#(!=>?6@046@#2'!;ABA<?/'6'*/'*2!'*C:D'!2@#2!%:!.#2#(:C)*E!2@'!/'.#$?
%09:(#2)0*!0F!B?806#!#*/!B?=?@:/$09:2$:6206@#*!6$0/G.'4!2@'!*'G$02$#*4D)22'$4!/06#D)*'!#*/!4'$020*)*H!I@'!FG*.2)0*#(!
6$06'$2)'4!0F!6)E!J)/*':!#*/!@GD#*!88&!'*C:D'4!@#K'!%''*!'92'*4)K'(:!.@#$#.2'$)C'/,!#*/!2@'!.$:42#(!42$G.2G$'!0F!2@'!
'*C:D'!)*!2@'!@0(0?!#*/!#60?F0$D4!@#4!%''*!'(G.)/#2'/H!88&!)4!#!.()*).#((:!$'('K#*2!'*C:D'!4)*.'!)2!)4!)*K0(K'/!)*!A#$J?
)*40*>4!/)4'#4'!;A8<!#*/!)*!#$0D#2).!#D)*0!#.)/!/'.#$%09:(#4'!;LL8&<!/'F).)'*.:H!A8,!#!.@$0*).!6$0E$'44)K'!*'G$0(0E)?
.#(!/)40$/'$!.@#$#.2'$)C'/!%:!2$'D0$,!%$#/:J)*'4)#,!$)E)/)2:!#*/!6042G$#(! )*42#%)()2:,!$'4G(24!F$0D!2@'!/'E'*'$#2)0*!0F!/0?
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INTRODUCTION 
! A:$)/09#(! =>?6@046@#2'! ;ABA<?/'6'*/'*2! '*C:D'4,! '9?
.'62!E(:.0E'*!6@046@0$:(#4',!4:*2@'4)C',!/'E$#/'!#*/!)*2'$?
.0*K'$2! #D)*0! #.)/4H!I@':! .#2#(:C'! #!M)/'! K#$)'2:! 0F! $'#.?
2)0*4! )*.(G/)*E! $#.'D)4#2)0*! NOP,! 2$#*4#D)*#2)0*! NQP,! /'.#$?
%09:(#2)0*! NRP,! ??'()D)*#2)0*! NSP,! ??$'6(#.'D'*2! N=P! #*/! ??
$'6(#.'D'*2! NTPH! I@':! 6(#:! )*/)46'*4#%('! $0('4! )*! 2@'! 6$)?
D#$:!D'2#%0()4D! 0F! .'((4! #4! M'((! #4! )*! 4'.0*/#$:!D'2#%0?
()4D,!4:*2@'4)C)*E!)D60$2#*2!4)E*#()*E!D0('.G('4H!&0*4)42'*2!
M)2@!2@'4'!D'2#%0().!$0('4,!)*@)%)20$4!0F!D#*:!ABA?'*C:D'4!
@#K'!%''*!#*/U0$!#$'!G4'/!#E#)*42!.'$2#)*!2:6'4!0F!*'G$0(0E)?
.#(! #FF'.2)0*4! NV,! WP,! )*F'.2)0G4! /)4'#4'4! NX?OOP,! #*/! .#*.'$!
NOQPH!I@'!D#)*!@)*/$#*.'!)*!/'4)E*)*E!#!ABA?'*C:D'!)*@)%)?
20$! )4! 2@'! .0DD0*! .@'D)42$:! 0F! 2@)4! F#D)(:! ('#/)*E! 20! (0M!
46'.)F).)2:! #*/! %$0#/! #.2)0*H! "T! '*C:D'! )*@)%)20$4! )*! D'?
/).)*#(! G4'! #$'! 4G%42$#2'! #*#(0E4! %G2! 2@':! F0((0M! /)FF'$'*2!
D'.@#*)4D4! F0$! )*@)%)2)*E! 2@')$! 2#$E'2! '*C:D'4H! Y*! F#.2,! K)?
E#%#2$)*,! /)F(G0$0D'2@:(0$*)2@)*'! #*/! 8?.:.(04'$)*'! #.2! #4!
4G).)/'! )*@)%)20$4! 0F! @GD#*! ??#D)*02$#*4F'$#4'! NOOP,! 0$?
*)2@)*'! /'.#$%09:(#4'! NOQP! #*/! #(#*)*'! $#.'D#4'! NOOP,! $'?
46'.2)K'(:,!M@)('! 6$'E#%()*! .0D6'2)2)K'(:! )*@)%)24! @GD#*! ??
#D)*02$#*4F'$#4'! NWP,! #*/! %'*4'$#C)/'! #*/! .#$%)/06#! )$$'?
K'$4)%(:!%)*/!806#!/'.#$%09:(#4'! ;88&<,! 2@G4!%(0.J)*E! )24!
#.2)K'! 4)2'H! -'.'*2(:,! #! E'*'$#(! 6$0.'/G$'! F0$! /'4)E*)*E!
6@046@06:$)/09:(?! 4G%42$#2'?.0*ZGE#2'! )*@)%)20$4! 0F! ABA?!
!
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Y2#(:]!I'(^_RX`S=W`QVOV=]!a#9^!_RX`S=W`QVOV`]!!
3?D#)(4^.#$(#H%0$$)K0(2#220$*)bG*)K$H)2]!%#$%#$#H.'(()*)bG*)K$H)2!
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%''*! /'4.$)%'/! NVPH! a#K0$#%('! 2#$E'24! F0$! 2@)4! #66$0#.@! #6?
6'#$! 20!%'!'*C:D'4! 2@#2!@#K'!$'(#2)K'(:! (0M!ABA!#FF)*)2:!0$!
G*/'$E0! 2$#*4#D)*#2)0*! #4! #! 4)E*)F).#*2! 4)/'! $'#.2)0*! M)2@!
2@')$!#D)*0!#.)/!4G%42$#2',! 2@G4!F0$D)*E!2@'!*0*!.0K#('*2(:,!
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.0F#.20$H!!
! 10$'0K'$,! 40D'! ABA?'*C:D'4! #$'! 6@#$D#.02@'$#6'G2).!
2#$E'24! 4)*.'! 2@')$! /'F).)2! )4! $'460*4)%('! F0$! $#$'! /)4'#4'4,! #!
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6#2@0E'*).!K#$)#*24!')2@'$!)*!2@')$!$'.0D%)*#*2!6G$)F)'/!F0$D!
NOR?OVP! 0$! '96$'44'/! )*! .'((G(#$! 4:42'D4! NOW,! OXPH! L! 6#$2)?
.G(#$!'D6@#4)4!@#4!%''*!#//$'44'/!20!6#2@0E'*).!K#$)#*24!0F!
@GD#*! 6'$09)40D#(! ()K'$! #(#*)*'^E(:09:(#2'! #D)*02$#*4?
F'$#4'! NQ`?QTP! #*/! .:42@#2@)0*)*'?! ??4:*2@#4'! NQV?QXPH! Y2!
4@0G(/!%'!#(40!D'*2)0*'/! 2@#2!4'K'$#(!*'G$0(0E).#(!6#2@0(0?
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0F!ABA,!0F2'*!/'2'$D)*'/!%:!#! $'/G.'/!#.2)K)2:!0F!ABA!4#(?
K#E'!6#2@M#:!'*C:D'4!)*.(G/)*E!6:$)/09#(!J)*#4'!#*/!6:$)?
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F0$!2@'!4:*2@'4)4!0F!2@'!*'G$02$#*4D)22'$4!/06#D)*'!#*/!4'$0?
2    The Open Biochemistry Journal, 2012, Volume 6 Cellini et al. 
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)4! )*K0(K'/! %02@! )*! A#$J)*40*>4! /)4'#4'! ;A8<! #*/! )*! #! $#$'!
*'G$0D'2#%0().! /)40$/'$! *#D'/! #$0D#2).! #D)*0! #.)/!/'.#$?
%09:(#4'!;LL8&<!/'F).)'*.:H!Y*! 2@)4!$'K)'M!2@'!#22'*2)0*!)4!
F0.G4'/!0*!2@'!42$G.2G$#(!'('D'*24!#*/!FG*.2)0*#(!F'#2G$'4!0F!
88&,! 0*! 2@'! .G$$'*2! 88&?/)$'.2'/! 2@'$#6)'4! F0$! A8! #*/!
LL8&! /'F).)'*.:! #4! M'((! #4! 0*! $'.'*2! F)*/)*E4! 6$0K)/)*E!
)D60$2#*2! EG)/'()*'4! F0$! 2@'! FG2G$'!D#*#E'D'*2! 0F! 6#2)'*24!
#FF'.2'/!%:!2@'4'!/)4'#4'4H!
DDC: STRUCTURAL AND FUNCTIONAL PROPER-
TIES 
! 88&,!#!ABA?/'6'*/'*2!@0D0/)D'$).!'*C:D',! )4!#*!
??/'.#$%09:(#4'!2@#2!.#2#(:C'4!2@'!.0*K'$4)0*!0F!B?#$0D#2).!
#D)*0! #.)/4! )*20! 2@')$! .0$$'460*/)*E! #D)*'4H!88&,! #%G*?
/#*2!)*!2@'!*'$K0G4!4:42'D!#*/!J)/*':,!)4!.'*2$#(!)*!2@'!
4:*2@'4)4!0F!/06#D)*'!#*/!4'$020*)*H!I@G4,! )24! '44'*2)#(!
FG*.2)0*! )4! 20! 6$0K)/'! 2@'! 0$E#*)4D! M)2@! 2@'4'! %)0E'*).!
#D)*'4H!A)E!J)/*':,!$#2!()K'$!#*/!@GD#*!88&!'*C:D'4!@#K'!
%''*!.(0*'/,! '96$'44'/! )*!E. coli! #*/!6G$)F)'/! NOT,!RR,!RSPH!
5G$!E$0G6!@#4!%''*!)*K0(K'/!F0$!(0*E!2)D'!)*!2@'!.@#$#.2'$)?
C#2)0*!0F!2@'!6)E!J)/*':!'*C:D'!NO`,!R=?SQP,!#*/!$'.'*2(:!)*!
2@#2!0F!@GD#*!88&!NOTPH!A)E!J)/*':!88&!#*/!@GD#*!88&!
/)46(#:! 4)D)(#$! 46'.2$04.06).! F'#2G$'4,! J)*'2).! 6#$#D'2'$4,!
4G4.'62)%)()2:! 20! 6$02'0(:4)4! #*/! 2@'$D042#%)()2:! NOTPH! I@'!
$'40(G2)0*!0F!2@'!2@$''?/)D'*4)0*#(!42$G.2G$'!0F!@0(088&!)*!
)24! ()E#*/?F$''!F0$D!#*/! )*!.0D6('9!M)2@! 2@'!#*2)?A#$J)*40*!
/$GE!.#$%)/06#!@#4!#((0M'/!20!60)*2!0G2!2@#2!2@'!42$G.2G$'!)4!#!
2)E@2(:! #440.)#2'/! /)D'$! )*! M@).@! 2@'! #.2)K'! 4)2'! )4! (0.#2'/!
Table 1. Rare Diseases Involving PLP-enzymes 
Rare Disease Involved Enzyme Main Symptoms 
Aromatic L-amino acid decarboxylase defi-
ciency [61] 
85AL!/'.#$%09:(#4'!
/'(#:!)*!/'K'(06D'*2,!#%*0$D#(!D0K'D'*24,!0.G?
(0E:$).!.$)4)'4,!K'E'2#2)K'!4:D620D4!
Cystathioninuria [69] &:42#2@)0*)*'???(:#4'! #%*0$D#(!G$)*#$:!'9.$'2)0*!0F!.:42#2@)0*)*',!F)?
%$02).!()K'$!
GABA-transaminase deficiency [70] ??#D)*0%G2:$).!#.)/?2$#*4#D)*#4'! @:6'$$'F('9)#,!@:6020*)#,!('2@#$E)#,!D#.$040D)#,!
D'*2#(!$'2#$/#2)0*,!#*/!4)'CG$'4!
Gilles de la tourette syndrome [71] c)42)/)*'!/'.#$%09:(#4'!
#$D!2@$G42)*E,!':'!%()*J)*E,!$'6'#2'/!2@$0#2!.('#$?
)*E!0$!4*)FF)*E,!4@0G(/'$!4@$GEE)*E!
Glycine encephalopathy [72] 
A!6$02')*!;#!6:$)/09#(!6@046@#2'?/'6'*/'*2!E(:?
.)*'!/'.#$%09:(#4'<!
D'*2#(!$'2#$/#2)0*,!@:6020*)#,!4')CG$'4,!%$#)*!D#(?
F0$D#2)0*4,!#2#9)#!
Hereditary sensory and autonomic neuropathy 
Type I [73] 
['$)*'!6#(D)20:(2$#*4F'$#4'!
4'*40$:!/'F).)2!)*!2@'!/)42#(!60$2)0*!0F!2@'!(0M'$!
'92$'D)2)'4,!.@$0*).!6'$F0$#2)*E!G(.'$#2)0*4!0F!2@'!
F''2!#*/!6$0E$'44)K'!/'42$G.2)0*!0F!G*/'$(:)*E!
%0*'4,!4M'#2)*E!
Homocystinuria [74] &:42#2@)0*)*#???4:*2#4'! @)E@!('K'(!0F!@0D0.:42')*',!'*/02@'()#(!)*ZG$:,!)4J!
0F!02@'$!#$2'$:!0$!K')*!/)4'#4'4!
Ornithine aminotransferase deficiency (Gyrate 
atrophy) [75] 
5$*)2@)*'!#D)*02$#*4F'$#4'!
600$!K)4)0*!#2!*)E@2!0$!)*!/)D!()E@2,!6'$)6@'$#(!K)?
4)0*!(044!
Primary hyperoxaluria Type I [76] L(#*)*'^E(:09:(#2'!#D)*02$#*4F'$#4'!
09#(04)4,!*'6@$0.#(.)*04)4!G$0()2@)#4)4,!*'6@$0?
()2@)#4)4,!J)/*':!420*'4!
Smith-Magenis syndrome [77] ['$)*'!@:/$09:D'2@:(2$#*4F'$#4'!
4dG#$'?4@#6'/!F#.'!M)2@!/''6?4'2!':'4,!'*E#E)*E!
6'$40*#()2)'4,!4@0$2!42#2G$',!4.0()04)4,!$'/G.'/!4'*?
4)2)K)2:!20!6#)*!#*/!2'D6'$#2G$',!#*/!#!@0#$4'!
K0).'!
Stiff-Man Syndrome [78] e(G2#D).!L.)/!8'.#$%09:(#4'!
DG4.('!$)E)/)2:!2@#2!M#9'4!#*/!M#*'4!M)2@!.0*.G$?
$'*2!46#4D4,!'*.'6@#(0D:'()2)4,!'6)('64:,!.'$'%$#(!
6#(4:,!0$!.'$'%'((#$!/'F).)24!
Type II Tyrosinemia (Richner-Hanhart syn-
drome) [79] 
I:$04)*'!#D)*02$#*4F'$#4'!
'9.'44)K'!2'#$)*E,!6@0206@0%)#,!':'!6#)*!#*/!$'/?
*'44,!#*/!6#)*FG(!4J)*!('4)0*4!0*!2@'!6#(D4!#*/!
40('4,!D'*2#(!$'2#$/#2)0*!
Xanthurenic aciduria [80] B?f:*G$'*)*'!@:/$0(#4'!!
K0D)2)*E,!Z#G*/).',!@)E@!'9.$'2)0*!0F!g#*2@G$'*).!
#.)/!
"X-linked" sideroblastic anemia [81] ??#D)*0('KG()*#2'!4:*2@#4'! D).$0.:2).!$'/!%(00/!.'((4!@:60.@$0D).!#*!#%?
*0$D#(!#..GDG(#2)0*!0F!)$0*!)*!$'/!%(00/!.'((4!
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*'#$! 2@'! D0*0D'$?D0*0D'$! )*2'$F#.',! #(2@0GE@! %')*E!
D#)*(:!.0D604'/!0F!$'4)/G'4!F$0D!0*'!D0*0D'$H!10$'0K'$,!
2@#*J4!20!40(K'/!42$G.2G$'4,!M'!M'$'!#%('!20!)/'*2)F:!2@'!$'4)?
/G'4! )*K0(K'/! )*! 2@'! %)*/)*E! 0F! 2@'! .0'*C:D',! 20! 'K)/'*.'!
2@'! #*2)6#$J)*40*)#*! /$GE! %)*/)*E! D0/',! #*/! 20! 4GEE'42!
M@).@!#D)*0!#.)/!$'4)/G'4!D#:!%'!)*K0(K'/!)*!.#2#(:4)4!NSRPH!
3#.@!0F!2@'!2M0!D0*0D'$4!)4!.0D604'/!0F!2@$''!/)42)*.2!/0?
D#)*4H!I@'! (#$E'!/0D#)*!.0*2#)*4! 2@'!ABA!%)*/)*E!4)2'!#*/!
)*.(G/'4! #! .0$'! F0$D'/! %:! #! 4'K'*?42$#*/'/!D)9'/! ??4@''2!
4G$$0G*/'/!%:! ')E@2!??@'().'4! )*! #! 2:6).#(!?U?! F0(/H!I@'!&?
2'$D)*#(!4D#((!/0D#)*!.0D6$)4'4!#!F0G$?42$#*/'/!#*2)6#$#(('(!
??4@''2!M)2@!2@$''!@'().'4!6#.J'/!#E#)*42!2@'!F#.'!06604)2'!20!
2@'!(#$E'!/0D#)*H!I@'!h?2'$D)*#(!/0D#)*,!.0D604'/!0F!2M0!
6#$#(('(!@'().'4!()*J'/!%:!#*!'92'*/'/!42$#*/,!()'4!()J'!#!F(#6!
0K'$!2@'!206!0F!2@'!4'.0*/!4G%G*)2H!\*2)(!*0M,!0*(:!F'M!42G/?
)'4!@#K'!%''*!6G%()4@'/! 2@#2!/'4.$)%'! 2@'! FG*.2)0*#(! $0('!0F!
2@'!h?2'$D)*G4! 0F! ABA?'*C:D'4! NSS?STPH! a0$! @GD#*!88&,!
2@'!$'.'*2!$'40(G2)0*!0F!2@'!.$:42#(!42$G.2G$'!0F!2@'!'*C:D'!)*!
)24!#60!F0$D!@#4!6$0K)/'/!'K)/'*.'! F0$!#*!G*'96'.2'/!06'*!
%)K#(K'! .0*F0$D#2)0*! ;#4! .0D6#$'/! M)2@! 2@'! @0(0'*C:D'<!
M)2@!2@'!)*2'$F#.'!%'2M''*!2@'!h?2'$D)*#(!/0D#)*4!FG*.2)0*?
)*E! #4! 2@'! @)*E'! NSVP,! 2@G4! 4GEE'42)*E! #! $0('! F0$! 2@'! h?
2'$D)*G4!)*!2@'!F0$D#2)0*!0F!2@'!.(04'/!/)D'$).!.0*F0$D#2)0*!
0F!2@'!@0(0'*C:D'H!!
PD 
! A8! )4! #! *'G$0/'E'*'$#2)K'! /)40$/'$! .@#$#.2'$)C'/! %:!
2$'D0$,!%$#/:J)*'4)#,!$)E)/)2:,!#*/!6042G$#(!)*42#%)()2:H!I@'4'!
4:D620D4! #$'! .#G4'/! %:! 2@'! $'/G.'/! ('K'(4! 0F! /06#D)*',!
.0*4'dG'*2! 20! 2@'! 6$0E$'44)K'! /'E'*'$#2)0*! 0F! /06#D)*'?
6$0/G.)*E!.'((4!)*!2@'!substantia nigra!0F!2@'!%$#)*!NSWPH!80?
6#D)*'!)24'(F!.#**02!6#44!2@'!%(00/?%$#)*!%#$$)'$!#*/,!2@'$'?
F0$',!.#**02!%'!G4'/!#4!#!/$GE!)*!2@'!A8!2$'#2D'*2H!I@G4,!0*'!
0F! 2@'!D042!'FF'.2)K'!.()*).#(! 2$'#2D'*24!0F! 2@'!/)4'#4'! )4! 20!
$0G2)*'(:! #/D)*)42'$! B?806#,! )*! .0D%)*#2)0*! M)2@! #! 88&!
)*@)%)20$H!I@'!$#2)0*#(!0F!2@)4!2$'#2D'*2!)4!2@#2!4)*.'!B?806#!
)4!$#6)/(:!.0*K'$2'/!20!/06#D)*'!)*!2@'!%(00/!42$'#D,!0*(:!#!
4D#((! 6'$.'*2#E'! 0F! #! E)K'*! /04'! 0F! 806#,! M@'*! #/D)*)4?
2'$'/!#4!#!/$GE,!.#*!$'#.@!2@'!*'$K0G4!4:42'D!;[.@'D'!1A<H!
":!#//)*E!#!88&!)*@)%)20$,!E$'#2'$!#D0G*24!0F!B?806#!.#*!
$'#.@! 2@'! %$#)*! ;[.@'D'!1B<,!M@'$'! 2@'! ('K'(! 0F! /06#D)*'!
M)((!$'4G(2!20!%'!4G%42#*2)#((:!)*.$'#4'/H!I@'!D042!.0DD0*(:!
88&! )*@)%)20$4! G4'/! )*! 2@'! 2$'#2D'*2! 0F! A8! #$'! .#$%)/06#!
;;QS<?R?;R,S?/)@:/$09:6@'*:(<?Q?@:/$#C)*0?Q?D'2@:(6$06#?
*0).! #.)/]! 1fSW=<! #*/! %'*4'$#C)/'! ;;RS<?Q?#D)*0?R?
@:/$09:?N??;Q,R,S?2$)@:/$09:%'*C:(<6$06#*'@:/$#C)/']! -0?
S?ST`Q<H! Y*! #*)D#(4! #*/! @GD#*4! %'*4'$#C)/'! )4! .0D6('2'(:!
D'2#%0()C'/!20!4'$)*'!#*/!2$)@:/$09:%'*C:(@:/$#C)*'!;-0?S?
=OQV<! %'F0$'! )2! $'#.@'4! 2@'! #$2'$)#(! %(00/! NSXPH! I@G4,! )2! )4!
()J'(:! 2@#2! 2$)@:/$09:%'*C:(@:/$#C)*'! $'6$'4'*24! 2@'! #.2G#(!
88&! )*@)%)20$H! Y*/''/,!M@)('!%'*4'$#C)/'! )4!*02!#!60M'$FG(!
88&! )*@)%)20$! N=`P,! .#$%)/06#! #*/! 2$)@:/$09:%'*C:(@:/$#?
C)*',!%02@!4G%42$#2'!#*#(0E4!'*/0M'/!M)2@!#!4G%42)2G2'/!@:?
/$#C)*'! FG*.2)0*,!@#K'!%''*! F0G*/! 20!%)*/!6)E!J)/*':!88&!
%:!F0$D)*E!#!@:/$#C0*'!()*J#E'!M)2@!ABA,!#*/!M0$J!#4!60M?
'$FG(!)$$'K'$4)%('!88&!)*@)%)20$4!N=`,!=OPH!c0M'K'$,!4'K'$#(!
4)/'!'FF'.24!;*#G4'#,!@:602'*4)0*,!#$$@:2@D)#4,!E#42$0)*2'42)?
*#(!%(''/)*E! #*/! 4'$)0G4!64:.@)#2$).! 4:D620D4<! '*4G'! F$0D!
.0?#/D)*)42$#2)0*!0F!B?806#!M)2@! .#$%)/06#! 0$! %'*4'$#C)/'!
N=Q,!=RP,!M@).@!#$'!6044)%(:!$'(#2'/!20!2@'!F0((0M)*E!F)*/)*E4^!
;)<! .#$%)/06#! #*/! 2$)@:/$09:%'*C:(@:/$#C)*'! $'#.2! *0*?
'*C:D#2).#((:! M)2@! F$''! ABA! N=Q?=SP,! ;))<! 2@'! .0*/'*4#2)0*!
6$0/G.24!F0$D'/!%'2M''*!ABA!#*/!@:/$#C)*'!/'$)K#2)K'4!#$'!
2@'! D042! 602'*2! )*@)%)20$4! 0F! 6:$)/09#(! J)*#4',! #*! '*C:D'!
)*K0(K'/!)*!ABA!%)04:*2@'4)4!N==,!=TP,!#*/!;)))<!@)E@!('K'(4!0F!
@0D0.:42')*'!)*K'$4'(:!.0$$'(#2'!M)2@!ABA!.0*.'*2$#2)0*4!)*!
2@'!2$'#2'/!6#2)'*24!N=V?=XPH!I@G4,!2@'!.G$$'*2!6$020.0(!4''D4!
20!#(2'$!2@'!ABA!D'2#%0()4DH!-'.'*2(:,!#!6$0D)4)*E!42'6!F0$?
M#$/! )*! 2@'! /$GE! /'K'(06D'*2! F0$! A8! @#4! %''*! #..0D?
6()4@'/H!L!K)$2G#(!4.$''*)*E!6$020.0(,! )*2'E$#2)*E!6@#$D#.0?
F0$'!4'#$.@!#*/!D0('.G(#$!/0.J)*E,!@#4!%''*!/'K'(06'/!42#$2?
)*E!F$0D!2@'!#20D).!42$G.2G$'!0F!2@'!88&?.#$%)/06#!.0D6('9!
NSRPH!I@'! .0D%)*#2)0*!0F! 2@'4'! .0DG6#2)0*#(!D'2@0/4!M)2@!
'*C:D#2).! #44#:4! #*/! 46'.2$04.06).! #*#(:4'4! @#4! 6$0K)/'/!
Peripheral tissues
E
hem
atoencephalic barrel
B
lood brain barrier
Brain         
(substantia nigra) Peripheral tissues
B
lood brain barrier
Brain         
(Substantia nigra)
! "
 
Scheme (1).!LK#)(#%)()2:!0F!#/D)*)42$#2'/!B?806#!)*!2@' substantia nigra 0F!%$#)*!)*!2@'!#%4'*.'!;L<!0$!)*!2@'!6$'4'*.'!;"<!0F!#*!)*@)%)20$!0F!
6'$)6@'$#(!88&H!I@'!:'((0M!#*/!2@'!$'/!4:D%0(4!$'6$'4'*2!88&!#*/!88&!)*@)%)20$,!$'46'.2)K'(:]!2@'!%(G'!4dG#$'4!$'6$'4'*2!B?806#H 
 
4    The Open Biochemistry Journal, 2012, Volume 6 Cellini et al. 
2'*! .0D60G*/4! )/'*2)F)'/! #4! .0D6'2)2)K'! )*@)%)20$4! M)2@!f)!
K#(G'4! )*! 2@'! (0M! D).$0D0(#$! $#*E'! #*/! 6$'/).2'/! 20! *02!
.$044! 2@'! %(00/?%$#)*! %#$$)'$! NT`PH! I@)4! #66$0#.@,! 2@'! F)$42!
$'60$2'/!)*!2@'!F)'(/!0F!88&!)*@)%)20$4!/)4.0K'$:,!@#4!$'6$'?
4'*2'/!#*!'9.'(('*2!42#$)*E!60)*2!20!FG$2@'$!@)2?20?('#/!/'K'(?
06D'*2H! Y*! F#.2,! )2! )4! $'('K#*2! 2@#2! 2@'4'! D0('.G('4,! G*()J'!
.#$%)/06#! #*/! 2$)@:/$09:%'*C:(@:/$#C)*',! #$'! /'K0)/! 0F! #*!
@:/$#C)*).!E$0G6,!/0!*02!%)*/! F$''!ABA!#*/!#.2!#4!E00/!$'?
K'$4)%('!)*@)%)20$4H!&0D60G*/4!'*/0M'/!M)2@!4G.@!.@'D).#(!
F'#2G$'4!#$'!D0$'!4'('.2)K'!2@#*!2@'!/$GE4!.0DD0*(:!G4'/!)*!
2@'!2$'#2D'*2!0F!A8H!I@G4,!M@'*!)D6$0K'/!#*/!/'K'(06'/!#4!
/$GE4,!2@':!.0G(/!$'/G.'!2@'!K'$:!G*/'4)$#%('!4)/'!'FF'.24!0F!
2@'! .G$$'*2! 2@'$#6'G2).! 42$#2'E:H! 5*! 2@'! %#4)4! 0F! 2@'! #%0K'!
.0*4)/'$#2)0*4!#*/!$'4G(24,!2@'!/$GE!/'K'(06D'*2!F0$!2@'!A8!
2@'$#6:!4''D4!20!%'!#!6$0D)4)*E!'*/'#K0$H!
AADC DEFICIENCY 
! -'.'44)K'!)*@'$)2'/!/'F).)'*.:!0F!88&!;51Y1iT`WTSR<!
$'4G(24! )*! #! 4'K'$'! *'G$0D'2#%0().! /)40$/'$! M)2@! /'K'(06?
D'*2#(! /'(#:,! #%*0$D#(! D0K'D'*24,! 0.G(0E:$).! .$)4'4! #*/!
K'E'2#2)K'! 4:D620D4H! [)*.'! 2@'! F)$42! $'60$2! )*! OXX`! NTOP,!
#%0G2!=`!.#4'4!0F!88&!/'F).)'*.:!@#K'!%''*!$'60$2'/!NTQPH!
A#2)'*24!/)46(#:!#! 2:6).#(!6#22'$*!.@#$#.2'$)C'/!%:!#!/)42)*.2!
$'/G.2)0*!0F!2@'!42#%('!/'E$#/#2)0*!6$0/G.24!0F!/06#D)*'!#*/!
4'$020*)*,!@0D0K#*)(().!#.)/!#*/!=?@:/$09:)*/0(#.'2).!#.)/,!
#..0D6#*)'/!%:!2@'!)*.$'#4'!0F!2@'!('K'(!0F!2@'!6$'.G$40$4!0F!
/06#D)*'! #*/! 4'$020*)*,!B?806#! #*/!=?@:/$09:2$:6206@#*,!
$'46'.2)K'(:H!L//)2)0*#((:,!2@'!('K'(4!0F!R?0$2@0?D'2@:(/06#,!
$'4G(2)*E! F$0D! D'2@:(#2)0*! 0F! #..GDG(#2)*E! B?806#,! #$'!
.('#$(:!)*.$'#4'/!NTRPH!I@'!/)#E*04)4!)4!.0*F)$D'/!%:!D'#4?
G$)*E! 2@'! '*C:D'! #.2)K)2:! 0F!88&! )*! 6(#4D#! 0$! .'((4! NTSPH!
L(2@0GE@!#%0G2!R`!DG2#2)0*4!0*!2@'!LL8&!E'*'!@#K'!%''*!
)/'*2)F)'/!#*/!DG.@!)4!J*0M*!#%0G2!2@'!.()*).#(!6@'*02:6'!0F!
2@'!6#2)'*24,!2@'!'*C:D#2).!6@'*02:6'4!#$'!40!F#$!(#$E'(:!G*?
J*0M*! #4! M'((! #4! 0F! .0G$4'! 2@'! D0('.G(#$! D'.@#*)4D4! %:!
M@).@!'#.@!DG2#2)0*!('#/4!20!2@'!/'F).)'*.:!0F!88&H!j@)('!
2@'!'FF'.2!0F!*0*4'*4'!#*/!F$#D'4@)F2!DG2#2)0*4! 2@#2! ('#/!20!
2@'!.0D6('2'!(044!0F!2@'!E'*'!6$0/G.2!)4!42$#)E@2F0$M#$/,!4)*?
E('! #D)*0! #.)/! 4G%42)2G2)0*4! ('#/)*E! 20! 2@'! 4:*2@'4)4! 0F! #*!
#%'$$#*2! E'*'!6$0/G.2! .#*! )*! 6$)*.)6('! #FF'.2! 2@'! '*C:D#2).!
#.2)K)2:,! 2@'! %)*/)*E! 0F! 2@'! .0'*C:D',! 2@'! 6$02')*! 42#%)()2:!
#*/! U0$! F0(/)*E,! 2@'! '*C:D'! @#(F?()F'! )*4)/'! 2@'! .'((,! '2.H!
10$'0K'$,! )2! 4@0G(/! %'! 'D6@#4)C'/! 2@#2! D#*:! 6#2)'*24! #F?
F'.2'/!%:!88&!/'F).)'*.:! #$'! .0D60G*/!@'2'$0C:E0G4! #*/!
2@')$! '*C:D#2).! 6@'*02:6'! /'6'*/4! 0*! 2@'! .0D%)*#2)0*! 0F!
2@'!'FF'.2!0F!0*'!DG2#2)0*!0*!#!D0*0D'$!#*/!#!/)FF'$'*2!DG?
2#2)0*!0*!2@'!02@'$!D0*0D'$H!I@'!.0$'!2$'#2D'*24!F0$!LL8&!
/'F).)'*.:!#$'!6:$)/09)*',!1L5?"!)*@)%)20$4,!#*/!/06#D)*'!
#E0*)424H! L/D)*)42'$'/! 6:$)/09)*'! )4! 6@046@0$:(#2'/! %:!
6:$)/09#(!J)*#4'!#*/!2@'*!4G%4'dG'*2(:!.0*K'$2'/!20!ABA!%:!
6:$)/09#(!09)/#4'H!I@'!#)D!0F!2@)4!2$'#2D'*2!)4!20!6$0K)/'!#*!
'9.'44!0F!ABA,!M@).@!D#:!)*!2G$*!%0(42'$!0$!'*@#*.'!$'4)/G#(!
88&! #.2)K)2:H! 1L5?"! )*@)%)20$4! ;2$#*:(.:6$0D)*',! 4'?
('E)()*',!D0.(0%'D)/'<! #$'! E)K'*! 20! 6$'K'*2! 2@'! %$'#J/0M*!
0F!2@'!()D)2'/!#D0G*24!0F!/06#D)*'!#*/!4'$020*)*!6$0/G.'/!
%:! LL8&! /'F).)'*2! 6#2)'*24H! 806#D)*'! #E0*)424! ;%$0?
D0.$)62)*',! 6'$E0()/',! 6$#D)6'90('! #*/! $06)*)$0('<! #$'! #/?
D)*)42'$'/! )*! LL8&! /'F).)'*.:! )*! #*! #22'D62! 20! 42)DG(#2'!
/06#D)*'!$'.'620$4!#*/!.0*4'dG'*2(:!$'6(#.'!/06#D)*'!*'G?
$02$#*4D)44)0*!;[.@'D'!2<!NT=PH!Y2!4@0G(/!%'!D'*2)0*'/!2@#2!
)*!2@'!(#42!:'#$4!#!E'*'!2@'$#6:!#66$0#.@!@#4!%''*!'96(0$'/,!
#*/! E00/! )*/).#2)0*4! @#K'! %''*! 6$0K)/'/! F0$! 2@'! 602'*2)#(!
4G..'44!0F!2@)4!2'.@*)dG'!F0$!LL8&!/'F).)'*.:!NT=,!TTPH!I@'!
$'460*4'! 20! 2@'! 2@'$#6)'4! )*! .()*).#(! G4'! @#4! %''*! K#$)#%(',!
%G2!2@'!0K'$#((!0G2.0D'!$'D#)*4!600$,!6$0%#%(:!$'F('.2)*E!2@'!
#(('().!@'2'$0E'*')2:H!10$'0K'$,!4)*.'!/$GE4!M'$'!#(D042!#(?
M#:4! E)K'*! )*! .0D%)*#2)0*,! 2@'! $'460*4'! )4! @#$/! 20! %'! #4?
.$)%'/!20!#!4)*E('!/$GEH!LE#)*,! 2@'4'!.(#44).! 2$'#2D'*24! 2'*/!
20!#//$'44!2@'!D0$'!/)42#(!#46'.24!0F!2@'!/)4'#4'!6$0.'44,!)H'H!
4:D620D4!$#2@'$!2@#*!.#G4'4H!L!K'$:!)D60$2#*2!)44G'!F0$!2@'!
/)#E*04)4! #*/! 2@'! 2@'$#6:! 0F! /)4'#4'4! .0$$'(#2'/! 20! 6$02')*!
D#(FG*.2)0*!)4!2@'!G*/'$42#*/)*E!0F!2@'!DG(2)6('!D'.@#*)4D4!
2@#2! $'(#2'! 2@'! 46'.)F).!DG2#*24!M)2@! 2@'! 6#2@0(0E:H! Y*! F#.2,!
2@'! J*0M('/E'! 0F! 2@'! '*C:D#2).! 6@'*02:6'! #440.)#2'/!M)2@!
'#.@! DG2#2)0*! $'6$'4'*24! 2@'! %#4)4! F0$! 6$'/).2)*E! 2@'! $'?
460*4'!0F!6#2)'*24!20!2@'!#K#)(#%('!2@'$#6)'4!#4!M'((!#4!20!6$0?
Z'.2! *'M! 2@'$#6'G2).! 42$#2'E)'4H! I@'! 42$G.2G$#(! #*/U0$! FG*.?
##$
%?#&'(
#&'()*+,
-!.
/0,(1),+12
#&'()*+,?
(3&+*212
#&'()*+,?
0,4,'1&02
-!.?
*+5*6*1&02
7%7
8&)&9(+*::*4
(4*;?
 
Scheme 2H!&G$$'*2!.()*).#(!D#*#E'D'*2!0F!LL8&!/'F).)'*.:H!
 
Dopa Decarboxylase as Pharmacotherapeutic Target The Open Biochemistry Journal, 2012, Volume 6    5!
2)0*#(! 'FF'.2;4<! 2@#2! #D)*0! #.)/! 4G%42)2G2)0*4! 6$0/G.'! 0*!
88&!@#4!%''*!$'.'*2(:!)*K'42)E#2'/H!L!F)$42!#66$0#.@!)*!2@)4!
/)$'.2)0*!)4!2@'!#*#(:4)4!0F!2@'!.$:42#(!42$G.2G$'!0F!2@'!'*C:D'!
20! $#2)0*#()C'! #*/! )*2'$6$'2! 2@'! )D6#.2! 0F! 40D'! /)4'#4'?
46'.)F).! DG2#2)0*4! )*! 2'$D4! 0F! 2@')$! ()J'(:! 'FF'.24! 0*! '*?
C:D'>4! 2'$2)#$:!#*/!dG#2'$*#$:!42$G.2G$'H!a)EH! ;1<! $'6$'4'*24!
#*! 0K'$K)'M! 0F! 88&! 6#2@0E'*).!DG2#2)0*! 4)2'4H! 7)4G#(! )*?
46'.2)0*! 0F! 2@'! 2@$''?/)D'*4)0*#(! 42$G.2G$'! 0F! 88&! )*! )24!
@0(0?F0$D! 4GEE'424! 2@#2,! /'46)2'! 2@'!K#$)#%)()2:! )*! 2@'! 46#.'!
/)42$)%G2)0*,! 40D'! 6@:4).0?.@'D).#(! 'FF'.24! 4@#$'/! %:! 2@'!
/)4'#4'?#440.)#2'/!DG2#2)0*4!D)E@2!('#/!20!4)D)(#$!'*C:D#2).!
6@'*02:6'4H! Y*! 6#$2).G(#$,! 40D'! 60)*2! DG2#2)0*4! ;[OSV-,!
eO`Q[,!aR`XB,!LQV=I,!#*/!-RSVk<!D#:!#FF'.2!2@'!)*2'E$)2:!
0F!2@'!#.2)K'!4)2',!40D'!;BRWA!#*/!LOO`k<!D)E@2!#FF'.2!2@'!
42#%)()2:!0F!2@'!/)D'$!)*2'$F#.',!M@)('!40D'!;ASVc!#*/!BRWA<!
#$'! '96'.2'/! 20! D042(:! .0D6$0D)4'! 2@'! 42#%)()2:! 0F! 2@'!
D0*0D'$).! F0$D! 0F! 2@'! '*C:D'H! a0$! #! *GD%'$! 0F! DG2#*24!
;-R=Wc,!7ST`e,!eOQRe,![Q=`a,!-QW=j<!2@'!4G%42)2G2)0*!)4!
'96'.2'/! 20! 6'$2G$%! )D60$2#*2! @:/$06@0%).! 6#2.@'4! M)2@)*!
2@'!42$G.2G$',!M@).@!D)E@2! ('#/! 20!D)4F0(/)*E!0$!6$02')*!#E?
E$'E#2)0*!)*!.#4'4!M@'$'!2@'!6'$2G$%#2)0*!0..G$4! )*!40(K'*2?
'9604'/! #$'#4H!I@$''!DG2#*24! ;BS`WY,!-SOQj,!-SSVc<! #$'!
(0.#2'/! )*! 2@'! 4D#((! &?2'$D)*#(! /0D#)*! )*! 4)2'4! *')2@'$! )*?
K0(K'/!)*!2@'!/)D'$)C#2)0*,!*0$!)*!2@'!.#2#(:2).!#$'#4H![G.@!#!
l@02! 4602m! )*! #!M'((?/'F)*'/! /0D#)*!D)E@2! @#K'! FG*.2)0*#(!
.0*4'dG'*.'4,! M@).@! #$'! .G$$'*2(:! G*J*0M*H! a)*#((:,! 2@'!
$'40(G2)0*!0F! 2@'! 42$G.2G$'! 0F! #6088&! NSVP! @#4! @)E@()E@2'/!
2@#2! 40D'! 6#2@0E'*).! DG2#2)0*4! ;4G.@! #4! nVX&,! cV`I,!
cVQn!#*/!ITX1<!;a)EH!2<!)*K0(K'!$'4)/G'4!)D60$2#*2!F0$!2@'!
.0*F0$D#2)0*#(! .@#*E'4! 0..G$$)*E! G60*! ABA! %)*/)*E,! 2@G4!
6044)%(:!#FF'.2)*E!2@'!#60?20?@0(0!2$#*4)2)0*H!
! -'.'*2(:,! %)0.@'D).#(! #*/! %)0)*F0$D#2).! )*K'42)E#2)0*4!
0F!4'K'$#(!6#2@0E'*).!88&!K#$)#*24!)*!2@'!$'.0D%)*#*2!6G$)?
 
Fig. (1). Overview of DDC pathogenic mutation sites. 
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Fig. (2). Pathogenic mutation sites belonging to the loop 66-84. 
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Dopa or aromatic amino acid decarboxylase (DDC, AADC) is a pyridoxal 5′-phosphate-dependent enzyme that
catalyses the production of the neurotransmitters dopamine and serotonin. Among the so far identified muta-
tions associated with AADC deficiency, an inherited rare neurometabolic disease, the S250F mutation is the
most frequent one. Here, for the first time, the molecular basis of the deficit of the S250F variant was inves-
tigated both in vitro and in cellular systems. Ser250 is not essential for the catalytic activity of the enzyme.
However, its mutation to Phe causes a ∼7-fold reduction of catalytic efficiency and a conformational
change in the proximity of the mutated residue that is transmitted to the active site. In cellular extracts of
E. coli and mammalian cells, both the specific activity and the protein level of the variant decrease with re-
spect to the wild-type. The results with mammalian cells indicate that the mutation does not affect intracel-
lular mRNA levels, and are consistent with a model where S250F undergoes a degradation process via the
proteasome, possibly through an ubiquitination process occurring faster than in the wild-type. Overall, bio-
chemical and cell biology experiments show that loss of function of S250F occurs by two distinct but not ex-
clusive mechanisms affecting activity and folding. Importantly, 4-phenylbutirric acid (4-PBA) or, to a major
extent, pyridoxine increase the expression level and, in a dose-dependent manner, the decarboxylase specif-
ic activity of mutant-expressing cells. This strongly suggests that 4-PBA and/or pyridoxine administration
may be of important value in therapy of patients bearing the S250F mutation.
INTRODUCTION
Aromatic amino acid decarboxylase (AADC) deficiency, a
rare neurometabolic disorder, is a loss-of-function disease
whose symptoms are directly related to the absence of func-
tional dopa decarboxylase (DDC), a pyridoxal 5′-phosphate
(PLP)-dependent enzyme responsible for the production of
the neurotransmitters dopamine and serotonin. More than 50
patients with DDC deficiency have been tabulated on the
BIOMDB database (http://www.biopku.org/biomdb/biom
db_start.asp), and 23 missense pathogenic mutations have
been identified, half of which in homozygous patients. Al-
though the clinical phenotype associated with the disease
has been widely investigated (1,2), the molecular effect(s)
that any mutation induces on DDC is almost unknown.
Nonsense and frameshifts mutations lead to the complete
loss of the gene product, while missense point mutations
cause the synthesis of an aberrant gene product which can
be characterized by defects of enzymatic activity, PLP
binding, protein stability and/or folding, protein half-life,
etc. Current treatments for AADC deficiency are the adminis-
tration of pyridoxine or PLP to increase the residual DDC ac-
tivity, or MAO-B inhibitors to minimize the dopamine
degradation or dopamine agonists to mime the action of the
neurotransmitter (3). The response to these therapies is vari-
able, but the overall outcome is rather poor, probably reflect-
ing the allelic heterogeneity. Moreover, since drugs are almost
always given in combination, response is hardly ascribable to
a single drug. In diseases related to protein malfunction, it is
diagnostically and therapeutically essential to understand the
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multiple mechanisms that relate the specific mutants with the
pathology. Therefore, the knowledge of the structural and/or
functional effect(s) that each amino acid substitution produces
on DDC would be highly desirable. A first example of this
approach is a recent study in which, by means of biochemical
and bioinformatic analyses, the molecular defects of four
recombinant purified pathogenic variants whose mutations
concern residues located at or near the active site have been
identified. On these bases, a therapeutic treatment has also
been proposed (4). In the present work, we tried to understand
the structural and/or functional defects of the S250F variant,
the most common one associated with AADC deficiency
(1,5–7). A combination of biochemical analyses on the puri-
fied recombinant protein paired with expression studies
using a well-characterized mammalian tissue culture cell line
[Chinese hamster ovary (CHO) cells] has been used. From
our investigations, it can be deduced that the S250F mutation
causes both catalytic and folding defects consisting in a reduc-
tion in catalytic activity and an enhanced susceptibility to deg-
radation mediated by the proteasome pathway. Importantly,
4-phenylbutirric acid (4-PBA) and, to a major extent, pyridox-
ine partially rescue the functionality of the variant. This sug-
gests that these molecules may be of value in therapy of
patients bearing the S250F mutation.
RESULTS
Expression studies of S250F variant in E. coli
Decarboxylase assays and western blotting analyses of crude
cellular extracts of E. coli reveal that the specific activity
and the immunoreactivity of the S250F variant are 14 and
66%, respectively, of the corresponding ones of the wild-type
(Table 1). Although these data confirm the pathogenicity of
S250F mutation, they do not allow the identification of the
mechanism(s) producing the enzyme malfunction. In fact,
the low specific activity appears to be due not only to the
drop of the expression yield, but also to the decrease in the
catalytic activity of the mutant. Since the expression in E.
coli offers the possibility to produce and purify sufficient
quantities of the S250F variant for detailed structural and func-
tional analyses, we followed this approach in order to eluci-
date the molecular basis of the deficit of the S250F variant.
Biochemical studies of recombinant purified S250F
The purified S250F variant is homogeneous as indicated by a
single band on SDS PAGE with a mobility identical to that of
wild-type human DDC. The equilibrium dissociation constant
value for PLP, [KD(PLP)] of the variant (62+ 24 nM) does not
significantly change when compared with that of the wild-type
[43+ 12 nM (4)]. This is consistent with the fact that Ser250,
belonging to the large domain of DDC, is located at 12 A˚ from
PLP. However, several lines of evidence indicate that substitu-
tion of Ser by Phe at position 250 alters the PLP binding
mode and microenvironment. First, while wild-type human
DDC displays two absorbance bands centred at 420 and
335 nm with a ratio A335nm/A420nm of 2 (4), these bands in
the S250F variant show a lower intensity and a 3-nm blue
shift with a ratio A417nm/A332nm of 1.5 (Fig. 1). Second,
although the absorbance bands of both wild-type and mutant
are associated with positive dichroic bands, the magnitudes
of the 420 nm dichroic signal of wild-type and variant are
identical, while that of the 332 nm band of the variant is about
half with respect to that of the wild-type (inset of Fig. 1).
Thus, the wild-type and S250F enzymes display optical activity
(mdeg/absorbance unit) values of 54 and 32 mdeg/A420 and of
102 and 59 mdeg/A335, respectively. Third, upon excitation at
335 nm, the NaBH4-reduced S250Fmutant exhibits a decreased
emission fluorescence intensity at 390 nm with respect to wild-
type DDC (Fig. 2). Again, as shown in the inset of Figure 2, the
reduced variant, when excited at 280 nm, displays a decreased
energy transfer efficiency between tryptophan residues(s) and
the reduced coenzyme. Phenylalanine at position 250 might
perturb the active site directly through unfavourable electrostat-
ic or steric interactions with PLP or indirectly by inducing con-
formational changes in the vicinity of the mutation site. The
latter possibility may be favoured on the basis of the following
data of the mutant compared with the corresponding ones of the
wild-type: (i) a consistent decrease in the 280-nm optically
active band (inset of Fig. 1), (ii) a reduction in the intrinsic fluor-
escence emission intensity accompanied by a 2-nm blue shift of
the emission maximum (Fig. 3A) and (iii) an increase in
aniline-1-naphtalenelsulphonic acid (ANS) fluorescence emis-
sion intensity and a shift of the emission maximum from 479
to 475 nm (Fig. 3B). However, circular dichroism (CD)
spectra taken in the far-UV region were practically superimpos-
able for wild-type and S250F variant, indicating no gross altera-
tions in the secondary structure (data not shown). Moreover, the
profile and the kinetics of limited proteolysis of the variant were
identical to those of wild-type DDC (data not shown). Finally,
dynamic light scattering (DLS) measurements indicate that
S250F has a hydrodynamic diameter of #10 nm, identical to
that of the wild-type. This value is consistent with either that
derived from the crystal structure of pig kidney DDC (9.5 nm)
(8) or that calculated by an appropriate empirical equation
(7+ 2 nm) (9).
The steady-state turnover and apparent Km values of L-dopa
for the wild-type and S250F mutant enzymes have been com-
pared (Table 2). At pH 7.4 and 258C, the kcat value of the
variant drops by a factor of #3.5, while the Km value increases
by a 2-fold factor, resulting in a #7-fold reduction of the cata-
lytic efficiency. Thus, taking into account the kcat value of the
variant in comparison with that of the wild-type, it could be
deduced that the true specific activity of the S250F variant
in the crude cellular extracts of E. coli is # 49% that of the
wild-type.
Like the apo wild-type, the apo variant does not display ab-
sorbance and CD bands in the visible region. However, in
comparison with the apo wild-type, a modest reduction in
the magnitude of the dichroic signal in the near UV region,
in the intensity of the intrinsic fluorescence emission and
Table 1. Specific activity (nmol/min/mg/) of crude extracts in E. coli and CHO
cells
Enzyme E. coli CHO cells
Wild-type 124+3 35+1
S250F 16.8+0.3 5.4+0.4
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in the ANS emission intensity can be detected in the apo
variant (data not shown).
To understand if the S250F mutation has an impact on the
thermostability of the holo and/or apo forms of the variant,
their thermal inactivation kinetics has been examined at
378C over a period of 3 h and compared with that of the wild-
type (Fig. 4). No loss of decarboxylase activity of the holo
forms of both wild-type and variant has been observed. In con-
trast, we detected a time-dependent apoS250F-inactivation
more consistent than that of the apo wild-type. This would in-
dicate that the apoS250F at physiological temperature is more
susceptible to inactivation than the apo-wild-type.
Molecular modelling
To rationalize how Ser250 replacement with Phe could affect
the DDC structure, we performed a molecular modelling study
based on the crystal structure of pig kidney holo DDC (8).
This structure might be a good model, being the overall
degree of identity with human DDC equal to 88.7%. Ser250
belongs to the loop 243–252 with the stretch 243–246
facing the active site and the stretch 247–252 facing the
surface of the molecule. The Og of Ser250 is in a proper pos-
ition to form an H-bond interaction with the Og of Thr245.
Figure 5 shows the superimposition of the active site of the
solved DDC structure with the putative one of the S250F
variant obtained by energy minimization means. In the
variant the Phe250 side chain is predicted to be oriented
toward the protein surface and to possibly make an hydropho-
bic interaction with Phe215. Thus, the Ser-to-Phe substitution
could not only destabilize the conformation of the loop 243–
252, as a consequence of the loss of the H-bond between
Ser250 and Thr245, but also alter the chemical features of
the DDC surface that is predicted to become more hydropho-
bic.
S250F variant: cell biology analyses in a cellular system
To ascertain whether the replacement of Ser250 with Phe
affects the functional features of DDC in a mammalian
cellular system, wild-type and variant were transiently
expressed in CHO cells. The specific activity and the expres-
sion level of the S250F mutant were 14 and 30% (Fig. 6), re-
spectively, of those of wild-type DDC (Table 1). Considering
that the S250F mutation causes an #70% reduction in the kcat
value of the purified recombinant enzyme, the decreased spe-
cific activity in CHO cells can be ascribed partly to the
reduced catalytic activity and partly to the low expression
level of the variant.
As a first step, we checked if the difference in the protein
expression levels between wild-type DDC and the S250F
variant was due to a varied transfection efficiency or to a dif-
ferent mRNA intracellular stability. No differences in the
levels of mRNA for wild-type DDC and the S250F variant
were observed, as revealed by the amount of the encoding
transcripts quantified by real-time PCR (data not shown).
Therefore, the low mutant expression appears to be due to a
failure at the protein level rather than at the transcriptional
level, thus suggesting that the S250F mutation could affect
the folding process and/or the susceptibility of DDC to intra-
cellular degradation. Nevertheless, the finding that the relative
amounts of soluble and insoluble protein recovered from
lysates of CHO cells expressing wild-type and mutant DDC
are similar indicates that the mutation does not make DDC
prone to intracellular aggregation, which is consistent with
the data obtained with the purified protein. Thereafter, we
measured the half-life of wild-type and mutant DDC by
cycloheximide chase assays. As shown in Figure 7A–C,
the S250F mutation decreases the DDC half-life in CHO
cells from 19+ 1 to 11+ 1 h, thus suggesting that the
variant could be more susceptible than wild-type DDC to
intracellular degradation. To have insights about the mechan-
ism of degradation, cycloheximide chase assays have been
carried out in the presence of the lysosome inhibitor, chloro-
quine, or the proteasome inhibitor, MG132. Chloroquine does
not change the half-life of the two enzymatic species, while
MG132 partly slows down protein degradation. However,
this effect is higher for the variant than for the wild-type
Figure 1. Absorbance and CD spectra of wild-type and S250F variant. Ab-
sorbance spectra of DDC wild-type (- - -) and S250F variant (-) in 100 mM po-
tassium phosphate buffer, pH 7.4, at an enzyme concentration of 5 mM. (inset):
CD spectra, same as absorption.
Figure 2. Intrinsic and coenzyme fluorescence emission spectra of NaBH4
reduced wild-type and S250F variant. The excitation wavelength was at
280 nm (inset): excitation wavelength was at 330 nm. For all spectra, the
protein concentration was 1 mM in 100 mM potassium phosphate buffer, pH
7.4. Symbols as in Figure 1.
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(Fig. 7A–C). These data mean that (i) the DDC turnover
inside the cell is partly mediated by the proteasome instead
of the lysosome pathway, and (ii) the mutation makes
DDC more susceptible to proteasomal degradation. On
these bases, since poly-ubiquitination is an important
process for targeting proteins to proteasome, we investigated
whether S250F is more susceptible than wild-type DDC to
ubiquitination. CHO cells transiently expressing wild-type
DDC or the S250F variant were immunoprecipitated with
antibodies against ubiquitin and subsequently immunoblotted
with the anti-DDC antibody. The results shown in Supple-
mentary Material, Fig. S1A and B, show that while no
signal is detected, as expected, in CHO cells transfected
with the empty vector, a broad smear pattern typical of the
poly-ubiquitin-conjugated DDC is observed in cells expres-
sing wild-type and mutant. It should be noticed that, even
if the smear pattern prevents a precise densitometric analysis,
the signal relative to the mutant is higher than that relative to
wild-type DDC. These data indicate that DDC is conjugated
to ubiquitin prior to proteasomal degradation and corroborate
the idea that the S250F variant is more prone to degradation
upon poly-ubiquitination.
Following these results, we investigated the effects of pyri-
doxine, a precursor of PLP used in the clinical practice for
patients with inherited diseases associated with deficit of
PLP enzymes, and of some compounds (betaine and 4-PBA)
known to act as small-molecule chaperones on the expression
level and the specific activity of wild-type and mutant DDC
transiently expressed in CHO cells. As shown in Figure 8A,
while betaine does not affect the expression of wild-type and
mutant DDC, either pyridoxine or 4-PBA increase the expres-
sion level of both enzymatic species. Accordingly, the results
reported in Figure 8B indicate that: (i) pyridoxine increases
the specific activity measured in CHO cells expressing wild-
type or S250F variant, but the change is statistically significant
only in the case of the variant, (ii) pyridoxine plus betaine or
4-PBA significantly increase the specific activity detected in
cells expressing wild-type, and, to a major extent, that of
cells expressing the pathogenic variant, (iii) pyridoxine plus
betaine has an effect on the specific activity of CHO cells
expressing wild-type and mutant, which is not significantly
different from that of pyridoxine alone, which is consistent
with the null effect of betaine. The increase in the specific ac-
tivity of the S250F variant is dependent on vitamin B6 or
4-PBA concentration, reaching its maximum at 10 mM pyri-
doxine and 1 mM 4-PBA (Fig. 8B)
Taken together, the results obtained in the CHO cellular
model system allow us to conclude that (i) the S250F mutation
causes a structural defect in DDC that makes the protein more
susceptible to intracellular degradation and (ii) pyridoxine or
4-PBA are able to rescue for the effect of the mutation by in-
creasing the expression level and specific activity of the
variant.
DISCUSSION
Several diseases mainly of neurological and metabolic origin
are associated with inherited mutations of genes encoding
PLP-enzymes (10–12). AADC deficiency is a rare neurometa-
bolic disorder whose molecular bases are poorly understood.
Since the S250F mutation is the most frequent one being
present in one-tenth of all reported cases of patients with
AADC deficiency, we decided to investigate the molecular
basis of this mutation both in vitro and in cellular systems.
Steady-state kinetic parameters of the purified recombinant
S250F variant show that the mutation does not involve a
residue essential for catalytic activity, since it only causes
a # 7-fold reduction of the catalytic efficiency. Although the
far-UV and DLS data exclude any gross alteration in the con-
formation of the S250F variant, the finding that the variant has
an intrinsic fluorescence emission spectrum, a CD spectrum in
Figure 3. Intrinsic and ANS fluorescence emission spectra of wild-type and
S250F variant. (A) Intrinsic fluorescence emission spectra (exc. at 280 nm);
(B) Fluorescence emission spectra (exc. at 365 nm) in the presence of
15 mM ANS. For all spectra, the protein concentration was 1 mM in 100 mM po-
tassium phosphate buffer, pH 7.4. Symbols as in Figure 1.
Table 2. Kinetic parameters for wild-type and S250F variant DDCs
Enzyme kcat (s
21) Km (mM) kcat/Km mM
21/s21
Wild-typea 7.6+0.1 0.11+0.01 70.6+8.4
S250F 2.1+0.1 0.22+0.04 9.3+1.7
aFrom ref. (4).
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the near-UV region and ANS binding properties different from
the corresponding ones of the wild-type suggests that it has a
slightly altered tertiary structure. Moreover, S250F has a per-
turbed active site, as can be inferred from the altered absorb-
ance and CD bands of the bound PLP and the decreased
intensity of the coenzyme emission of the NaBH4-reduced
protein. An explanation for all these data is that the mutation
at position 250 of Ser to Phe possibly induces a conformation-
al change in the proximity of the mutation site that is transmit-
ted to the active site. According to the computational analysis,
substitution to Phe predictably (i) breaks a hydrogen bond
between Ser250 and Thr245, an interaction which could be
important to stabilize the loop 243–252, (ii) causes an
altered mobility of this loop due to the bulky side chain of
Phe and (iii) enhances the hydrophobic surface of the
enzyme. Although the information derived from the molecular
modelling of the S250F variant is of course not an experimen-
tal evidence, it is not in contrast with the in vitro data.
Based on these results, one can consider S250F a catalytic
mutation. However, DDC assays and western immunoblot
analyses of the crude cellular extracts of E. coli and of CHO
cells transiently expressing wild-type or S250F variant indi-
cate, in addition to a reduced specific activity, a decreased
amount of immunoreactive S250F protein with respect to
wild-type. This implies that the molecular defect of the
S250F variant does not only rely on the decreased catalytic ac-
tivity of the protein compared with wild-type DDC, but also
on a decreased expression level that exacerbates the molecular
defect responsible for the decreased specific activity of the
variant. It should be noted that the reduced protein level
caused by the mutation in the mammalian cellular milieu is
(i) not produced by differences at the level of transcription
since the intracellular mRNA levels are not decreased, and
(ii) not ascribable to intracellular protein aggregation
because the relative amounts of soluble and insoluble S250F
are comparable with those of the wild-type. The latter
finding is in agreement with the fact that DLS measurements
do not reveal any aggregation propensity of recombinant
S250F. Instead, considering that the half-life drops from
19 h for the wild-type to 11 h for the S250F, it is reasonable
to suggest that the variant is expressed in cells but is degraded
faster than the wild-type. We have also shown that the degrad-
ation of wild-type and mutant depends, at least in part, on the
activity of the proteasome instead of the lysosome pathway.
Indeed, MG132 does not completely block protein degrad-
ation, thus suggesting that other proteolytic pathways could
contribute to DDC turnover, as already proposed for other pro-
teins (13). Remarkably, MG132 preserves from the degrad-
ation process more efficiently the S250F variant than the
wild-type, and ubiquitination is more pronounced in the
S250F variant than in the wild-type. Ubiquitination is often
driven by conformational changes and/or order–disorder tran-
sition since unstructured region or newly exposed surface of
the target protein is recognized by ubiquitin ligase. Indeed,
the S250F mutation generates a conformational change that
possibly leads to a more hydrophobic surface (as indicated
by ANS experiments, and predicted by molecular modelling).
Altogether, these data reinforce the view that the reduction in
the S250F protein level might be ascribable to its degradation
by the proteasomal pathway, and allow us to advance that the
mutation might affect the folding pathway leading to accumu-
lation of denatured and/or partially denatured forms of the
variant prone to proteolytic degradation. It has been already
reported that mis- or unfolded proteins are usually processed
by cellular degradation pathways (14).
For this reason, small-molecule chaperones, which could
help to improve the folding of S250F variant, have been
tested. Exposure of mutant-expressing CHO cells to betaine
Figure 4. Time-dependent loss of decarboxylase activity of the holo and apo
forms of DDC wild-type and S250F upon incubation at 378C. Holo (closed
circle) or apo (closed square) DDC wild-type at 0.2 mM concentration, holo
(open circle) or apo (open square) S250F variant at 0.5 mM were incubated
at 378C. Aliquots were withdrawn at the indicated times and assayed for de-
carboxylase activity, as reported under the ‘Materials and Methods’ section.
Figure 5. Comparison of the 3D structure of wild-type DDC and S250F
variant. Overlapping of the crystal structure of wild-type DDC (orange)
with the averaged structure of the S250F mutant (purple) obtained by molecu-
lar modelling analysis. The amino acids belongings to the loop 243–252 are
represented as sticks. Ser 250 and Phe250 side chains are highlighted in
cyan and red, respectively. The position of Thr245 and Phe215 are indicated.
PLP is represented as green stick. The image was constructed by means of
PyMol software (Delano Scientific).
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does not affect the specific activity and immunoreactivity of
the variant. In contrast, 4-PBA at 1 mM concentration raises
the specific activity of the variant to # 34% of wild-type, a
good improvement over the specific activity (15%) of this
mutant under non-treated cells. Notably, 4-PBA is of clinical
use in the treatment of patients affected by cystic fibrosis
bearing the DF508 responsible for a folding defect (15).
Quite intriguing is the effect of pyridoxine, a PLP precursor,
which results to be more effective than 4-PBA since at
10 mM concentration increases the specific activity to # 60%
of wild-type. The effect of pyridoxine and/or PLP, even if at
a variable degree of responsiveness, has already been demon-
strated for some inborn errors associated with PLP-dependent
enzymes: 90% in d-aminolevulinate synthase deficiency,
50% in cystathionine b-synthase deficiency, 10–30% in
alanine glyoxylate aminotransferase and 5% in ornithine
d-aminotransferase deficiency (10,16). For some patients, the
obvious explanation could be that they carry mutations that
impair the PLP binding to the enzyme. However, since the
mutation site in some pyridoxine-responsive patients makes
this explanation unlike (10,17), it has already been proposed
that PLP could assist protein folding, thus reducing the likeli-
hood of degradation of misfolded proteins (18–20). This
appears to be the case for the S250F variant associated with
AADC deficiency. A question remains to be elucidated: is
the chaperoning activity of pyridoxine exerted on the apo or
the holo form of the variant? Some conclusions can be
drawn from our data and literature. Cell biology studies pro-
vided evidence that the apo form of rat liver DDC is degraded
in PC12 cells faster than the holo form (21). The structural
basis of this behaviour has been recently related to the strik-
ing difference between the crystal structure of apo- (22)
and holo-DDC (8). At physiological temperature, while the
S250F mutation does not affect the kinetic stability of the
holo form of the variant, it causes a time-dependent more sig-
nificant inactivation of the apo variant compared with that of
the apo wild-type. The inactivation, not dependent on the
protein concentration and not accompanied by generation of
aggregates, presumably originates from an enhanced amount
of denatured and/or misfolded forms of the apovariant in com-
parison with the apowild-type. Based on these in vitro results,
the hypothesis could be advanced that in vivo the coenzyme
plays a prosthetic role shifting from the less stable apo to
the more stable holo form, thus preventing the degradation
process. However, several lines of evidence argue against
this view. First, since, on the basis of the medium composition,
the pyridoxine concentration in CHO cells is #0.3 mM, and
both the apo forms of wild-type and variant exhibit a
KD(PLP) value of #50 nM, both these enzymatic species
should be mainly in the holo form. Second, the effect of pyri-
doxine on the variant is not limited to an increase in the spe-
cific activity but also in the expression level. Third, the effect
of pyridoxine observed in CHO cells is dose-dependent, reach-
ing its maximum at a concentration # 200-fold higher than the
KD(PLP).
On these bases, it can be proposed that pyridoxine could act
as a pharmacological chaperone on the holo form of the S250F
variant. Such a role has been already raised for tyrosine ami-
notransferase (18) and alanine glyoxylate aminotransferase
folding (19,20). For both these enzymes, a degradation via a
proteasome pathway has been reported (18,23).
This is the first study in which the molecular basis of
the AADC deficiency has been elucidated by a combination
of biochemical and cell biology analyses. This approach
allowed us to highlight that the S250F mutation results in
catalytic and folding effects, thus confirming its pathological
involvement and paving the way for the implementation of a
useful tailored treatment. The yet undescribed chaperoning
effect of pyridoxine on the S250F variant may be useful
in patients bearing this mutation as well as other mutations
associated with AADC deficiency giving rise to structural
defects.
MATERIALS AND METHODS
Materials
PLP, L-dopa, 2,4,6-trinitrobenzene-1-sulfonic acid, isopropyl-
b-D-thiogalactopyranoside, protease inhibitor cocktail, betaine,
pyridoxine hydrochloride and 4-PBA were purchased from
Sigma. ANS was purchased from Molecular Probes. The poly-
clonal goat anti-DDC (C-16), the anti-ubiquitin antibody and
the anti-glyceraldehyde 3′-phosphate dehydrogenase (GAPDH)
antibody were purchased from Santa Cruz Biotechnology,
from AbCam and from Millipore, respectively. All other chemi-
cals were of the highest purity available.
Expression constructs
The full-length cDNA coding for human DDC cloned on a
pCMV-XL5 vector (pCMV-DDC) was purchased from
Origine Technologies and cloned on a pTrcHis2A vector
to give the construct pDDChis as previously described (4).
The S250F mutation was inserted into the pDDChis and
pCMV-DDC expression vectors by the QuikChange II site-
directed mutagenesis kit (Stratagene) using the
Figure 6. Analyses of DDC expression in CHO cells expressing DDC wild-
type or the S250F variant. CHO cells, 24 h after transfection, were harvested
and lysed; 15 mg of cell lysate was subjected to SDS PAGE, immunoblotted
with anti-DDC from goat (1:250) and detected by chemiluminescence;
GAPDH was used as loading control. The immunoblot lanes are coded as
follow: 1. untransfected CHO cells, 2. CHO cells expressing wild-type
DDC, 3. CHO cells expressing S250F variant.
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oligonucleotide 5′ GGACCACAACATGCTGCTTCTTTGA-
CAATCTCTTAGAAG 3′ and its complement (the mutated
codon is underlined). The mutation was confirmed by
DNA sequencing.
Protein purification and determination of the coenzyme
equilibrium dissociation constant
Purification of his-tagged wild-type DDC and of the S250F
variant was performed following the procedure previously
described (4). Protein concentration was determined using
the 1M ¼ 142 000 M21cm21 at 280 nm. The PLP content
of the S250F variant was determined by releasing the coen-
zyme in 0.1 M NaOH and by using 1M ¼ 6600 M21cm21
at 388 nm. For the apoenzyme preparation, the S250F
variant was incubated with 5 mM hydroxylamine in 0.5 M
potassium phosphate buffer, pH 6.9 at 258C for 3 h and
the mixture was loaded on a desalting 26/10 column (GE
Healtcare) pre-equilibrated with the same buffer without
hydroxylamine (24).
The equilibrium dissociation constant for PLP, KD(PLP),
from the S250F variant was determined by measuring the
quenching of the intrinsic fluorescence of the apoenzyme
(0.1 mM) in the presence of PLP at a concentration range of
0.01–10 mM in 100 mM potassium phosphate buffer, pH 7.4
and by fitting the data to the following equation:
where [E]t and [PLP]t represent the total concentrations of the
enzyme and PLP, respectively, Y refers to the intrinsic quench-
ing changes at a PLP concentration, [PLP], and Ymax refers to
the aforementioned changes when all enzyme molecules are
complexed with coenzyme.
Enzyme activity assays
The decarboxylase activity toward L-dopa of wild-type DDC
and the S250F variant in the purified form was measured by
the spectrophotometric assay described by Sherald et al.
(25), and modified by Charteris and John (26). Measurements
were performed in the presence of 100 mM PLP in 100 mM po-
tassium phosphate buffer, pH 7.4. Data of enzymatic activity
as a function of substrate concentration were fitted to the
Michaelis–Menten equation. The effect of PLP on thermo-
stability of the apo form of wild-type and mutant was mea-
sured as follows: wild-type (0.2 mM) or S250F (0.5 mM)
either in the holo or apo form was incubated in 100 mM phos-
phate buffer, pH 7.4, at 378C. Aliquots were withdrawn at
various times, and, after incubation with 10 mM PLP for
10 min, assayed as above described.
The DDC decarboxylase activity toward L-dopa in the
soluble fraction of cellular lysates of CHO cells was deter-
mined through HPLC analysis (27). Thirty micrograms of
Figure 7. Measurement of protein half-lives by cycloheximide chase assays. CHO cells, 24 h after transfection, were treated with cycloheximide (final concen-
tration 10 mg/ml) for the indicated times. Where indicated 10 mM MG132 or 100 mM chloroquine was added 1 h before cycloheximide treatment. GAPDH was
used as loading control. (A) Immunoblot (B) quantification of results in (A) by the QuantityOne software. The colour code is black (wild-type DDC), blue (wild-
typeDDC plus MG132), magenta (wild-type DDC plus chloroquine), red (S250F variant), green (S250F variant plus MG132) and cyan (S250F variant plus
chloroquine). The lines represent a linear regression fit of the data. (C) Table showing the half-life values derived from data in (B). Data come from the
mean of three different experiments.
Y = Ymax
[E]t + [PLP]t + KD(PLP) −
NameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMe
[([E]t + [PLP]t + KD(PLP))2 − 4[E]t[PLP]t]
√
2[E]t
,
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cell lysate were incubated in 100 mM potassium phosphate
buffer pH 7.4 at 258C in the presence of 2 mM L-dopa and
10 mM PLP. After 30 min (a time within which a linear
product formation is observed) the reaction was stopped by
adding trichloracetic acid to a final concentration of 10%
(v/v). After centrifugation to remove precipitated proteins,
the supernatants were analysed using a Supelcosyl C18
(250 × 4.6 mM) (Supelco) column connected to a Jasco
PU-2080 Plus HPLC control system. The eluent was 50 mM po-
tassium phosphate buffer, pH 2.35, at flow rate of 1 ml/min.
A Jasco UV-2075 Plus detector set at 280 nm was employed
for dopamine detection. Peaks corresponding to dopamine
eluting at 9 min were integrated with Jasco Borwin software.
A standard curve of peak area as function of dopamine
concentration was prepared using commercially available
dopamine.
Spectroscopic measurements
Absorption measurements were performed with a Jasco V-550
spectrophotometer at a protein concentration of 5 mM. Fluores-
cence spectra were recorded with a FP750 Jasco
spectrofluorimeter using 5 nm excitation and emission band-
widths at a protein concentration of 0.1–1 mM. CD measure-
ments were made with a Jasco J-710 spectropolarimeter at a
protein concentration of 5 mM. All the spectroscopic measure-
ments were carried out in 100 mM potassium phosphate buffer,
pH 7.4, at 258C.
DLS analyses were performed on a ZetasizerNano S instru-
ment (Malvern Instruments) by using disposable 12.5 ×
45-mm cells with stopper (20). Wild-type DDC and S250F
variant were diluted to 4 mM concentration in 60 mM potas-
sium phosphate buffer, pH 7.4 in the presence of 20 mM
PLP. The temperature was kept at 37+ 0.18C during the mea-
surements by a Peltier temperature controller.
Limited proteolysis
DDC wild-type and S250F variant at 10 mM enzyme concen-
tration were treated with proteinase K at a 1/50 (w/w) protease
to enzyme ratio in 100 mM potassium phosphate buffer, pH
7.4, at 258C in the presence of 20 mM PLP. At various
times, 15 ml aliquots were withdrawn and the reaction was
stopped by addition of PMSF to a final concentration of
2 mM. Samples were analysed by SDS PAGE. After staining
with Coomassie brilliant blue, the band intensities were
visualized and analysed using ImageJ software (Wajne
Rasband).
Molecular modelling analysis
The structural model of the S250F mutant was generated start-
ing from the pig kidney crystal structure of DDC in complex
with PLP (pdb file 1JS6). Protonation state assignment and
local energy minimization were performed setting a protein
and solvent dielectric constant of 2.0 and 80.0, respectively,
a pH value of 7.4, a ionic strength of 150 mM, and a tempera-
ture of 378C. For all calculation, the force field adopted was
AMBER99. The analysis was performed using the Molecular
Operating Environment software (CCG group).
Cell culture, transfection and lysis
CHO cells were cultured at 378C under O2/CO2 (19:1) atmos-
phere in Ham’s F12 Glutamax medium (Invitrogen) supple-
mented with foetal bovine serum (10%,v/v), penicillin
(100 units/ml) and streptomycin (100 mg/ml), as previously
described (28). Cell transfection was performed using the
TurbofectTM Transfection Reagent (Fermentas) according to
the manufacturer’s instructions. After 4 h the medium contain-
ing the DNA–lyposome complex was replaced with fresh
complete Ham’s F12 medium. Cells were harvested after
24 h and pellets were stored at 2808C until lysis. The effect
of pyridoxine, betaine, and 4-PBA was tested by adding
each of the compounds or their combination to the medium
4 h after transfection.
Cells were lysed in phosphate-buffered saline (PBS) plus
protease inhibitor cocktail (Complete Mini, Roche) and sub-
jected to five freeze-thaw cycles. Samples were treated with
DNAse (10 U) at 378C for 45 min. The whole cell extract
was separated by centrifugation (28 400g, 10 min, 48C) to
obtain the soluble fraction. The pellet was then resuspended
Figure 8. Effect of betaine, 4-PBA and pyridoxine on expression level and
specific activity of DDC wild-type and S250F variant. CHO cells, 4 h after
transfection, were treated with these compounds, and, 24 h after transfection,
were harvested and lysed. (A) Fifteen micrograms of cell lysate were subjected
to SDS PAGE, immunoblotted with anti-DDC from goat (1: 250) and detected
by chemiluminescence. GAPDH was used as loading control. (B) Thirty
micrograms of cell lysate were incubated with 2 mM L-dopa, and the amount
of dopamine produced after 30 min was determined by HPLC as described
under the ‘Materials and Methods’ section. The immunoblot lanes and histo-
gram bars are coded as follow: CHO cells expressing wild-type DDC, 1. un-
treated, 2. treated with 100 mM pyridoxine, 3. treated with 15 mM betaine,
4. treated with 100 mM pyridoxine plus 15 mM betaine, 5. treated with 1 mM
4-PBA; CHO cells expressing the S250F variant, 6 untreated, 7. treated with
pyridoxine at the indicated concentrations, 8. treated with 15 mM betaine,
9. treated with 100 mM pyridoxine plus 15 mM betaine and 10. treated with
4-PBA at the indicated concentrations. Data are representative of three differ-
ent experiments. Bar graphs represent the mean+SEM ∗∗P , 0.01; ∗∗∗P ,
0.001.
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in an equal volume of denaturing gel loading buffer to obtain
the insoluble fraction. The total protein concentration of the
soluble fraction was measured using the Bio-Rad DCTM
protein assay according to the manufacturer’s instructions.
Transcript expression analysis
CHO cells were grown in a 6-well plate and transfected using
Turbofect (Fermentas) as described above. Cells were har-
vested, washed with PBS, and RNA was extracted using the
RNeasy mini kit (Qiagen). The cDNA was synthetized from
1 mg of mRNA using the Supersctipt VILO cDNA synthesis
kit (Invitrogen, Carlsbad, CA) according to manufacturer’s
instructions. Real-time PCR was performed using 3 ml of a
1:10 cDNA dilution in a 25 ml reaction volume using SYBR
Premix Ex Taq master mix (TaKaRa) on a Corbett RotorGene
6000 thermocycler. The reaction conditions included initial
denaturation at 958C for 15 min followed by 45 cycles of
PCR which included 15 s melting at 958C, 30 s annealing at
558C and 30 s extension at 728C. The samples were examined
for the expression of human DDC using the forward primer
5′-GAAGGAGAGGGAAGGAGATGG-3′ and the reverse
primer 5′-GGAAGTAGGCGAAGAAGTAGG-3′. The
amount of the wild-type and S250F hDDC mRNA was calcu-
lated in relation to the GAPDH mRNA in the same sample.
Quantitation of individual transcripts was performed using
the ‘Comparative Quantitation’ software supplied by Corbett
Research for the RotorGene. The mean efficiency of a group
of cycling curves is calculated at the point that the cycling
curves take off and used to calculate a fold change according
to the formula: fold change ¼ efficiency Ct1–Ct2, where Ct1
and Ct2 are the take-off values of the cycling curves being
compared. All reactions were performed in duplicate.
Western blotting
Fifteen micrograms of lysate were loaded per lane on a Mini
Protean TGXTM pre-cast gel (Biorad) along with Precision
plus protein KaleidoscopeTM (Bio-Rad) as molecular mass
markers. Following transfer on a nitrocellulose membrane by
the iBlot device (Invitrogen) the membrane was blocked in
5% bovine serum albumin for 1 h at 378C. For DDC detection,
the membrane was incubated with polyclonal goat anti-DDC
(C-16) (Santa Cruz Biotechnology) (dilution 1:250) and
peroxidase-conjugated donkey-anti-goat IgG (dilution
1:2000) as primary and secondary antibody, respectively.
Blotted proteins were detected and quantified with ECLw
(Millipore), using the ChemiDoc XRS Imaging System
(Bio-Rad, Hercules, CA). As a gel loading control, the
amount of GAPDH was determined using the mouse monoclo-
nal antibody anti GAPDH (Millipore) (dilution 1:1000).
Pulse-chase experiments and DDC immunoprecipitation
The half-life of DDC in the wild-type and S250F mutant form
was determined by treating transfected CHO cells with cyclo-
heximide (10 mg/ml) 24 h post-transfection. After 4, 8, 12 and
24 h of cycloheximide treatment, cells were lysed and DDC
levels were quantified by immunoblotting as described
above. Where indicated, cells were treated with the
proteasomal inhibitor, MG132 (10 mM), or the lysosome in-
hibitor, chloroquine (100 mM), 1 h before the addition of
cycloheximide. To assess the increase in total ubiquitinated
proteins, which confirms the proteasome inhibition in the pres-
ence of 10 mM MG132, CHO cell lysates were immunoblotted
with the rabbit anti-ubiquitin antibody (AbCam).
To check the ubiquitination level of wild-type and S250F
DDC, the soluble fraction of each cell lysate (100 mg) was
incubated over night with 2 mg of rabbit anti-ubiquitin anti-
body (AbCam) on a rotator at 48C. Thereafter, the immunopre-
cipitation reaction was performed at room temperature by
adding 30 ml of agarose-protein A (GE, Healthcare) to the
mixture and by incubating the solution for 1 h on a rotator.
The immunoprecipitated complex was collected by centrifu-
ging at 29 200 g at 48C for 5 min, washed three times with
IP wash/lysis buffer (Thermo Scientific), and resuspended in
20 ml of denaturing gel loading buffer. Proteins were separated
on SDS PAGE and DDC was detected by immunoblotting as
described above. Untransfected and non-immunoprecipitated
DDC-transfected CHO cell lysates were used as negative
and positive control, respectively.
Statistical analysis
The two-way ANOVA algorithm for repeated measures was
used for data analysis. Differences with P , 0.05 were consid-
ered significant.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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